WO2010125831A1 - Sulfamoyl benzoic acid derivatives as trpm8 antagonists - Google Patents

Sulfamoyl benzoic acid derivatives as trpm8 antagonists Download PDF

Info

Publication number
WO2010125831A1
WO2010125831A1 PCT/JP2010/003121 JP2010003121W WO2010125831A1 WO 2010125831 A1 WO2010125831 A1 WO 2010125831A1 JP 2010003121 W JP2010003121 W JP 2010003121W WO 2010125831 A1 WO2010125831 A1 WO 2010125831A1
Authority
WO
WIPO (PCT)
Prior art keywords
chloro
sulfamoyl
trifluoromethyl
pyridin
benzoic acid
Prior art date
Application number
PCT/JP2010/003121
Other languages
French (fr)
Inventor
Tadashi Inoue
Masashi Ohmi
Kiyoshi Kawamura
Kazuo Ando
Yuji Shishido
Original Assignee
Raqualia Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc. filed Critical Raqualia Pharma Inc.
Priority to BRPI1010017-2A priority Critical patent/BRPI1010017A2/en
Priority to KR1020117026215A priority patent/KR20140071518A/en
Priority to CA2757761A priority patent/CA2757761A1/en
Priority to EP10769531A priority patent/EP2424517A4/en
Priority to MX2011011428A priority patent/MX2011011428A/en
Priority to RU2011148937/15A priority patent/RU2011148937A/en
Priority to US13/318,212 priority patent/US20120094964A1/en
Priority to CN2010800189757A priority patent/CN102427810A/en
Priority to JP2011546471A priority patent/JP2012525326A/en
Publication of WO2010125831A1 publication Critical patent/WO2010125831A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to sulfamoyl benzoic acid derivatives that act as modulators of the TRPM8 receptor.
  • the present invention also relates to processes for the preparation of novel sulfamoyl benzoic acid derivatives and to their use in the treatment of a wide range of diseases, syndromes, and disorders, in particular for the treatment of inflammatory, pain and urological diseases or disorders.
  • TRP channels are one of the largest groups of ion channels, and they are divided into 6 sub-families (TRPV, TRPM, TRPA, TRPC, TRPP and TRPML). TRP channels are cation-selecive channels that are activated by a variety of physical (e.g., temperature, osmolarity, mechanical) and chemical stimuli. TRPM8 is a member of TRP channel family.
  • TRPM8 can sense temperature changes in the range of both innocuous cold (15-28 o C) and noxious cold ( ⁇ 15 o C) as well as by chemical agents such as menthol and icilin.
  • TRPM8 is located on primary nociceptive neurons including A-delta and C-fibers and is also modulated by inflammation-mediated second messenger signals (Abe, J., et al Neurosci Lett 2006, 397(1-2), 140-144; Premkumar, L.S., et al, J. Neurosci, 2005, 25(49), 11322-11329).
  • the localization of TRPM8 on both A-delta and C-fibers may provide a basis for abnormal cold sensitivity in pathologic conditions wherein these neurons are altered, resulting in pain, often of a burning nature (Kobayashi, K., et al, J Comp Neurol, 2005, 493(4), 596-606; Roza, C, et al.
  • TRPM8 is also known to be expressed in the brain, lung, bladder, gastrointestinal tract, blood vessels, prostate and immune cells, thereby providing the possibility for therapeutic modulation in a wide range of maladies.
  • TRPM8 antagonists that can be used to treat a disease, syndrome, or condition in a mammal in which the disease, syndrome, or condition is affected by the modulation of TRPM8 receptors, such as chronic pain, neuropathic pain including cold allodynia and diabetic neuropathy, postoperative pain, osteoarthritis, rheumatoid arthritic pain, cancer pain, neuralgia, neuropathies, algesia, nerve injury, migraine, cluster and tension headaches, ischaemia, irritable bowel syndrome, neurodegeneration, fibromyalgia, stroke, itch, psychiatric disorders including anxiety and depression and inflammatory disorders such as asthma and chronic obstructive pulmonary, or airways, disease i.e., COPD, pulmonary hypertension, anxiety, including other stress-related disorders, urological diseases or disorders such as detrusor overactivity or overactive bladder, urinary incontinence, neurogenic detrusor overactivity or detrusor hyperflexi
  • TRPM8 receptors such
  • TRPM8 antagonists should be well absorbed from the GI tract, be metabolically stable and possess favorable pharmacokinetic properties. They should be non-toxic. Furthermore, the ideal drug candidate will exist in a physical form that is stable, non-hygroscopic and easily formulated. In particular, it has been desired that compounds must bind potently to the TRPM8 receptor and show functional activity as antagonists. The present invention provides novel compounds which have excellent TRPM8 antagonistic activities.
  • the compounds of the present invention differ structurally from the cited arts above by the presence of 5 to 7 heterocyclic group at Ar 1 in the formula I.
  • WO 2009/025793 discloses sulfamoyl benzoic acid compounds. Some of the compounds are formally fallen into the claims in the patent. However, the compounds relate to human type 2 taste receptors for modulating taste perception, particularly bitter taste, which is quite different from TRPM8 receptor antagonist for the treatment of various disorders mediated via the TRPM8 receptor. Namely the sulfamoyl benzoic acid derivatives in the present invention are neither disclosed as working examples in the patent nor TRPM8 receptor antagonist activity which are useful for the treatment of various disorders mediated via the TRPM8 receptor.
  • the present invention provides a use of a compound of the following formula (I) for the manufacture of a medicament for the treatment of a condition or disorder mediated by TRPM8 receptor antagonistic activity
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from the group consisting of hydrogen, C 1 -C 4 alkyl , hydroxy C 1 -C 4 alkyl, C 1 -C 4 alkoxy C 1 -C 4 alkyl, and C 3 -C 7 cycloalkyl; or alternatively R 1 and R 2 , together with the atom to which they are attached, form a 3 to 6 membered ring which may contain oxygen and/or nitrogen; said ring is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, C 1 -C 4 alkyl, and C 1 -C 4 alkoxy; R 3 and R 4 , together with the atom to which they are attached, form a 3 to 6 membere
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
  • the present invention provides a compound as described in formula (I) wherein the definition described above: m is 0, or a pharmaceutically acceptable salt thereof.
  • Preferable compounds of the invention are represented by formula (I) wherein the definition described above: m is 0; and Ar 1 is a 5 to 7 heterocyclic group.
  • More preferable compounds of the invention are represented by formula (I) wherein the definition described above: m is 0; and Ar 1 is a 5 to 7 heterocyclic group selected from pyridinyl, pyrimidinyl, pyridazinyl, and triazinyl.
  • the most preferable compounds of the invention are represented by formula (I), wherein m is 0; Ar 1 is 2-pyridinyl or 3-pyridinyl; and A 1 , A 2 , A 3 and A 4 are carbon atom.
  • Suitable individual compounds of the invention are: N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide; 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzamide; 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-N-methylbenzamide; 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-N,N-dimethylbenzamide; 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-N-(2-hydroxyethyl)benzamide; 4-(N-(3
  • More suitable individual compounds of the invention are: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid; 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-fluorobenzyl)sulfamoyl)benzoic acid; 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid; 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid; 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-y
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, each as described herein, together with a pharmaceutically acceptable carrier for said compound.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, each as described herein, together with a pharmaceutically acceptable carrier for said compound and another pharmacologically active agent.
  • the present invention provides a process for preparing a pharmaceutical composition, the process comprising mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
  • the present invention provides an intermediate in a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method for the treatment of a condition or disorder mediated by TRPM8 receptor activity, in a mammalian subject, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, each as described herein.
  • the present invention provides a process for preparing a pharmaceutical composition, the process comprising mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
  • TRPM8 receptor activity examples include, but are not limited to, TRPM8 related diseases.
  • the compounds of the present invention show the TRPM8 receptor antagonistic activity.
  • the compounds of the present invention may show less toxicity, good absorption, distribution, good solubility, less protein binding affinity other than TRPM8 receptor, less drug-drug interaction, and good metabolic stability.
  • alkyl as a group or part of a group e.g. alkoxy or hydroxyalkyl refers to a straight or branched alkyl group in all isomeric forms.
  • C 1 -C 4 alkyl refers to an alkyl group, as defined above, containing at least 1, and at most 4 carbon atoms. Examples of such alkyl groups include methyl, ethyl, propyl, iso-propyl, n-butyl, iso- butyl, sec-butyl, or tert-butyl. Examples of such alkoxy groups include methoxy, ethoxy, propoxy, iso-propoxy, butoxy, iso-butoxy, sec-butoxy and tert-butoxy.
  • cycloalkyl means a mono- or bicyclic ring, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norboranyl, and adamantyl groups and the like.
  • halogen refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) and the term “halo” refers to the halogen: fluoro (-F), chloro (-Cl), bromo (-Br) and iodo (-I).
  • haloalkyl means an alkyl radical which is substituted by halogen atom(s) as defined above including, but not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, 3-fluoropropyl, 4-fluorobutyl, chloromethyl, trichloromethyl, iodomethyl and bromomethyl groups and the like.
  • haloalkoxy means haloalkyl-O-, including, but not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, 3-fluoropropoxy, 4-fluorobutoxy, chforomethoxy, trichloromethoxy, iodomethoxy and bromomethoxy groups and the like.
  • alkenyl means a hydrocarbon radical having at least one double bond including, but not limited to, ethenyl, propenyl, 1-butenyl, 2-butenyl and the like.
  • alkynyl means a hydrocarbon radical having at least one triple bond including, but not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl and the like.
  • alkoxy means an O-alkyl group wherein “alkyl” is defined above.
  • aryl means mono-carbocyclic or mono-heterocyclic group which may contain 0-4 heteroatoms selected from O, N and S; the said heterocyclic group includes both unsaturated and saturated heterocyclic moieties; wherein the unsaturated heterocyclic moieties include furyl, furazanyl, imidazolyl, isooxazolyl, isothiazolyl, oxazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrazinyl, pyridazinyl, thienyl, tetrazolyl, thiazolyl, triazinyl, thiophenyl, triazolyl, and N-oxides thereof and S-oxides thereof; and wherein the saturated heterocyclic moieties include azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperaz
  • heterocyclyl means a saturated ring which comprises one or more heteroatoms selected from nitrogen, oxygen and sulphur.
  • heterocyclyl groups include azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, thiomorpholinyl, and tetrahydrothienyl, and N-oxides thereof and S-oxides thereof.
  • C 0 means direct bond
  • protecting group means a hydroxy or amino protecting group which is selected from typical hydroxy or amino protecting groups described in Protective Groups in Organic Synthesis edited by T. W. Greene et al. (John Wiley & Sons, 1991);
  • treating refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • treatment refers to the act of treating, as “treating” is defined immediately above.
  • treating refers to curative, palliative and prophylactic treatment, including reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • the compounds of formula (I) can form acid addition salts thereof. It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in J. Pharm. Sci, 1977, 66, 1-19, such as acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g.
  • succinic maleic, formic, acetic, trifluoroacetic, propionic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid.
  • Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid.
  • the present invention includes within its scope all possible stoichiometric and non-stoichiometric forms.
  • certain compounds containing an acidic function such as a carboxy can be isolated in the form of their inorganic salt in which the counter ion can be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as from organic bases.
  • the compounds of formula (I) and salts thereof may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated.
  • This invention includes within its scope stoichiometric hydrates or solvates as well as compounds containing variable amounts of water and/or solvent.
  • Salts and solvates having non-pharmaceutically acceptable counter-ions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of formula (I) and their pharmaceutically acceptable salts.
  • a prodrug of a compound of formula (I) is a functional derivative of the compound which, upon administration to a patient, eventually liberates the compound of formula (I) in vivo.
  • Administration of a compound of formula (I) as a prodrug may enable the skilled artisan to do one or more of the following: (a) modify the onset of action of the compound in vivo; (b) modify the duration of action of the compound in vivo; (c) modify the transportation or distribution of the compound in vivo; (d) modify the solubility of the compound in vivo; and (e) overcome a side effect or other difficulty encountered with the compound.
  • Typical functional derivatives used to prepare prodrugs include modifications of the compound that are chemically or enzymatically cleaved in vivo. Such modifications, which include the preparation of phosphates, amides, esters, thioesters, carbonates, and carbamates, are well known to those skilled in the art.
  • compounds of formula (I) there may be some chiral carbon atoms.
  • compounds of formula (I) exist as stereoisomers.
  • the invention extends to all optical isomers such as stereoisomeric forms of the compounds of formula (I) including enantiomers, diastereoisomers and mixtures thereof, such as racemates.
  • the different stereoisomeric forms may be separated or resolved one from the other by conventional methods or any given isomer may be obtained by conventional stereoselective or asymmetric syntheses.
  • the invention also includes isotopically-labeled compounds, which are identical to those described herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 3 H, 11 C, 14 C, 18 F, 123 I and 125 I.
  • Compounds of the invention that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the present invention.
  • Isotopically-labeled compounds of the present invention for example those into which radioactive isotopes such as 3 H, 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability. 11 C and 18 F isotopes are particularly useful in PET (positron emission tomography), and 125 I isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging.
  • lsotopically labeled compounds of the invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, then substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • potencies and efficacies of the compounds of this invention for TRPM8 can be determined by reporter assay performed on the human cloned receptor as described herein.
  • Compounds of formula (I) have demonstrated antagonistic activity at the TRPM8 receptor, using the functional assay described herein.
  • Compounds of formula (I) and pharmaceutically acceptable salts thereof are therefore of use in the treatment of conditions or disorders which are mediated via the TRPM8 receptor.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof are of use in the treatment of a wide range of diseases, syndromes, and disorders, in particular for the treatment of inflammatory, pain and urological diseases or disorders, such as chronic pain, neuropathic pain including cold allodynia and diabetic neuropathy, postoperative pain, osteoarthritis, rheumatoid arthritic pain, cancer pain, neuralgia, neuropathies, algesia, nerve injury, migraine, cluster and tension headaches, ischaemia, irritable bowel syndrome, neurodegeneration, fibromyalgia, stroke, itch, psychiatric disorders including anxiety and depression and inflammatory disorders such as asthma and chronic obstructive pulmonary, or airways, disease i.e., COPD, pulmonary hypertension, anxiety, including other stress-related disorders, urological diseases or disorders
  • treatment includes prophylaxis as well as alleviation of established symptoms.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrate compositions are generally preferred. Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g.
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g.
  • lactose microcrystalline cellulose or calcium hydrogen phosphate
  • tabletting lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium starch glycollate
  • acceptable wetting agents e.g. sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e.g. lecithin or acacia), non-aqueous vehicles (which may include edible oils e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils), preservatives (e.g.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound or pharmaceutically acceptable salt thereof.
  • fluid unit dosage forms are prepared utilising a compound of formula (I) or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose, utilising a compound of formula (I) or pharmaceutically acceptable salt thereof and a sterile vehicle, optionally with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds of formula (I) or pharmaceutically acceptable salts may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds of formula (I) or pharmaceutically acceptable salts may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compounds formula (I) or pharmaceutically acceptable salts thereof may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.
  • compounds of formula (I) or pharmaceutically acceptable salts thereof may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Ointments for administration to the eye may be manufactured in a sterile manner using sterilized components.
  • a TRPM8 antagonist may be usefully combined with another pharmacologically active compound, or with two or more other pharmacologically active compounds, particularly in the treatment of inflammatory, pain and urological diseases or disorders.
  • a TRPM8 antagonist particularly a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as defined above, may be administered simultaneously, sequentially or separately in combination with one or more agents selected from: - an opioid analgesic, e.g.
  • morphine heroin, hydromorphone, oxymorphone, levorphanol, levallorphan, methadone, meperidine, fentanyl, cocaine, codeine, dihydrocodeine, oxycodone, hydrocodone, propoxyphene, nalmefene, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine or pentazocine; - a nonsteroidal antiinflammatory drug (NSAID), e.g.
  • NSAID nonsteroidal antiinflammatory drug
  • dextromethorphan (+)-3-hydroxy-N-methylmorphinan) or its metabolite dextrorphan ((+)-3-hydroxy-N-methylmorphinan), ketamine, memantine, pyrroloquinoline quinine, cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid, budipine, EN-3231 (MorphiDex (registered trademark), a combination formulation of morphine and dextromethorphan), topiramate, neramexane or perzinfotel including an NR2B antagonist, e.g.
  • doxazosin tamsulosin, clonidine, guanfacine, dexmetatomidine, modafinil, or 4-amino-6,7-dimethoxy-2-(5-methane-sulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline;
  • a tricyclic antidepressant e.g. desipramine, imipramine, amitriptyline or nortriptyline
  • an anticonvulsant e.g.
  • a tachykinin (NK) antagonist particularly an NK-3, NK-2 or NK-1 antagonist, e.g. (alphaR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]-naphthyridine-6-13-dione (TAK-637), 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-4-morpholinyl]-methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one (MK-869), aprepitant, lanepitant, dapitant or 3-[[[
  • resinferatoxin or antagonist (e.g. capsazepine); - a beta-adrenergic such as propranolol; - a local anaesthetic such as mexiletine; - a corticosteroid such as dexamethasone; - a 5-HT receptor agonist or antagonist, particularly a 5-HT 1B/1D agonist such as eletriptan, sumatriptan, naratriptan, zolmitriptan or rizatriptan; - a 5-HT 2A receptor antagonist such as R(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol (MDL-100907); - a cholinergic (nicotinic) analgesic, such as ispronicline (TC-1734), (E)-N-methyl-4-(3-pyridinyl)-3-buten-1-amine (R
  • composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • the dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors.
  • a therapeutically effective amount of a compound of formula (I) or a pharmaceutical composition thereof includes a dose range from about 0.05 mg to about 3000 mg, in particular from about 1 mg to about 1000 mg or, more particularly, from about 10 mg to about 500 mg of active ingredient in a regimen of about once a day or more than once a day, for example two, three or four times a day for an average (70 kg) human; although, it is apparent to one skilled in the art that the therapeutically effective amount for active compounds of the invention will vary as will the diseases, syndromes, conditions, and disorders being treated.
  • a pharmaceutical composition is preferably provided in the form of tablets containing about 0.01, about 10, about 50, about 100, about 150, about 200, about 250, and about 500 milligrams of the inventive compound as the active ingredient.
  • a compound of formula (I) may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three and four times daily.
  • Optimal dosages of a compound of formula (I) to be administered may be readily determined and will vary with the particular compound used, the mode of administration, the strength of the preparation, and the advancement of the disease, syndrome, condition, or disorder.
  • factors associated with the particular subject being treated including subject age, weight, diet and time of administration, will result in the need to adjust the dose to achieve an appropriate therapeutic level.
  • Compounds of formula (I) may be administered in any of the foregoing compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever use of a compound of formula (I) is required for a subject in need thereof.
  • the compounds of formula (I) are useful in methods for treating and preventing a disease, a syndrome, a condition, or a disorder in a subject, including an animal, a mammal and a human in which the disease, the syndrome, the condition, or the disorder is affected by the modulation of TRPM8 receptors.
  • Such methods comprise, consist of, and consist essentially of administering to a subject, including an animal, a mammal, and a human in need of such treatment or prevention a therapeutically effective amount of a compound, salt, or solvate of formula (I).
  • the compounds of formula (I) are useful for preventing or treating pain, or diseases, syndromes, conditions, or disorders causing such pain, or pulmonary or vascular dysfunction. More particularly, the compounds of formula (I) are useful for preventing or treating inflammatory pain, inflammatory hypersensitivity conditions, neuropathic pain, anxiety, depression, and cardiovascular disease aggravated by cold, including peripheral vascular disease, vascular hypertension, pulmonary hypertension, Raynaud's disease, and coronary artery disease, by administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I).
  • inflammatory pain examples include pain due to a disease, condition, syndrome, disorder, or a pain state including inflammatory bowel disease, visceral pain, migraine, post operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, sinus headache, tension headache, or arachnoiditis.
  • inflammatory bowel disease visceral pain, migraine, post operative pain, osteoarthritis
  • inflammatory hyperalgesia which can be further distinguished as inflammatory somatic hyperalgesia or inflammatory visceral hyperalgesia.
  • Inflammatory somatic hyperalgesia can be characterized by the presence of an inflammatory hyperalgesic state in which a hypersensitivity to thermal, mechanical and/or chemical stimuli exists.
  • Inflammatory visceral hyperalgesia can also be characterized by the presence of an inflammatory hyperalgesic state, in which an enhanced visceral irritability exists.
  • inflammatory hyperalgesia examples include a disease, syndrome, condition, disorder, or pain state including inflammation, osteoarthritis, rheumatoid arthritis, back pain, joint pain, abdominal pain, musculoskeletal diseases, skin diseases, post operative pain, headaches, toothache, burn, sunburn, insect sting, neurogenic bladder, urinary incontinence, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, enteritis, irritable bowel syndrome, inflammatory bowel diseases including Crohn's Disease or ulcerative colitis.
  • a disease, syndrome, condition, disorder, or pain state including inflammation, osteoarthritis, rheumatoid arthritis, back pain, joint pain, abdominal pain, musculoskeletal diseases, skin diseases, post operative pain, headaches, toothache, burn, sunburn, insect sting, neurogenic bladder, urinar
  • One embodiment of the present invention is directed to a method for treating inflammatory somatic hyperalgesia in which a hypersensitivity to thermal, mechanical and/or chemical stimuli exists, comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of formula (I).
  • a further embodiment of the present invention is directed to a method for treating inflammatory visceral hyperalgesia in which a enhanced visceral irritability exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound, salt or solvate of formula (I).
  • a further embodiment of the present invention is directed to a method for treating neuropathic cold allodynia in which a hypersensitivity to a cooling stimuli exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound, salt or solvate of formula (I).
  • Examples of an inflammatory hypersensitivity condition include urinary incontinence, benign prostatic hypertrophy, cough, asthma, rhinitis and nasal hypersensitivity, itch, contact dermatitis and/ or dermal allergy, and chronic obstructive pulmonary disease.
  • a neuropathic pain examples include pain due to a disease, syndrome, condition, disorder, or pain state including cancer, neurological disorders, spine and peripheral nerve surgery, brain tumor, traumatic brain injury (TBI), spinal cord trauma, chronic pain syndrome, fibromyalgia, chronic fatigue syndrome, neuralgias (trigeminal neuralgia, glossopharyngeal neuralgia, postherpetic neuralgia and causalgia), lupus, sarcoidosis, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, central pain, neuropathies associated with spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, multiple sclerosis, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, oral neuropathic pain, Charcot's pain, complex regional pain syndrome I and II (CRPS I/II), radiculopathy, Guillain-Barre
  • neuropathic cold allodynia which can be characterized by the presence of a neuropathy-associated allodynic state in which a hypersensitivity to cooling stimuli exists.
  • neuropathic cold allodynia include allodynia due to a disease, condition, syndrome, disorder or pain state including neuropathic pain or neuralgia, pain arising from spine and peripheral nerve surgery or trauma, traumatic brain injury (TBI), trigeminal neuralgia, postherpetic neuralgia, causalgia, peripheral neuropathy, diabetic neuropathy, central pain, stroke, peripheral neuritis, polyneuritis, complex regional pain syndrome I and II (CRPS I/II) and radiculopathy.
  • TBI traumatic brain injury
  • anxiety examples include social anxiety, post traumatic stress disorder, phobias, social phobia, special phobias, panic disorder, obsessive compulsive disorder, acute stress, disorder, separation anxiety disorder, and generalized anxiety disorder.
  • depression examples include major depression, bipolar disorder, seasonal affective disorder, post natal depression, manic depression, and bipolar depression.
  • bases are likewise no particular restriction on the nature of the bases used, and any base commonly used in reactions of this type may equally be used here.
  • bases include: alkali metal hydroxides, such as lithium hydroxide, sodium hydroxide, potassium hydroxide, and barium hydroxide; alkali metal hydrides, such as lithium hydride, sodium hydride, and potassium hydride; alkali metal alkoxides, such as sodium methoxide, sodium ethoxide, and potassium t-butoxide; alkali metal carbonates, such as lithium carbonate, sodium carbonate, potassium carbonate, and cesium carbonate; alkali metal hydrogencarbonates, such as lithium hydrogencarbonate, sodium hydrogencarbonate, and potassium hydrogencarbonate; amines, such as N-methylmorpholine, triethylamine, tripropylamine, tributylamine, diisopropylethylamine, N-methylpiperidine, pyridine, 4-pyrrolidinopyridine, picoline,
  • the reactions are normally and preferably effected in the presence of inert solvent.
  • solvent there is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve reagents, at least to some extent.
  • Suitable solvents include, but not limited to: halogenated hydrocarbons, such as dichloromethane, chloroform, carbon tetrachloride, and dichloroethane; ethers, such as diethyl ether, diisopropyl ether, THF, and dioxane; aromatic hydrocarbons, such as benzene, toluene and nitrobenzene; amides, such as, DMF, N,N-dimethylacetamide, and hexamethylphosphoric triamide; amines, such as N-methylmorpholine, triethylamine, tripropylamine, tributylamine, diisopropylethylamine, N-methylpiperidine, pyridine, 4-pyrrolidinopyridine, N,N-dimethylaniline, and N,N-diethylaniline; alcohols, such as methanol, ethanol, propanol, isopropanol, and butanol; n
  • solvents including but not limited to DMF, DMSO, THF, diethylether, diisopropylether, dimethoxyethane, acetonitrile, dichloromethane, dichloroethane and chloroform are preferred.
  • Flash column chromatography was carried out using Merck silica gel 60 (230-400 mesh ASTM) or Fuji Silysia Chromatorex (registered trademark) DU3050 (Amino Type, 30-50 micrometer) or Biotage silica (32-63 mm, KP-Sil) or Biotage amino bounded silica (35-75 mm, KP-NH).
  • HPLC("Process B") The purification using HPLC("Process B") was performed by the following apparatus and conditions: Apparatus; UV-trigger preparative HPLC system, Waters (Column; XTerra MS C18, 5 micrometer, 19 x 50 mm or 30 x 50 mm), Detector; UV 254 nm, Conditions; acetonitrile:0.05% formic acid aqueous solution or acetonitrile:0.01% aqueous ammonia solution; 20 mL/min (19 x 50 mm) or 40 mL/min (30 x 50 mm) at room temperature.
  • ESI mass spectral data
  • microL microliter(s)
  • microg microgram(s)
  • M mol(s) per liter
  • L liter
  • mL milliliter
  • g gram(s)
  • mg milligram(s)
  • mol molecular weight
  • millimoles Chemical symbols have their usual meanings; microL (microliter(s)), microg (microgram(s)), M (mol(s) per liter), L(liter(s)), mL (milliliter(s)), g (gram(s)), mg(milligram(s)), mol (moles), mmol (millimoles).
  • Method A Apparatus: Waters Acquity Ultra Performance LC on TUV Detector and ZQ mass spectrometer Column: XTerra MS C18 3.5 micrometer, 2.1x30 mm Column Temperature: 45 o C Solvents: A1: acetonitrile B1: 5 mM ammonium acetate aqueous solution
  • Method B Apparatus: Waters Acquity Ultra Performance LC on TUV Detector and ZQ mass spectrometer Column: XTerra MS C18 3.5micrometer, 2.1x30 mm Column Temperature: 45 o C Solvents: A1: acetonitrile B1: 5 mM ammonium acetate aqueous solution
  • Method C Apparatus: Waters Acquity Ultra Performance LC on TUV Detector and ZQ mass spectrometer Column: Waters ACQUITY C18, 2.1x100mm, 1.7 micrometer particle Column Temperature: 60 o C Solvents: A1: 10 mM ammonium acetate aqueous solution B1: Acetonitrile
  • Method D Apparatus: Waters Alliance HPLC system on ZQ mass spectrometer and UV detector Column: Waters SunFire C18 2.1x50mm, 3.5 micrometer particle Column Temperature: 40 o C Solvents: A: Water (Mili-Q) B: Acetonitrile C: 1% formic acid aqueous solution D: 1% ammonia aqueous solution
  • Method E Apparatus: Waters Alliance HPLC system on ZQ mass spectrometer and UV detector Column: Waters XBridge C18 2.1x50mm, 3.5 micrometer particle Column Temperature: 40 o C Solvents: A: Water (Mili-Q) B: acetonitrile C: 1% formic acid aqueous solution D: 1% ammonia aqueous solution
  • Ar 1 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, Y, m, n, p, and q are as previously defined for sulfamoyl benzoic acid derivatives of the formula (I) unless otherwise stated.
  • the compounds of formula (IV) can be prepared by sulfonylation of the compound of formula (III) with the compound of formula (II) under, for example, known sulfonylation conditions in the presence of a base in an inert solvent.
  • a preferred base is selected from, for example, but not limited to: an alkali or alkaline earth metal hydroxide, alkoxide, carbonate, halide or hydride, such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium tert-butoxide, sodium carbonate, potassium carbonate, potassium fluoride, sodium hydride or potassium hydride; or an amine such as triethylamine, tributylamine, diisopropylethylamine, 2,6-lutidine, pyridine or dimethylaminopyridine.
  • an alkali or alkaline earth metal hydroxide, alkoxide, carbonate, halide or hydride such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium tert-butoxide, sodium carbonate, potassium carbonate, potassium fluoride, sodium hydride or potassium hydride
  • an amine such as triethylamine,
  • Suitable inert aqueous or non-aqueous organic solvents include: alcohols, such as methanol or ethanol; ethers, such as THF or 1,4-dioxane; acetone; dimethylformamide; halogenated hydrocarbons, such as DCM, 1,2-dichloroethane or chloroform; and pyridine; or mixtures thereof.
  • the reaction can be carried out at a temperature in the range of from -10 o C to 150 o C, preferably in the range of from 20 o C to 60 o C. Reaction times are, in general, from 10 minutes to 4 days, preferably from 30 minutes to 24 hrs.
  • a compound of formula (I) can be prepared by N-substitution reaction of a compound of formula (IV) with alkyl halide (V) in the presence of a base in an inert solvent.
  • Suitable bases include: potassium carbonate, sodium carbonate and cesium carbonate.
  • suitable solvents include: 1,4-dioxane, acetonitrile, DMSO and DMF.
  • This reaction can be carried out in the presence of a suitable additive agent.
  • additive agents include: sodium iodide and potassium iodide.
  • the reaction can be carried out at a temperature of from 20 o C to 150 o C, more preferably from 20 o C to 100 o C. Reaction times are, in general, from 5 minutes to 96 hours, more preferably from 30 minutes to 24 hrs.
  • a compound of formula (VIII) can be prepared by N-alkylation and/or N-arylation of a compound of formula (VII) with a compound of formula (VI) in the presence of a base in an inert solvent.
  • suitable bases include: potassium carbonate, sodium carbonate and cesium carbonate.
  • suitable solvents include: 1,4-dioxane, acetonitrile, DMSO and DMF.
  • the reaction can be carried out at a temperature of from 0 o C to 200 o C, more preferably from 20 o C to 160 o C. Reaction times are, in general, from 5 minutes to 96 hrs, more preferably from 30 minutes to 24 hrs. In an alternative case, the reaction can be carried out with microwave system in the presence of a same base in a same inert solvent. The reaction can be carried out at a temperature in the range of from 100 o C to 200 o C, preferably in the range of from 120 o C to 150 o C. Reaction times are, in general, from 10 minutes to 5 hrs, preferably from 15 minutes to 3 hr.
  • Step B-b a compound of formula (I) can be prepared from a compound of formula (VIII) by the method described in Step A-a above.
  • a preferred inert solvent is pyridine.
  • the reaction can be carried out at a temperature in the range of from 100 o C to 150 o C, preferably in the range of from 110 o C to 140 o C. Reaction times are, in general, from 10 minutes to 4 days, preferably from 24 hrs to 48 hrs.
  • Step C-a a compound of formula (IX) can be prepared from a compound of formula (VII) by the method described in Step A-a above.
  • a compound of formula (I) can be prepared from a compound of formula (IX) by the method described in Step B-a above.
  • the compound of formula ((I)-b) can be prepared by coupling of a compound of formula ((I)-a) with (C 3 -C 6 ) cycloalkyl or aryl metal reagents in water-organic co-solvent mixture under coupling conditions in the presence of a suitable transition metal catalyst and in the presence or absence of a base.
  • transition metal catalysts include: tetrakis(triphenylphosphine)palladium(0), bis(triphenylphosphine)palladium(ll) chloride, copper(0), copper(l) acetate, copper(l) bromide, copper(l) chloride, copper(l) iodide, copper(l) oxide, copper(ll) trifluoromethanesulfonate, copper(ll) acetate, copper(ll) bromide, copper(ll) chloride, copper(ll) iodide, copper(ll) oxide, copper(ll) trifluoromethanesulfonate, palladium(ll) acetate, palladium(ll) chloride, bis(acetonitrile)dichloropalladium(II), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0) and [1,1'-bis(diphenylphosphino)ferroc
  • Preferred catalysts are tetrakis(triphenylphosphine)palladium(0), bis(triphenylphosphine)palladium(ll) chloride, palladium(ll) acetate, palladium(ll) chloride, bis(acetonitrile)dichloropalladium(0), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0) and [1,1-bis(diphenylphosphino)ferrocene]palladium(ll) dichloride.
  • Suitable (C 3 -C 6 ) cycloalkyl and aryl metal reagents include, but not limited to, boronic acids such as cyclopropylboronic acid, benzene boronic acid and 4-pyridinyl boronic acid; boronic esters such as cyclopropylboronic acid pinacol ester and benzeneboronic acid pinacol ester, benzeneboronic acid neopentyl glycol ester; benzeneboronic acid N-methyldiethanolamine ester; and trifluoroborate salts such as potassium phenyltrifluoroborate.
  • boronic acids such as cyclopropylboronic acid, benzene boronic acid and 4-pyridinyl boronic acid
  • boronic esters such as cyclopropylboronic acid pinacol ester and benzeneboronic acid pinacol ester, benzeneboronic acid neopentyl glycol ester
  • suitable organic solvent for the water-organic co-solvent mixture include: THF; 1,4-dioxane; DMF; acetonitrile; alcohols, such as methanol or ethanol; halogenated hydrocarbons, such as DCM, 1,2-dichloroethane, chloroform or carbon tetrachloride; and diethylether; in the presence or absence of an aqueous base such as aqueous potassium hydroxide, sodium hydroxide, lithium hydroxide, sodium bicarbonate, sodium cabonate or potassium carbonate. This reaction can be carried out in the presence of a suitable additive agent.
  • additive agents include: triphenylphosphine, tri-tert-butylphosphine, 1,1'-bis(diphenylphosphino)ferrocene, tri-2-furylphosphine, tri-o-tolylphosphine, 2-(dichlorohexylphosphino)biphenyl, triphenylarsine, tetrabutylammonium chloride, tetrabutylammonium fluoride, lithium acetate, lithium chloride, triethylamine, potassium or sodium methoxide, sodium hydroxide, cesium carbonate, tripotassium phosphate, sodium carbonate, sodium bicarbonate, and/or sodium iodide.
  • the reaction can be carried out at a temperature of from 0 o C to 200 o C, more preferably from 20 o C to 150 o C. Reaction times are, in general, from 5 minutes to 96 hrs, more preferably from 30 minutes to 24 hrs. In an alternative case, the reaction can be carried out with microwave system in the presence of a base in an inert solvent. The reaction can be carried out at a temperature in the range of from 100 o C to 200 o C, preferably in the range of from 120 o C to 150 o C. Reaction times are, in general, from 10 minutes to 3 hrs, preferably from 15 minutes to 1 hr.
  • an amide compound of formula ((I)-d) can be prepared by coupling reaction of a compound of formula ((I)-c) with alkyl, cycloalkyl or aryl metal reagents (D-metal reagents) according to the method described in Step D-a above.
  • Suitable akyl metal regents include boronic acids such as methyl boronic acid (or trimethylboroxine), boronic esters such as tert-butyllboronic acid pinacol ester; and trifluoroborate salts such as potassium methyltrifluoroborate
  • the compound of formula ((I)-f) can be prepared by reacting the compound of formula ((I)-e) with carbon monoxide and alcohol (e.g. MeOH or EtOH) in the presence of a catalyst and/or base in an inert solvent.
  • suitable catalysts include: palladium reagents, such as palladium(II) acetate or bis(dibenzylideneacetone)palladium(II).
  • Suitable bases include: N,N-diisopropylethylamine, N-methylmorpholine or triethylamine. If desired, this reaction may be carried out in the presence or absence of an additive such as 1,1'-bis(diphenylphosphino)ferrocene, triphenylphosphine or 1,3-bis(diphenylphosphino)propane (DPPP).
  • an additive such as 1,1'-bis(diphenylphosphino)ferrocene, triphenylphosphine or 1,3-bis(diphenylphosphino)propane (DPPP).
  • Suitable solvents include: acetone; nitromethane; DMF; sulfolane; DMSO; NMP; 2-butanone; acetonitrile; halogenated hydrocarbons such as DCM, 1,2-dichloroethane or chloroform; or ethers, such as THF or 1,4-dioxane.
  • the reaction can be carried out at a temperature of from 0 o C to 200 o C, more preferably from 20 o C to 120 o C. Reaction times are, in general, from 5 minutes to 96 hrs, more preferably from 30 minutes to 24 hrs.
  • an acid compound of formula ((I)-g) can be prepared by hydrolysis of the ester compound of formula ((I)-f) in an inert solvent.
  • the hydrolysis can be carried out by conventional procedures. In a typical procedure, the hydrolysis is carried out under basic conditions, e.g. in the presence of sodium hydroxide, potassium hydroxide or lithium hydroxide.
  • Suitable solvents include, for example: alcohols such as methanol, ethanol, propanol, butanol, 2-methoxyethanol, and ethylene gylcol; ethers such as THF, DME, and 1,4-dioxane; amides such as DMF and hexamethylphospholictriamide; and sulfoxides such as DMSO.
  • Preferred solvents are methanol, ethanol, propanol, THF, DME, 1,4-dioxane, DMF, and DMSO. This reaction can be carried out at a temperature in the range of from -20 o C to 100 o C, usually from 20 o C to 65 o C for from 30 minutes to 24 hrs, usually from 60 minutes to 10 hrs.
  • an amide compound of formula ((I)-h) can be prepared by the coupling reaction of an amine compound (R 11 R 12 NH) with the acid compound of formula ((I)-g) in the presence or absence of a coupling reagent in an inert solvent. This reaction can be also carried out via activated carboxylic derivatives.
  • Suitable coupling reagents are those typically used in peptide synthesis including, for example, not limited to, phosgene, triphosgene, ethyl chloroformate, isobutyl chloroformate, diphenyl phosphoryl azide (DPPA), diethyl phosphoryl cyanide (DEPC), carbodiimides [e.g., N,N'-dicyclohexylcarbodiimide(DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI)], imidazolium derived reagents [e.g., 1, 1'-carbonyldiimidazole (CDI), 2-chloro-1, 3-dimethylimidazolidinium hexafluorophosphate (CIP)], phosphonium salts [e.g., Benzotriazol-1-yl-oxy-tris(dimethylamino)phosphonium
  • the reaction can be carried out in the presence of a base such as, 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), N,N-diisopropylethylamine, N-methylmorpholine or triethylamine.
  • a base such as, 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), N,N-diisopropylethylamine, N-methylmorpholine or triethylamine.
  • the reaction is normally and preferably effected in the presence of a solvent.
  • a solvent There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved and that it can dissolve the reagents, at least to some extent.
  • Suitable solvents include: acetone; nitromethane; DMF; N-Methyl-2-piperidone (NMP); sulfolane; DMSO; 2-butanone; acetonitrile; halogenated hydrocarbons, such as DCM, 1,2-dichloroethane, chloroform; and ethers, such as THF and 1,4-dioxane.
  • NMP N-Methyl-2-piperidone
  • sulfolane such as DCM, 1,2-dichloroethane, chloroform
  • ethers such as THF and 1,4-dioxane.
  • reaction in general, we find it convenient to carry out the reaction at a temperature of from -20 o C to 100 o C, more preferably from about 0 o C to 60 o C.
  • the time required for the reaction can also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 5 minutes to 1 week, more preferably from 30 minutes to 24 hrs, will usually suffice.
  • a compound of formula ((I)-j) can be prepared by hydrogenation of a compound of formula ((I)-i) under, for example, known hydrogenolysis conditions in the presence of a suitable metal catalyst under a hydrogen atmosphere, or in the presence of hydrogen sources such as formic acid or ammonium formate, in an inert solvent. If desired, the reaction is carried out under acidic conditions, for example, in the presence of hydrochloric acid or acetic acid.
  • a preferred metal catalyst is selected from, for example, nickel catalysts such as Raney nickel; Pd-C; palladiumhydroxide-carbon; platinumoxide; platinum-carbon; ruthenium-carbon; Fe; Zn; Sn; and SnCl 2 .
  • Suitable inert aqueous or non-aqueous organic solvents include: alcohols, such as methanol, ethanol or ammonic methanol; ethers, such as THF or 1,4-dioxane; acetone; dimethylformamide; halogenated hydrocarbons, such as DCM, 1,2-dichloroethane or chloroform; and acetic acid; or mixtures thereof.
  • the reaction can be carried out at a temperature in the range of from 20 o C to 150 o C, preferably in the range of from 20 o C to 80 o C. Reaction times are, in general, from 10 minutes to 4 days, preferably from 30 minutes to 24 hrs. This reaction can be carried out under a hydrogen atmosphere at a pressure ranging from 1 to 100 atoms, preferably from 1 to 10 atoms.
  • the compounds of formula ((I)-k) can be prepared by amidation reaction via the compound of formula ((I)-j) according to the method described in Step G-b above.
  • the compounds of formula ((I)-l) can be prepared by reduction of the compound of formula ((I)-f).
  • the reduction may be carried out in the presence of a suitable reducing agent in an inert solvent or without solvent.
  • a preferred reducing agent is selected from, for example, but not limited to, NaBH 4 , LiAIH 4 , LiBH 4 , BH 3 -complex and (iso-butyl) 2 AlH.
  • Reaction temperatures are generally in the range of from -78 o C to 100 o C, preferably in the range of from -70 o C to 60 o C.
  • Reaction times are, in general, from 1 minute to a day, preferably from 3 hrs to 12 hrs.
  • suitable solvents include: THF; 1,4-dioxane; DMF; acetonitrile; alcohols, such as methanol or ethanol, and halogenated hydrocarbons, such as DCM, 1,2-dichloroethane, chloroform or carbon tetrachloride.
  • a compound of formula ((I)-o) can be prepared from a compound of formula ((I)-m) and/or ((I)-n) by the method described in Step H-a above.
  • a compound of formula ((I)-p) can be prepared from a compound of formula ((I)-o) by the method described in Step A-a above.
  • a preferred reagent is selected from, for example, but not limited to, acid chloride such as acetyl chloride and acid anhydride such as acetic anhydride.
  • Step J-b a compound of formula ((I)-q) can be prepared from a compound of formula ((I)-o) by the method described in Step A-a above.
  • E presents NH 2 the corresponding compound is prepared from a compound of formula ((I)-o) and sulfamine.
  • a compound of formula ((I)-r) can be prepared from a compound of formula ((I)-o) by the method described in Step A-a above.
  • a preferred reagent is selected from, for example, but not limited to, isocyanate reagent such as trimethylsilyl isocyanate and N-carbonyl chloride such as N,N-dimethylcarbamoyl chloride.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • Step-2 Methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1, 550 mg, 1.4 mmol) was dissolved into DMF (5 mL). To the mixture were added K 2 CO 3 (2.1 g, 15.0 mmol) and benzyl bromide (1.7 g, 10.0 mmol) at room temperature. The mixture was refluxed for 18 hrs.
  • Step-3 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • Step-2 4-(N-Benzyl-N-(3-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • step-1 of Example 2 To a solution of N-benzyl-3-(trifluoromethyl)pyridin-2-amine (step-1 of Example 2, 40 mg; 0.16 mmol) in pyridine (1 mL) was added 4-(chlorosulfonyl)benzoic acid (350 mg, 1.6 mmol) at room temperature. The reaction mixture was stirred at 80 o C for 2 hrs. After the reaction mixture was cooled to room temperature, DMAP (3.9 mg, 0.03 mmol) was added to the mixture. The reaction mixture was refluxed with stirring for 2 days. After the reaction mixture was cooled to room temperature, the reaction was quenched with sat. NaHCO 3 aqueous solutions and the product was extracted with DCM.
  • Step-2 N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide
  • Step-1 tert-Butyl 2-(N-(3-(trifluoromethyl)phenyl)phenylsulfonamido)acetate
  • Step-2 2-(N-(3-(Trifluoromethyl)phenyl)phenylsulfonamido)acetic acid
  • Step-3 N-(2-(4-Methylpiperazin-1-yl)-2-oxoethyl)-N-(3-(trifluoromethyl)phenyl)benzenesulfonamide
  • step-2 of Example 1 To a solution of methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 1, 40 mg, 0.08 mmol) in THF (1 mL) was added lithium alminium hydride (3.1 mg, 0.08 mmol) at room temperature. After being stirred at room temperature for 30 min, EtOAc was added to the reaction mixture. H 2 O and 2 M NaOH aqueous solution were added carefully until forming white precipitate. MgSO 4 was added to the suspension. After being filtered off, the filtrate was concentrated in vacuo.
  • Example 5 Prepared as in Example 5 - step-3 from 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid (Example 1) and ammonium chloride.
  • Example 5 Prepared as in Example 5 - step-3 from 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid (Example 1) and methyl amine.
  • Example 5 Prepared as in Example 5 - step-3 from 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid (Example 1) and dimethyl amine.
  • Example 5 Prepared as in Example 5 - step-3 from 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid (Example 1) and ethanolamine.
  • Step-2 Methyl 4-(N-benzyl-N-(5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • Step-3 4-(N-Benzyl-N-(5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoate
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxybenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-methoxybenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxybenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxybenzyl)sulfamoyl)benzoate (step-1 of Example 16).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-fluorobenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoate (step-1 of Example 17).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(4-(tert-butyl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-(tert-butyl)benzene;
  • Step-2 4-(N-(4-tert-Butylbenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-(tert-butyl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 18).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-cyclohexylethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and (2-bromoethyl)cyclohexane;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-cyclohexylethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-cyclohexylethyl)sulfamoyl)benzoate (step-1 of Example 19).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-fluorobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-2-fluorobenzene;
  • Step-2 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-fluorobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-fluorobenzyl)sulfamoyl)benzoate (step-1 of Example 20).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-benzyl-N-(4-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 14 from methyl 4-(N-benzylsulfamoyl)benzoate (step-1 of Example 14) and 2-chloro-4-(trifluoromethyl)pyridine;
  • Step-2 4-(N-Benzyl-N-(4-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(4-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 21).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-benzyl-N-(6-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 14 from methyl 4-(N-benzylsulfamoyl)benzoate (step-1 of Example 14) and 2-chloro-6-(trifluoromethyl)pyridine;
  • Step-2 4-(N-Benzyl-N-(6-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(6-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 22).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(chloromethyl)-3-(trifluoromethyl)benzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 23).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-methoxybenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-3-methoxybenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-methoxybenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-methoxybenzyl)sulfamoyl)benzoate (step-1 of Example 24).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethoxy)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-3-(trifluoromethoxy)benzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethoxy)benzyl)sulfamoyl)benzoate (step-1 of Example 25).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,4-difluorobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-2,4-difluorobenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,4-difluorobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,4-difluorobenzyl)sulfamoyl)benzoate (step-1 of Example 26).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methylbenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-methylbenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methylbenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methylbenzyl)sulfamoyl)benzoate (step-1 of Example 27).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-isopropylbenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(chloromethyl)-4-isopropylbenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-isopropylbenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-isopropylbenzyl)sulfamoyl)benzoate (step-1 of Example 28).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopropylmethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and (bromomethyl)cyclopropane;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopropylmethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopropylmethyl)sulfamoyl)benzoate (step-1 of Example 29).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(2-bromoethoxy)-4-fluorobenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoate (step-1 of Example 30).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(chloromethyl)-2-(trifluoromethyl)benzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 31).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-chlorobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-chloro-4-(chloromethyl)benzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-chlorobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-chlorobenzyl)sulfamoyl)benzoate (step-1 of Example 32).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyanobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(bromomethyl)benzonitrile;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyanobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyanobenzyl)sulfamoyl)benzoate (step-1 of Example 33).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 3-methylpyridin-2-amine in the presence of DMAP (0.2 eq.);
  • Step-2 Methyl 4-(N-benzyl-N-(3-methylpyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 34) and (bromomethyl)benzene;
  • Step-3 4-(N-Benzyl-N-(3-methylpyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-methylpyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 34).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 3,5-dichloropyridin-2-amine in the presence of DMAP (0.2 eq.);
  • Step-2 Methyl 4-(N-benzyl-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and (bromomethyl)benzene;
  • Step-3 4-(N-Benzyl-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 35).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-methylpyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 3-chloro-5-methylpyridin-2-amine in the presence of DMAP (0.2 eq.);
  • Step-2 Methyl 4-(N-benzyl-N-(3-chloro-5-methylpyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 36) and (bromomethyl)benzene;
  • Step-3 4-(N-Benzyl-N-(3-chloro-5-methylpyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-methylpyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 36).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloropyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 3-chloropyridin-2-amine in the presence of DMAP (0.2 eq.);
  • Step-2 Methyl 4-(N-benzyl-N-(3-chloropyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 37) and (bromomethyl)benzene;
  • Step-3 4-(N-Benzyl-N-(3-chloropyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 37).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 5-chloro-3-methylpyridin-2-amine in the presence of DMAP (0.2 eq.);
  • Step-2 Methyl 4-(N-benzyl-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and (bromomethyl)benzene;
  • Step-3 4-(N-Benzyl-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 38).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-(trifluoromethyl)benzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 39).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(2-chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-2-chloro-4-fluorobenzene;
  • Step-2 4-(N-(2-Chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(2-chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 40).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(2,2,2-trifluoroethoxy)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-(2,2,2-trifluoroethoxy)benzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(2,2,2-trifluoroethoxy)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(2,2,2-trifluoroethoxy)benzyl)sulfamoyl)benzoate (step-1 of Example 41).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,5-difluorobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-3,5-difluorobenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,5-difluorobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,5-difluorobenzyl)sulfamoyl)benzoate (step-1 of Example 42).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(bromomethyl)-1-fluoro-2-(trifluoromethyl)benzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 43).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,6-difluorobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 2-(bromomethyl)-1,3-difluorobenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,6-difluorobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,6-difluorobenzyl)sulfamoyl)benzoate (step-1 of Example 44).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-difluorobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(bromomethyl)-1,2-difluorobenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-difluorobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-difluorobenzyl)sulfamoyl)benzoate (step-1 of Example 45).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,5-difluorobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 2-(bromomethyl)-1,4-difluorobenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,5-difluorobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,5-difluorobenzyl)sulfamoyl)benzoate (step-1 of Example 46).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-dichlorobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(bromomethyl)-1,2-dichlorobenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-dichlorobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-dichlorobenzyl)sulfamoyl)benzoate (step-1 of Example 47).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-chlorobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-3-chlorobenzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-chlorobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-chlorobenzyl)sulfamoyl)benzoate (step-1 of Example 48).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(chloromethyl)-4-(1-methylcyclopropyl)benzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoate (step-1 of Example 49).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(chloromethyl)-4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzyl)sulfamoyl)benzoate (step-1 of Example 50).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethoxy)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-2-(trifluoromethoxy)benzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethoxy)benzyl)sulfamoyl)benzoate (step-1 of Example 51).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 3-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • THF THF
  • 3-chloro-5-(trifluoromethyl)pyridin-2-amine 500 mg, 2.54 mmol
  • stirred at room temperature for 1 h to the mixture was added methyl 3-(chlorosulfonyl)benzoate (597 mg, 2.54 mmol) at 0 o C and stirred at room temperature for 2 hrs.
  • Step-2 Methyl 3-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 3-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 52) and (bromomethyl)benzene;
  • Step-3 3-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 3-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 52).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 3-fluoro-5-(trifluoromethyl)pyridin-2-amine;
  • Step-2 Methyl 4-(N-benzyl-N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 53) and (bromomethyl)benzene;
  • Step-3 4-(N-Benzyl-N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-Benzyl-N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 53).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(bromomethyl)-4-(trifluoromethyl)benzene;
  • Step-2 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 54).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-(trifluoromethyl)benzene;
  • Step-2 4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 55).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 2-chloro-4-(trifluoromethyl)aniline in the presence of DMAP (0.2 eq.);
  • Step-2 Methyl 4-(N-benzyl-N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoate (step-1 of Example 56) and (bromomethyl)benzene;
  • Step-3 4-(N-Benzyl-N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoate (step-2 of Example 56).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-morpholinoethyl)sulfamoyl)benzoic acid
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 2-(bromomethyl)pyridine hydrobromide;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoate (step-1 of Example 58).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-phenylpropyl)sulfamoyl)benzoate
  • step-1 of Example 1 To a mixture of methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1, 30 mg, 0.076 mmol) and (3-bromopropyl)benzene (30 mg, 0.152 mmol) in DMF (0.6 mL) were added Cs 2 CO 3 (99 mg, 0.304 mmol) and NaI (11 mg, 0.076 mmol) at room temperature. The mixture was irradiated with micro-wave (150 o C, 30 min). The mixture was acidified by 2 M aqueous HCl solution, extracted with DCM, dried over Na 2 SO 4 , filtered and concentrated. The residue was used next step without purification.
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-phenylpropyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-phenylpropyl)sulfamoyl)benzoate (step-1 of Example 59).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 4-(bromomethyl)-1-fluoro-2-(trifluoromethyl)benzene.
  • Step-2 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 60).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(bromomethyl)-4-fluorobenzene.
  • Step-2 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoate (step-1 of Example 61).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(4-chloro-3-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 4-(bromomethyl)-1-chloro-2-fluorobenzene.
  • Step-2 4-(N-(4-Chloro-3-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-chloro-3-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 62).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(bromomethyl)-4-(trifluoromethoxy)benzene.
  • Step-2 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoate (step-1 of Example 63).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(bromomethyl)-2-(trifluoromethyl)benzene.
  • Step-2 4-(N-(3,5-Dichloropyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 64).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(4-chloro-3-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(bromomethyl)-1-chloro-2-fluorobenzene.
  • Step-2 4-(N-(4-Chloro-3-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-chloro-3-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 65).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(4-chloro-3-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 4-(bromomethyl)-1-chloro-2-(trifluoromethyl)benzene.
  • Step-2 4-(N-(4-Chloro-3-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-chloro-3-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 66).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(3-fluoro-4-methylbenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 4-(bromomethyl)-2-fluoro-1-methylbenzene.
  • Step-2 4-(N-(3,5-Dichloropyridin-2-yl)-N-(3-fluoro-4-methylbenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(3-fluoro-4-methylbenzyl)sulfamoyl)benzoate (step-1 of Example 67).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-methyl-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 4-(bromomethyl)-1-methyl-2-(trifluoromethyl)benzene.
  • Step-2 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-methyl-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-methyl-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 68).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-4-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 4-(bromomethyl)-2-chloro-1-fluorobenzene.
  • Step-2 4-(N-(3-Chloro-4-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-4-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 69).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(chloromethyl)-4-(1-methylcyclopropyl)benzene.
  • Step-2 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoate (step-1 of Example 70).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(bromomethyl)-2-chloro-1-fluorobenzene.
  • Step-2 4-(N-(3-chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 71).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(4-chloro-2-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(bromomethyl)-4-chloro-2-(trifluoromethyl)benzene.
  • Step-2 4-(N-(4-Chloro-2-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-chloro-2-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 72).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(2-bromoethoxy)-4-fluorobenzene.
  • Step-2 4-(N-(3,5-Dichloropyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoate.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(4-(chloromethyl)phenyl)pyrrolidin-2-one.
  • Step-2 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoate (step-1 of Example 74).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(4-chloro-2-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and 1-(bromomethyl)-4-chloro-2-(trifluoromethyl)benzene.
  • Step-2 4-(N-(4-Chloro-2-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-chloro-2-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 75).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and 4-(bromomethyl)-1-fluoro-2-(trifluoromethyl)benzene.
  • Step-2 4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 76).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(3-chloro-4-fluorobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and 4-(bromomethyl)-2-chloro-1-fluorobenzene.
  • Step-2 4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(3-chloro-4-fluorobenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(3-chloro-4-fluorobenzyl)sulfamoyl)benzoate (step-1 of Example 77).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and 1-(bromomethyl)-4-(trifluoromethoxy)benzene.
  • Step-2 4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoate (step-1 of Example 78).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(4-chloro-3-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and 4-(bromomethyl)-1-chloro-2-(trifluoromethyl)benzene.
  • Step-2 4-(N-(4-Chloro-3-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-chloro-3-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 79).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and 1-(4-(bromomethyl)phenyl)pyrrolidin-2-one.
  • Step-2 4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoate (step-1 of Example 80).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)-N-(2-morpholinoethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 59 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(2-chloroethyl)morpholine hydrochloride;
  • Step-2 4-(N-(2-Chloro-4-(trifluoromethyl)phenyl)-N-(2-morpholinoethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)-N-(2-morpholinoethyl)sulfamoyl)benzoate (step-1 of Example 81).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 2-(bromomethyl)pyridine hydrobromide;
  • Step-2 4-(N-(2-Chloro-4-(trifluoromethyl)phenyl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoate.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)-N-(2-(piperidin-1-yl)ethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 59 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(2-chloroethyl)piperidine hydrochloride.
  • Step-2 4-(N-(2-Chloro-4-(trifluoromethyl)phenyl)-N-(2-(piperidin-1-yl)ethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)-N-(2-(piperidin-1-yl)ethyl)sulfamoyl)benzoate.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Examples 84-139 were selected from commercially available compounds.
  • Example 140 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trimethylsilyl)benzyl)sulfamoyl)benzoic acid
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trimethylsilyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 1 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate and (4-(bromomethyl)phenyl)trimethylsilane;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trimethylsilyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-3 of Example 1 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trimethylsilyl)benzyl)sulfamoyl)benzoate (step-1 of Example 140).
  • the further purification was carried out by preparative LC-MS system using the condition in Table 6.
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-cyanocyclopropyl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 1 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate and 1-(4-(bromomethyl)phenyl)cyclopropanecarbonitrile;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-cyanocyclopropyl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-3 of Example 1 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-cyanocyclopropyl)benzyl)sulfamoyl)benzoate (step-1 of Example 141).
  • the further purification was carried out by preparative LC-MS system using the condition in Table 6.
  • Example 142 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoic acid
  • Step-1 Methyl 4-(N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate and (1-(pyridin-2-yl)piperidin-4-yl)methanamine hydrochloride;
  • Step-2 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoate (step-1 of Example 142);
  • Step-3 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoate (step-2 of Example 142).
  • the further purification was carried out by preparative LC-MS system using the condition in Table 6.
  • Step-1 methyl 4-(N-benzylsulfamoyl)-2-methylbenzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from N-benzyl-4-bromo-3-methylbenzenesulfonamide;
  • Step-2 Methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-methylbenzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-benzylsulfamoyl)-2-methylbenzoate (step-1 of Example 143);
  • Step-3 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-methylbenzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-methylbenzoate (step-2 of Example 143).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-6-hydroxypyridine-3-sulfonamide
  • step-2 A mixture of N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-6-methoxypyridine-3-sulfonamide (step-2 of Example 189, 166.9 mg, 0.365 mmol), 4 M HCl in 1,4-dioxane solution (0.18 mL, 0.729 mmol) in 1,4-dioxane (2 mL) was heated at 55 o C overnight.
  • the titled compound was prepared according to the procedure described in step-3 of Example 188 from N-benzyl-4-bromo-2-methylbenzenesulfonamide;
  • Step-2 Methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methylbenzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-benzylsulfamoyl)-3-methylbenzoate (step-1 of Example 145);
  • Step-3 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methylbenzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methylbenzoate (step-2 of Example 145).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-3 of Example 188 from N-benzyl-4-bromo-2-methoxybenzenesulfonamide;
  • Step-2 Methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methoxybenzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-benzylsulfamoyl)-3-methoxybenzoate (step-1 of Example 146);
  • Step-3 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methoxybenzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methoxybenzoate (step-2 of Example 146).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Ethyl 2-(4-(N-benzylsulfamoyl)phenyl)acetate
  • the titled compound was prepared according to the procedure described in step-1 of Example148 from ethyl 2-(4-(chlorosulfonyl)phenyl)acetate and benzylamine;
  • Step-2 Ethyl 2-(4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)phenyl)acetate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from ethyl 2-(4-(N-benzylsulfamoyl)phenyl)acetate (step-1 of Example 147) and 2,3-dichloro-5-(trifluoromethyl)pyridine;
  • Step-3 2-(4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)phenyl)acetic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from 2-(4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)phenyl)acetate (step-2 of Example 147).
  • Step-2 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-phenethylsulfamoyl)benzoate
  • Step-3 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-phenethylsulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-phenethylsulfamoyl)benzoate (step-2 of Example 148).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 52 from methyl 4-(chlorosulfonyl)benzoate and 3-bromo-5-(trifluoromethyl)pyridin-2-amine;
  • Step-2 Methyl 4-(N-benzyl-N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • Step-3 4-(N-Benzyl-N-(3-cyclopropyl-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • Example 150 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyclopropylbenzyl)sulfamoyl)benzoic acid
  • Step-1 Methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 149 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-bromo-4-(bromomethyl)benzene;
  • Step-2 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyclopropylbenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and cyclopropylboronic acid.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 149).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-benzyl-N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-Bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and 3-(1,3,2-dioxaborinan-2-yl)pyridine.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and thiophen-3-ylboronic acid.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and pyridin-4-ylboronic acid.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and furan-2-ylboronic acid.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and phenylboronic acid.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxazole.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-((6-(trifluoromethyl)pyridin-3-yl)methyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from (6-(trifluoromethyl)pyridin-3-yl)methanamine.
  • Step-2 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)sulfamoyl)benzoate
  • step-1 of Example 160 A mixture of methyl 4-( ⁇ [6-(trifluoromethyl)pyridin-3-yl]methyl ⁇ sulfamoyl)benzoate (step-1 of Example 160, 30 mg, 0.080 mmol), 2,3-dichloro-5-(trifluoromethyl)pyridine (104 mg, 0.401 mmol) and Cs 2 CO 3 (78 mg, 0.240 mmol) in DMSO (0.7 mL) was stirred at 90 o C for 3 hr. The reaction mixture was used next step without purification.
  • Step-3 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from the reaction mixture in step-2 of Example 160.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Example 161 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(picolinamido)benzyl)sulfamoyl)benzoic acid
  • Step-1 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-nitrobenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 149 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-nitrobenzene;
  • Step-2 Methyl 4-(N-(4-aminobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • Step-3 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(picolinamido)benzyl)sulfamoyl)benzoate
  • step-2 of Example 161 A mixture of methyl 4-(N-(4-aminobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 161, 75 mg, 0.15 mmol), picolinic acid (37 mg, 0.30 mmol), HBTU (114 mg, 0.30 mmol) and Et 3 N (61 mg, 0.60 mmol) in DCM was stirred at room temperature for 1 day. The mixture was quenched with sat. NaHCO 3 , extracted with DCM, dried over Na 2 SO 4 , filtered and concentrated to give the titled compound as crude.
  • Step-4 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(picolinamido)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(picolinamido)benzyl)sulfamoyl)benzoate (step-3 of Example161).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Example 162 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(6-methoxypyridin-3-yl)benzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and (6-methoxypyridin-3-yl)boronic acid.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and (6-methylpyridin-3-yl)boronic acid.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-([1,1'-biphenyl]-3-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 3-(bromomethyl)-1,1'-biphenyl.
  • Step-2 4-(N-([1,1'-Biphenyl]-3-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-([1,1'-biphenyl]-3-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 164).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-([1,1'-biphenyl]-2-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 2-(bromomethyl)-1,1'-biphenyl.
  • Step-2 4-(N-([1,1'-Biphenyl]-2-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-([1,1'-biphenyl]-2-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 165).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 (R)-Methyl 4-(N-(1-phenylethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate (step-1 of Example 1) and (R)-1-phenylethanamine;
  • Step-2 (R)-Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and (R)-methyl 4-(N-(1-phenylethyl)sulfamoyl)benzoate (step-1 of Example 166);
  • Step-3 (R)-4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from (R)-methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoate (step-2 of Example 166).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate and thiophen-2-ylmethanamine;
  • Step-2 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-2-ylmethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(thiophen-2-ylmethyl)sulfamoyl)benzoate (step-1 of Example 167);
  • Step-3 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-2-ylmethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-2-ylmethyl)sulfamoyl)benzoate (step-2 of Example 167).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(cyclohexylmethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate (step-1 of Example 1) and cyclohexylmethanamine;
  • Step-2 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclohexylmethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(cyclohexylmethyl)sulfamoyl)benzoate (step-1 of Example 168);
  • Step-3 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclohexylmethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclohexylmethyl)sulfamoyl)benzoate (step-2 of Example 168).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-2 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-phenoxybenzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(4-phenoxybenzyl)sulfamoyl)benzoate (step-1 of Example 169);
  • Step-3 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-phenoxybenzyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-phenoxybenzyl)sulfamoyl)benzoate (step-2 of Example 169).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Example 170 4-(N-(4-(1H-Pyrazol-1-yl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • Step-1 Methyl 4-(N-(4-(1H-pyrazol-1-yl)benzyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate and (4-(1H-pyrazol-1-yl)phenyl)methanamine;
  • Step-2 Methyl 4-(N-(4-(1H-pyrazol-1-yl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(4-(1H-pyrazol-1-yl)benzyl)sulfamoyl)benzoate (step-1 of Example 170);
  • Step-3 4-(N-(4-(1H-Pyrazol-1-yl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-(1H-pyrazol-1-yl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 170).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Example 171 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclobutylmethyl)sulfamoyl)benzoic acid
  • Step-1 Methyl 4-(N-(cyclobutylmethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate (step-1 of Example 1) and cyclobutylmethanamine;
  • Step-2 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclobutylmethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(cyclobutylmethyl)sulfamoyl)benzoate (step-1 of Example 171);
  • Step-3 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclobutylmethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclobutylmethyl)sulfamoyl)benzoate (step-2 of Example 171).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Example 172 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-3-ylmethyl)sulfamoyl)benzoic acid Step-1: Methyl 4-(N-(thiophen-3-ylmethyl)sulfamoyl)benzoate The titled compound was prepared according to the procedure described in step-1of Example 148 from methyl 4-(chlorosulfonyl)benzoate and thiophen-3-ylmethanamine;
  • Step-2 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-3-ylmethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(thiophen-3-ylmethyl)sulfamoyl)benzoate (step-1 of Example 172);
  • Step-3 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-3-ylmethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-3-ylmethyl)sulfamoyl)benzoate (step-2 of Example 172).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 N-benzyl-4-cyanobenzenesulfonamide
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from 4-cyanobenzene-1-sulfonyl chloride and phenylmethanamine;
  • Step-2 N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-cyanobenzenesulfonamide
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and N-benzyl-4-cyanobenzenesulfonamide (step-1 of Example 173).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(2H-tetrazol-5-yl)benzenesulfonamide
  • step-2 N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-cyanobenzenesulfonamide
  • step-2 of Example 173, 60 mg, 0.13 mmol) , NaN 3 (52 mg, 0.80 mmol), and NH 4 Cl (43 mg, 0.80 mmol) in DMF (5 mL) was heated at 110 o C overnight.
  • Step-1 N-Benzyl-4-methoxybenzenesulfonamide
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from 4-methoxybenzene-1-sulfonyl chloride and phenylmethanamine;
  • Step-2 N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-methoxybenzenesulfonamide
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and N-benzyl-4-methoxybenzenesulfonamide (step-1 of Example 175).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 4-(Aminomethyl)-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide
  • step-2 A mixture of N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-cyanobenzenesulfonamide (step-2 of Example 173, 188 mg, 0.42 mmol),and Raney Nickel (0.05 mL, Raney (registered trademark) 2800) in 1 M NH 3 in MeOH solution (20 mL) was stirred under hydrogen atmosphere for 16 hrs. The mixture was filtered through a pad of celite, washed with MeOH, the filtrate was concentrated to give a brown oil.
  • the residual oil was diluted with MeOH, applied onto a strong cation exchange cartridge (BondElute (registered trademark) SCX, 1 g/6 mL, Varian Inc.), and the solid phase matrix was rinsed with methanol (6 mL).
  • the crude mixture was eluted in a collection tube with 1 M NH 3 in MeOH (6 mL) and concentrated gave 179 mg (94% yield) of the titled compound as a clear colorless oil.
  • Step-2 N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(methylsulfonamidomethyl)benzenesulfonamide
  • Step-1 N-(4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzyl)acetamide
  • the titled compound was prepared according to the procedure described in step-2 of Example 176 from 4-(aminomethyl)-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide (step-1 of Example 176) and acetyl chloride.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(((N,N-dimethylsulfamoyl)amino)methyl)benzenesulfonamide
  • the titled compound was prepared according to the procedure described in step-2 of Example 176 from 4-(aminomethyl)-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide (step-1 of Example 176) and dimethylsulfamoyl chloride.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-((3,3-dimethylureido)methyl)benzenesulfonamide
  • the titled compound was prepared according to the procedure described in step-2 of Example 176 from 4-(aminomethyl)-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide (step-1 of Example 176) and dimethylcarbamic chloride.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 1 from 5-bromo-3-chloropyridin-2-amine and methyl 4-(chlorosulfonyl)benzoate.
  • Step-2 Methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 180) and (bromomethyl)benzene.
  • Step-3 4-(N-Benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Ethyl 4-(N-benzylsulfamoyl)-3-chlorobenzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from ethyl 3-chloro-4-(chlorosulfonyl)benzoate and phenylmethanamine;
  • Step-2 Ethyl 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-chlorobenzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and ethyl 4-(N-benzylsulfamoyl)-3-chlorobenzoate (step-1 of Example 181);
  • Step-3 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-chlorobenzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from ethyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-chlorobenzoate (step-2 of Example 181).
  • the further purification was carried out by preparative LC-MS system using the condition in Table 6.
  • Step-1 4-(N-Benzyl-N-(3-chloro-5-phenylpyridin-2-yl)sulfamoyl)benzoic acid
  • a mixture of methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180, 35 mg, 0.071 mmol), phenylboronic acid (17 mg, 0.14 mmol), Pd(PPh 3 ) 4 (8 mg, 7 micromol), and sat. NaHCO 3 (0.4 mL) in dioxane (0.8 mL) was irradiated with micro-wave (150 o C, 15 min). After cooling to room temperature, the mixture was added 2 M aqueous NaOH solution (0.5 mL), THF (1 mL), and the mixture was heated at 60 o C for 2 hrs.
  • Step-1 4-(N-Benzyl-N-(3-chloro-5-(furan-2-yl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-1 of Example 182 from methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180) and furan-2-ylboronic acid.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 4-(N-Benzyl-N-(3-chloro-5-(thiophen-3-yl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-1 of Example 182 from methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180) and thiophen-3-ylboronic acid.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 4-(N-Benzyl-N-(3-chloro-5-(2-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-1 of Example 182 from methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180) and (2-methoxyphenyl)boronic acid.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 4-(N-Benzyl-N-(3-chloro-5-(4-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-1 of Example 182 from methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180) and (4-methoxyphenyl)boronic acid.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 4-(N-Benzyl-N-(3-chloro-5-(3-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-1 of Example 182 from methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180) and (3-methoxyphenyl)boronic acid.
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from 4-bromo-3-chlorobenzene-1-sulfonyl chloride and phenylmethanamine;
  • Step-2 N-Benzyl-4-bromo-3-chloro-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and N-benzyl-4-bromo-3-chlorobenzenesulfonamide (step-1 of Example 188);
  • Step-3 Methyl 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-chlorobenzoate
  • Step-4 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-chlorobenzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-chlorobenzoate (step-3 of Example 188).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from 6-methoxypyridine-3-sulfonyl chloride and phenylmethanamine;
  • Step-2 N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-6-methoxypyridine-3-sulfonamide
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and N-benzyl-6-methoxypyridine-3-sulfonamide (step-1 of Example 189).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from 4-bromo-2-fluorobenzene-1-sulfonyl chloride and phenylmethanamine;
  • the titled compound was prepared according to the procedure described in step-3 of Example 188 from N-benzyl-4-bromo-2-fluorobenzenesulfonamide (step-1 of Example 190);
  • Step-3 Methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-fluorobenzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-benzylsulfamoyl)-3-fluorobenzoate (step-2 of Example 190);
  • Step-4 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-fluorobenzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-fluorobenzoate (step-3 of Example 190).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from 4-bromo-3-fluorobenzene-1-sulfonyl chloride and phenylmethanamine;
  • the titled compound was prepared according to the procedure described in step-3 of Example 188 from N-benzyl-4-bromo-3-fluorobenzenesulfonamide (step-1 of Example 191);
  • Step-3 Methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-fluorobenzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-benzylsulfamoyl)-2-fluorobenzoate (step-2 of Example 191);
  • Step-4 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-fluorobenzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-fluorobenzoate (step-3 of Example 191).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate and cyclopentylmethanamine;
  • Step-2 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopentylmethyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(cyclopentylmethyl)sulfamoyl)benzoate (step-1 of Example 192);
  • Step-3 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopentylmethyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopentylmethyl)sulfamoyl)benzoate (step-2 of Example 192).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • Step-1 Methyl 4-(N-(1-phenylcyclopropyl)sulfamoyl)benzoate
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate and 1-phenylcyclopropanamine, hydrochloride;
  • Step-2 Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylcyclopropyl)sulfamoyl)benzoate
  • Step-3 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylcyclopropyl)sulfamoyl)benzoic acid
  • the titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylcyclopropyl)sulfamoyl)benzoate (step-2 of Example 193).
  • the further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
  • the titled compound was prepared according to the procedure described in step-1 of Example 148 from 4-nitrobenzene-1-sulfonyl chloride and phenylmethanamine;
  • Step-2 N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-nitrobenzenesulfonamide
  • the titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and N-benzyl-4-nitrobenzenesulfonamide (step-1 of Example 194);
  • Step-3 4-Amino-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide
  • Step-4 N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-((N,N-dimethylsulfamoyl)amino)benzenesulfonamide
  • step-4 of Example 194 To a solution of 4-amino-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide (step-4 of Example 194, 25 mg, 0.057 mmol) and Et 3 N (7.44 mg, 0.074 mmol) in CH 3 CN (2 mL) was added dimethylsulfamoyl chloride (9.09 microL, 0.085 mmol) at room temperature. The resulting solution was stirred for 2 hrs at room temperature, then 70 o C for 3 hrs. The resulting mixture was concentrated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to sulfamoyl benzoic acid derivatives of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.

Description

SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS
This invention relates to sulfamoyl benzoic acid derivatives that act as modulators of the TRPM8 receptor. The present invention also relates to processes for the preparation of novel sulfamoyl benzoic acid derivatives and to their use in the treatment of a wide range of diseases, syndromes, and disorders, in particular for the treatment of inflammatory, pain and urological diseases or disorders.
Transient receptor potential (TRP) channels are one of the largest groups of ion channels, and they are divided into 6 sub-families (TRPV, TRPM, TRPA, TRPC, TRPP and TRPML). TRP channels are cation-selecive channels that are activated by a variety of physical (e.g., temperature, osmolarity, mechanical) and chemical stimuli. TRPM8 is a member of TRP channel family. The receptor was cloned in 2002 (McKemy, D.D., et al., Nature 416, 52-58, 2002; Peier, A.D., Cell 108, 705-715, 2002) and it was found to be sensitive to cold temperature and menthol, and therefore named as cold menthol receptor-1 (CMR-1). TRPM8 can sense temperature changes in the range of both innocuous cold (15-28oC) and noxious cold (<15 oC) as well as by chemical agents such as menthol and icilin.
TRPM8 is located on primary nociceptive neurons including A-delta and C-fibers and is also modulated by inflammation-mediated second messenger signals (Abe, J., et al Neurosci Lett 2006, 397(1-2), 140-144; Premkumar, L.S., et al, J. Neurosci, 2005, 25(49), 11322-11329). The localization of TRPM8 on both A-delta and C-fibers may provide a basis for abnormal cold sensitivity in pathologic conditions wherein these neurons are altered, resulting in pain, often of a burning nature (Kobayashi, K., et al, J Comp Neurol, 2005, 493(4), 596-606; Roza, C, et al. Pain, 2006, 120(1-2), 24-35; and Xing, H., et al, J Neurophysiol, 2006, 95(2), 1221-30). Gauchan et al. reported that the expression of TRPM8 in the primary afferents was increased in oxaliplatin-induced cold allodynia model in mice (Gauchan, P., et al. Neurosci Lett, 2009, 458, 93-95). Oxaliplatin, a third-generation platinum-based chemotherapy drug, induces serious sensory neurotoxicity in patients, which is aggravated by exposure to cold.
Cold intolerance and paradoxical burning sensations induced by chemical or thermal cooling closely parallel symptoms seen in a wide range of clinical disorders and thus provide a strong rationale for the development of TRPM8 modulators as novel antihyperalgesic or antiallodynic agents. TRPM8 is also known to be expressed in the brain, lung, bladder, gastrointestinal tract, blood vessels, prostate and immune cells, thereby providing the possibility for therapeutic modulation in a wide range of maladies.
International patent application WO 2006/040136 A1 from Bayer Healthcare AG purportedly describes substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (CMR-1) antagonists for the treatment of urological disorders. International patent application WO 2006/040103 A1 from Bayer Healthcare AG purportedly describes methods and pharmaceutical compositions for treatment and/or prophylaxis of respiratory diseases or disorders. An international patent application, WO 2009/012430, describes sulfonamides for the treatment of diseases associated with the cold menthol receptor (CMR), also known as TRPM8.
There is a need in the art for TRPM8 antagonists that can be used to treat a disease, syndrome, or condition in a mammal in which the disease, syndrome, or condition is affected by the modulation of TRPM8 receptors, such as chronic pain, neuropathic pain including cold allodynia and diabetic neuropathy, postoperative pain, osteoarthritis, rheumatoid arthritic pain, cancer pain, neuralgia, neuropathies, algesia, nerve injury, migraine, cluster and tension headaches, ischaemia, irritable bowel syndrome, neurodegeneration, fibromyalgia, stroke, itch, psychiatric disorders including anxiety and depression and inflammatory disorders such as asthma and chronic obstructive pulmonary, or airways, disease i.e., COPD, pulmonary hypertension, anxiety, including other stress-related disorders, urological diseases or disorders such as detrusor overactivity or overactive bladder, urinary incontinence, neurogenic detrusor overactivity or detrusor hyperflexia, idiopathic detrusor overactivity or detrusor instability, benign prostatic hyperplasia, and lower urinary tract symptoms, and combinations thereof.
TRPM8 antagonists should be well absorbed from the GI tract, be metabolically stable and possess favorable pharmacokinetic properties. They should be non-toxic. Furthermore, the ideal drug candidate will exist in a physical form that is stable, non-hygroscopic and easily formulated. In particular, it has been desired that compounds must bind potently to the TRPM8 receptor and show functional activity as antagonists. The present invention provides novel compounds which have excellent TRPM8 antagonistic activities.
The compounds of the present invention differ structurally from the cited arts above by the presence of 5 to 7 heterocyclic group at Ar1 in the formula I.
Then, WO 2009/025793 discloses sulfamoyl benzoic acid compounds. Some of the compounds are formally fallen into the claims in the patent. However, the compounds relate to human type 2 taste receptors for modulating taste perception, particularly bitter taste, which is quite different from TRPM8 receptor antagonist for the treatment of various disorders mediated via the TRPM8 receptor. Namely the sulfamoyl benzoic acid derivatives in the present invention are neither disclosed as working examples in the patent nor TRPM8 receptor antagonist activity which are useful for the treatment of various disorders mediated via the TRPM8 receptor.
The present invention provides a use of a compound of the following formula (I) for the manufacture of a medicament for the treatment of a condition or disorder mediated by TRPM8 receptor antagonistic activity
Figure JPOXMLDOC01-appb-C000001
 wherein
R1, R2, R3, R4, R5, and R6 are independently selected from the group consisting of hydrogen, C1-C4 alkyl , hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, and C3-C7 cycloalkyl; or alternatively R1 and R2, together with the atom to which they are attached, form a 3 to 6 membered ring which may contain oxygen and/or nitrogen; said ring is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, C1-C4 alkyl, and C1-C4 alkoxy; R3 and R4, together with the atom to which they are attached, form a 3 to 6 membered ring which may contain oxygen and/or nitrogen; said ring is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, C1-C4 alkyl, and C1-C4 alkoxy; R5 and R6, together with the atom to which they are attached, form a 3 to 6 membered ring which may contain oxygen and/or nitrogen; said ring is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, C1-C4 alkyl, and C1-C4 alkoxy;
m is 0 or 1;
n is 0, 1, 2 or 3;
q is 0, 1, 2 or 3;
A1, A2, A3 and A4 are independently selected from nitrogen atom and carbon atom; wherein the number of nitrogen is up to two;
Z is H, Ar2 or a substituent represented by the formula: R7N(R8)C(=O)-, in which
R7 and R8 are independently selected from hydrogen, C1-C4 alkyl, hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 alkylamino C1-C4 alkyl, di(C1-C4 alkyl)amino C1-C4 alkyl, 5 to 10 membered aryl, 5 to 10 membered aryl C0-C4 alkyl;
said aryl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C8 cycloalkyl, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, C1-C4 alkylthio, and nitro;
C3-C8 cycloalkyl, and 3 to 8 membered heterocyclyl C1-C4 alkyl;
said heterocyclyl and alkyl may have independently 1 to 4 substituents independently selected from C1-C4 alkyl and halogen;
or alternatively R7 and R8 together with nitrogen atom to which they are attached form a 4 to 8 membered ring which may contain nitrogen, oxygen or sulfur, wherein the 4 to 8 membered ring is optionally substituted with 1 to 6 substituents independently selected from the group consisting of hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C3-C7 cycloalkyl, amino, oxo, C1-C4 alkylamino, and di(C1-C4 alkyl)amino;
Ar1 is aryl, which may optionally be substituted with halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, nitro, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, cyano, hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, C1-C4 alkylsulfonyl, aminosulfonyl, C1-C4 alkyl C(=O)-, HO(O=)C-, C1-C4 alkyl-O(O=)C-, R9N(R10)C(=O)-, C1-C4 alkylsulfonylamino, C3-C7 cycloalkyl, R9C(=O)N(R10)-, NH2(HN=)C-, or 5 to 10 membered aryl C0-C4 alkyl; said aryl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C7 cycloalkyl, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, C1-C4 alkylthio, and nitro;
Ar2 is aryl, which may optionally be substituted with halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, nitro, C1-C4 alkylsilyl, di(C1-C4 alkyl)silyl, tri(C1-C4 alkyl)silyl, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, cyano, hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, C1-C4 alkylsulfonyl, aminosulfonyl, C1-C4 alkyl C(=O)-, HO(O=)C-, C1-C4 alkyl-O(O=)C-, R9N(R10)C(=O)-, C1-C4 alkylsulfonylamino, C3-C7 cycloalkyl, R9C(=O)N(R10)-, NH2(HN=)C-, 5 to 10 membered aryloxy or 5 to 10 membered aryl C0-C4 alkyl; said aryloxy, aryl and C3-C7 cycloalkyl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C7 cycloalkyl, cyano, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, C1-C4 alkylthio, R9N(R10)C(=O)- and nitro;
R9 and R10 are independently selected from the definitions of R7 and R8;
X is independently selected from HO(O=)C-C0-C4alkyl, hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C7 cycloalkyl, cyano, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, C1-C4 alkylthio, nitro, alkylsulfonyl, aminosulfonyl, C1-C4 alkyl C(=O)-, C1-C4 alkyl-O(O=)C-, R11N(R12)C(=O)-, C1-C4 alkylsulfonylamino, C1-C4 alkylsulfonylaminoalkyl, C3-C7 cycloalkyl, R11C(=O)N(R12)-, R11C(=O)N(R12)C1-C4alkyl, R11N(R12)SO2N(R13)C0-C4alkyl, R11N(R12)C(=O)N(R13)C0-C4alkyl, NH2(HN=)C-, C3-C7 cycloalkyl, 3 to 7 membered heterocyclyl, and 5 to 10 membered aryl C0-C4 alkyl; said heterocyclyl and alkyl may have independently 1 to 4 substituents independently selected from C1-C4 alkyl and halogen;
R11, R12 and R13 are independently selected from the definitions of R7 and R8;
p is 1, 2, 3, 4 or 5; when p is two or more than two, X may be same or different;
Y is a chemical bond, oxygen atom, sulfur atom, or nitrogen atom; when Y is oxygen atom, sulfur atom, or nitrogen atom, said substituent Y may have a substituent independently selected from the definitions of R7 and R8;
or a pharmaceutically acceptable salt thereof, each as described herein, for the manufacture of a medicament for the treatment of a condition or disorder mediated by TRPM8 receptor activity; in particular, TRPM8 antagonistic activity. In order to use the compounds of formula (I) and pharmaceutically acceptable salts thereof in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.
The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
The present invention provides a compound as described in formula (I) wherein the definition described above: m is 0, or a pharmaceutically acceptable salt thereof.
Preferable compounds of the invention are represented by formula (I) wherein the definition described above: m is 0; and Ar1 is a 5 to 7 heterocyclic group.
More preferable compounds of the invention are represented by formula (I) wherein the definition described above: m is 0; and Ar1 is a 5 to 7 heterocyclic group selected from pyridinyl, pyrimidinyl, pyridazinyl, and triazinyl.
The most preferable compounds of the invention are represented by formula (I), wherein m is 0; Ar1 is 2-pyridinyl or 3-pyridinyl; and A1, A2, A3 and A4 are carbon atom.
Suitable individual compounds of the invention are:
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzamide;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-N-methylbenzamide;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-N,N-dimethylbenzamide;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-N-(2-hydroxyethyl)benzamide;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxybenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(4-tert-Butylbenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-cyclohexylethyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-fluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-methoxybenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,4-difluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-isopropylbenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-chlorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyanobenzyl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(2-Chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(2,2,2-trifluoroethoxy)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,5-difluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-difluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,5-difluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-dichlorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-chlorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-phenylpropyl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(4-Chloro-3-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(4-Chloro-3-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(4-Chloro-3-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(3-fluoro-4-methylbenzyl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-methyl-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-4-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(4-Chloro-2-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(4-Chloro-2-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(3-chloro-4-fluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
4-(N-(4-Chloro-3-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trimethylsilyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-cyanocyclopropyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-methylbenzoic acid;
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-6-hydroxypyridine-3-sulfonamide;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methylbenzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methoxybenzoic acid;
2-(4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)phenyl)acetic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-phenethylsulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-cyclopropyl-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyclopropylbenzyl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-methyl-1H-pyrazol-4-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-methyl-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(pyridin-3-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(thiophen-2-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(pyridin-4-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(furan-2-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-([1,1'-Biphenyl]-4-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(oxazol-5-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(picolinamido)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(6-methoxypyridin-3-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(6-methylpyridin-3-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-([1,1'-Biphenyl]-3-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-([1,1'-Biphenyl]-2-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
(R)-4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-2-ylmethyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclohexylmethyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-phenoxybenzyl)sulfamoyl)benzoic acid;
4-(N-(4-(1H-Pyrazol-1-yl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclobutylmethyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-3-ylmethyl)sulfamoyl)benzoic acid;
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-cyanobenzenesulfonamide;
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(2H-tetrazol-5-yl)benzenesulfonamide;
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-methoxybenzenesulfonamide;
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(methylsulfonamidomethyl)benzenesulfonamide;
N-(4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzyl)acetamide;
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(((N,N-dimethylsulfamoyl)amino)methyl)benzenesulfonamide;
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-((3,3-dimethylureido)methyl)benzenesulfonamide;
4-(N-Benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-chlorobenzoic acid;
4-(N-Benzyl-N-(3-chloro-5-phenylpyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(furan-2-yl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(thiophen-3-yl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(2-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(4-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(3-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-chlorobenzoic acid;
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-6-methoxypyridine-3-sulfonamide;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-fluorobenzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-fluorobenzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopentylmethyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylcyclopropyl)sulfamoyl)benzoic acid;
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-((N,N-dimethylsulfamoyl)amino)benzenesulfonamide;
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-ureidobenzenesulfonamide;
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(sulfamoylamino)benzenesulfonamide;
(S)-4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((2-phenylthiazol-4-yl)methyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((5-phenyl-1,2,4-oxadiazol-3-yl)methyl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid; and
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(hydroxymethyl)benzene-1-sulfonamide;
or a pharmaceutically acceptable salt thereof.
More suitable individual compounds of the invention are:
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-fluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,4-difluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-chlorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyanobenzyl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(2-Chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,5-difluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-difluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,5-difluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-dichlorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-chlorobenzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(4-Chloro-3-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
4-(N-(3,5-Dichloropyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(4-Chloro-3-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(4-Chloro-3-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-4-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(4-Chloro-2-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(4-Chloro-2-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(3-chloro-4-fluorobenzyl)sulfamoyl)benzoic acid;
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
4-(N-(4-Chloro-3-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-cyanocyclopropyl)benzyl)sulfamoyl)benzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methylbenzoic acid;
4-(N-Benzyl-N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(pyridin-3-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(6-methoxypyridin-3-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(6-methylpyridin-3-yl)benzyl)sulfamoyl)benzoic acid;
4-(N-([1,1'-Biphenyl]-2-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(2H-tetrazol-5-yl)benzenesulfonamide;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-chlorobenzoic acid;
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid; and
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
or a pharmaceutically acceptable salt thereof.
Also, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, each as described herein, together with a pharmaceutically acceptable carrier for said compound.
Also, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, each as described herein, together with a pharmaceutically acceptable carrier for said compound and another pharmacologically active agent.
Also, the present invention provides a process for preparing a pharmaceutical composition, the process comprising mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
Also, the present invention provides an intermediate in a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Further, the present invention provides a method for the treatment of a condition or disorder mediated by TRPM8 receptor activity, in a mammalian subject, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, each as described herein.
In a further aspect, the present invention provides a process for preparing a pharmaceutical composition, the process comprising mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
Examples of conditions or disorders mediated by TRPM8 receptor activity include, but are not limited to, TRPM8 related diseases.
The compounds of the present invention show the TRPM8 receptor antagonistic activity. The compounds of the present invention may show less toxicity, good absorption, distribution, good solubility, less protein binding affinity other than TRPM8 receptor, less drug-drug interaction, and good metabolic stability.
As used herein, the term "alkyl" as a group or part of a group e.g. alkoxy or hydroxyalkyl refers to a straight or branched alkyl group in all isomeric forms. The term "C1-C4 alkyl" refers to an alkyl group, as defined above, containing at least 1, and at most 4 carbon atoms. Examples of such alkyl groups include methyl, ethyl, propyl, iso-propyl, n-butyl, iso- butyl, sec-butyl, or tert-butyl. Examples of such alkoxy groups include methoxy, ethoxy, propoxy, iso-propoxy, butoxy, iso-butoxy, sec-butoxy and tert-butoxy.
The term "cycloalkyl", as used herein, means a mono- or bicyclic ring, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norboranyl, and adamantyl groups and the like.
The term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) and the term "halo" refers to the halogen: fluoro (-F), chloro (-Cl), bromo (-Br) and iodo (-I).
The term "haloalkyl", as used herein, means an alkyl radical which is substituted by halogen atom(s) as defined above including, but not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, 3-fluoropropyl, 4-fluorobutyl, chloromethyl, trichloromethyl, iodomethyl and bromomethyl groups and the like.
The term "haloalkoxy", as used herein, means haloalkyl-O-, including, but not
limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, 3-fluoropropoxy, 4-fluorobutoxy, chforomethoxy, trichloromethoxy, iodomethoxy and bromomethoxy groups and the like.
The term "alkenyl", as used herein, means a hydrocarbon radical having at least one double bond including, but not limited to, ethenyl, propenyl, 1-butenyl, 2-butenyl and the like.
The term "alkynyl", as used herein, means a hydrocarbon radical having at least one triple bond including, but not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl and the like.
The term "alkoxy", as used herein, means an O-alkyl group wherein "alkyl" is defined above.
The term "aryl", as used herein, means mono-carbocyclic or mono-heterocyclic group which may contain 0-4 heteroatoms selected from O, N and S; the said heterocyclic group includes both unsaturated and saturated heterocyclic moieties;
wherein the unsaturated heterocyclic moieties include furyl, furazanyl, imidazolyl, isooxazolyl, isothiazolyl, oxazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrazinyl, pyridazinyl, thienyl, tetrazolyl, thiazolyl, triazinyl, thiophenyl, triazolyl, and N-oxides thereof and S-oxides thereof;
and wherein the saturated heterocyclic moieties include azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, piperidin-2-one-yl, pyrrolidin-2-one-yl, morpholinyl, tetrahydrofuranyl, thiomorpholinyl, and tetrahydrothienyl, and N-oxides thereof and S-oxides thereof.
The term "heterocyclyl", as used herein, means a saturated ring which comprises one or more heteroatoms selected from nitrogen, oxygen and sulphur. Examples of such heterocyclyl groups include azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, thiomorpholinyl, and tetrahydrothienyl, and N-oxides thereof and S-oxides thereof.
The term "C0", as used herein, means direct bond.
The term "protecting group", as used herein, means a hydroxy or amino protecting group which is selected from typical hydroxy or amino protecting groups described in Protective Groups in Organic Synthesis edited by T. W. Greene et al. (John Wiley & Sons, 1991);
The term "treating", as used herein, refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment" as used herein refers to the act of treating, as "treating" is defined immediately above.
The term "treating" and "treatment", as used herein, refers to curative, palliative and prophylactic treatment, including reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
As used herein, the article "a" or "an" refers to both the singular and plural form of the object to which it refers unless indicated otherwise.
Included within the scope of the "compounds of the invention" are all salts, solvates, hydrates, complexes, polymorphs, prodrugs, radiolabeled derivatives, stereoisomers and optical isomers of the compounds of formula (I).
The compounds of formula (I) can form acid addition salts thereof. It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in J. Pharm. Sci, 1977, 66, 1-19, such as acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, formic, acetic, trifluoroacetic, propionic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid. The present invention includes within its scope all possible stoichiometric and non-stoichiometric forms. In addition, certain compounds containing an acidic function such as a carboxy can be isolated in the form of their inorganic salt in which the counter ion can be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as from organic bases.
The compounds of formula (I) and salts thereof may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated. This invention includes within its scope stoichiometric hydrates or solvates as well as compounds containing variable amounts of water and/or solvent.
Salts and solvates having non-pharmaceutically acceptable counter-ions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of formula (I) and their pharmaceutically acceptable salts.
Additionally, the compounds of formula (I) may be administered as prodrugs. As used herein, a "prodrug" of a compound of formula (I) is a functional derivative of the compound which, upon administration to a patient, eventually liberates the compound of formula (I) in vivo. Administration of a compound of formula (I) as a prodrug may enable the skilled artisan to do one or more of the following: (a) modify the onset of action of the compound in vivo; (b) modify the duration of action of the compound in vivo; (c) modify the transportation or distribution of the compound in vivo; (d) modify the solubility of the compound in vivo; and (e) overcome a side effect or other difficulty encountered with the compound. Typical functional derivatives used to prepare prodrugs include modifications of the compound that are chemically or enzymatically cleaved in vivo. Such modifications, which include the preparation of phosphates, amides, esters, thioesters, carbonates, and carbamates, are well known to those skilled in the art.
In certain of the compounds of formula (I), there may be some chiral carbon atoms. In such cases, compounds of formula (I) exist as stereoisomers. The invention extends to all optical isomers such as stereoisomeric forms of the compounds of formula (I) including enantiomers, diastereoisomers and mixtures thereof, such as racemates. The different stereoisomeric forms may be separated or resolved one from the other by conventional methods or any given isomer may be obtained by conventional stereoselective or asymmetric syntheses.
Certain of the compounds herein can exist in various tautomeric forms and it is to be understood that the invention encompasses all such tautomeric forms.
The invention also includes isotopically-labeled compounds, which are identical to those described herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 3H, 11C, 14C, 18F, 123I and 125I. Compounds of the invention that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the present invention. Isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H, 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. 11C and 18F isotopes are particularly useful in PET (positron emission tomography), and 125I isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances, lsotopically labeled compounds of the invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, then substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
The potencies and efficacies of the compounds of this invention for TRPM8 can be determined by reporter assay performed on the human cloned receptor as described herein. Compounds of formula (I) have demonstrated antagonistic activity at the TRPM8 receptor, using the functional assay described herein.
Compounds of formula (I) and pharmaceutically acceptable salts thereof are therefore of use in the treatment of conditions or disorders which are mediated via the TRPM8 receptor. In particular the compounds of formula (I) and pharmaceutically acceptable salts thereof are of use in the treatment of a wide range of diseases, syndromes, and disorders, in particular for the treatment of inflammatory, pain and urological diseases or disorders, such as chronic pain, neuropathic pain including cold allodynia and diabetic neuropathy, postoperative pain, osteoarthritis, rheumatoid arthritic pain, cancer pain, neuralgia, neuropathies, algesia, nerve injury, migraine, cluster and tension headaches, ischaemia, irritable bowel syndrome, neurodegeneration, fibromyalgia, stroke, itch, psychiatric disorders including anxiety and depression and inflammatory disorders such as asthma and chronic obstructive pulmonary, or airways, disease i.e., COPD, pulmonary hypertension, anxiety, including other stress-related disorders, urological diseases or disorders such as detrusor overactivity or overactive bladder, urinary incontinence, neurogenic detrusor overactivity or detrusor hyperflexia, idiopathic detrusor overactivity or detrusor instability, benign prostatic hyperplasia, and lower urinary tract symptoms, and combinations thereof.
Activities of the compound (I) for each diseases, syndromes, and disorders described above can be confirmed in the suitable model known to skilled in the arts. For example, activities of compounds of formula (I) for neuropathic pain have been confirmed in chronic constriction injury (CCI)-induced model, such as cold allodynia and static allodynia model.
It is to be understood that "treatment" as used herein includes prophylaxis as well as alleviation of established symptoms.
A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrate compositions are generally preferred. Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); tabletting lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); and acceptable wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated according to methods well known in normal pharmaceutical practice.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e.g. lecithin or acacia), non-aqueous vehicles (which may include edible oils e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils), preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid), and, if desired, conventional flavourings or colorants, buffer salts and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the active compound or pharmaceutically acceptable salt thereof.
For parenteral administration, fluid unit dosage forms are prepared utilising a compound of formula (I) or pharmaceutically acceptable salt thereof and a sterile vehicle. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose, utilising a compound of formula (I) or pharmaceutically acceptable salt thereof and a sterile vehicle, optionally with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
The compounds of formula (I) or pharmaceutically acceptable salts thereof may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
The compounds of formula (I) or pharmaceutically acceptable salts may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of formula (I) or pharmaceutically acceptable salts may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
For intranasal administration, the compounds formula (I) or pharmaceutically acceptable salts thereof may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device. Thus compounds of formula (I) or pharmaceutically acceptable salts thereof may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose). The compounds of formula (I) and pharmaceutically acceptable salts thereof may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops). Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Ointments for administration to the eye may be manufactured in a sterile manner using sterilized components.
A TRPM8 antagonist may be usefully combined with another pharmacologically active compound, or with two or more other pharmacologically active compounds, particularly in the treatment of inflammatory, pain and urological diseases or disorders. For example, a TRPM8 antagonist, particularly a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as defined above, may be administered simultaneously, sequentially or separately in combination with one or more agents selected from:
- an opioid analgesic, e.g. morphine, heroin, hydromorphone, oxymorphone, levorphanol, levallorphan, methadone, meperidine, fentanyl, cocaine, codeine, dihydrocodeine, oxycodone, hydrocodone, propoxyphene, nalmefene, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine or pentazocine;
- a nonsteroidal antiinflammatory drug (NSAID), e.g. aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, meloxicam, nabumetone, naproxen, nimesulide, nitroflurbiprofen, olsalazine, oxaprozin, phenylbutazone, piroxicam, sulfasalazine, sulindac, tolmetin or zomepirac;
- a barbiturate sedative, e.g. amobarbital, aprobarbital, butabarbital, butabital, mephobarbital, metharbital, methohexital, pentobarbital, phenobartital, secobarbital, talbutal, theamylal or thiopental;
- a benzodiazepine having a sedative action, e.g. chlordiazepoxide, clorazepate, diazepam, flurazepam, lorazepam, oxazepam, temazepam or triazolam;
- an H1 antagonist having a sedative action, e.g. diphenhydramine, pyrilamine, promethazine, chlorpheniramine or chlorcyclizine;
- a sedative such as glutethimide, meprobamate, methaqualone or dichloralphenazone;
- a skeletal muscle relaxant, e.g. baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol or orphrenadine;
- an NMDA receptor antagonist, e.g. dextromethorphan ((+)-3-hydroxy-N-methylmorphinan) or its metabolite dextrorphan ((+)-3-hydroxy-N-methylmorphinan), ketamine, memantine, pyrroloquinoline quinine, cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid, budipine, EN-3231 (MorphiDex (registered trademark), a combination formulation of morphine and dextromethorphan), topiramate, neramexane or perzinfotel including an NR2B antagonist, e.g. ifenprodil, traxoprodil or (-)-(R)-6-{2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl-3,4-dihydro-2(1H)-quinolinone;
- an alpha-adrenergic, e.g. doxazosin, tamsulosin, clonidine, guanfacine, dexmetatomidine, modafinil, or 4-amino-6,7-dimethoxy-2-(5-methane-sulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline;
- a tricyclic antidepressant, e.g. desipramine, imipramine, amitriptyline or nortriptyline;
- an anticonvulsant, e.g. carbamazepine, lamotrigine, topiratmate or valproate;
- a tachykinin (NK) antagonist, particularly an NK-3, NK-2 or NK-1 antagonist, e.g. (alphaR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]-naphthyridine-6-13-dione (TAK-637), 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-4-morpholinyl]-methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one (MK-869), aprepitant, lanepitant, dapitant or 3-[[2-methoxy-5-(trifluoromethoxy)phenyl]-methylamino]-2-phenylpiperidine (2S,3S);
- a muscarinic antagonist, e.g oxybutynin, tolterodine, propiverine, tropsium chloride, darifenacin, solifenacin, temiverine and ipratropium;
- a COX-2 selective inhibitor, e.g. celecoxib, rofecoxib, parecoxib, valdecoxib, deracoxib, etoricoxib, or lumiracoxib;
- a coal-tar analgesic, in particular paracetamol;
- a neuroleptic such as droperidol, chlorpromazine, haloperidol, perphenazine, thioridazine, mesoridazine, trifluoperazine, fluphenazine, clozapine, olanzapine, risperidone, ziprasidone, quetiapine, sertindole, aripiprazole, sonepiprazole, blonanserin, iloperidone, perospirone, raclopride, zotepine, bifeprunox, asenapine, lurasidone, amisulpride, balaperidone, palindore, eplivanserin, osanetant, rimonabant, meclinertant, Miraxion (registered trademark) or sarizotan;
- a vanilloid receptor agonist (e.g. resinferatoxin) or antagonist (e.g. capsazepine);
- a beta-adrenergic such as propranolol;
- a local anaesthetic such as mexiletine;
- a corticosteroid such as dexamethasone;
- a 5-HT receptor agonist or antagonist, particularly a 5-HT1B/1D agonist such as eletriptan, sumatriptan, naratriptan, zolmitriptan or rizatriptan;
- a 5-HT2A receptor antagonist such as R(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol (MDL-100907);
- a cholinergic (nicotinic) analgesic, such as ispronicline (TC-1734), (E)-N-methyl-4-(3-pyridinyl)-3-buten-1-amine (RJR-2403), (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594) or nicotine;
- Tramadol (registered trademark);
- a PDEV inhibitor, such as 5-[2-ethoxy-5-(4-methyl-1-piperazinyl-sulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil), (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione (IC-351 or tadalafil), 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil), 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-(5-acetyl-2-propoxy-3-pyridinyl)-3-ethyl-2-(1-isopropyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide, 3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide;
- an alpha-2-delta ligand such as gabapentin, pregabalin, 3-methylgabapentin, (1alpha,3alpha,5alpha)(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-octanoic acid, (2S,4S)-4-(3-chlorophenoxy)proline, (2S,4S)-4-(3-fluorobenzyl)-proline, [(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]-methylamine, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-nonanoic acid, (3S,5R)-3-amino-5-methyl-octanoic acid, (3R,4R,5R)-3-amino-4,5-dimethyl-heptanoic acid and (3R,4R,5R)-3-amino-4,5-dimethyl-octanoic acid;
- a cannabinoid;
- metabotropic glutamate subtype 1 receptor (mGluR1) antagonist;
- a serotonin reuptake inhibitor such as sertraline, sertraline metabolite demethylsertraline, fluoxetine, norfluoxetine (fluoxetine desmethyl metabolite), fluvoxamine, paroxetine, citalopram, citalopram metabolite desmethylcitalopram, escitalopram, d,l-fenfluramine, femoxetine, ifoxetine, cyanodothiepin, litoxetine, dapoxetine, nefazodone, cericlamine and trazodone;
- a noradrenaline (norepinephrine) reuptake inhibitor, such as maprotiline, lofepramine, mirtazepine, oxaprotiline, fezolamine, tomoxetine, mianserin, buproprion, buproprion metabolite hydroxybuproprion, nomifensine and viloxazine (Vivalan (registered trademark)), especially a selective noradrenaline reuptake inhibitor such as reboxetine, in particular (S,S)-reboxetine;
- a dual serotonin-noradrenaline reuptake inhibitor, such as venlafaxine, venlafaxine metabolite O-desmethylvenlafaxine, clomipramine, clomipramine metabolite desmethylclomipramine, duloxetine, milnacipran and imipramine;
- an inducible nitric oxide synthase (iNOS) inhibitor such as S-[2-[(1-iminoethyl)amino]ethyl]-L-homocysteine, S-[2-[(1-iminoethyl)-amino]ethyl]-4,4-dioxo-L-cysteine, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteine, (2S,5Z)-2-amino-2-methyl-7-[(1-iminoethyl)amino]-5-heptenoic acid, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)-butyl]thio]-5-chloro-3-pyridinecarbonitrile, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-4-chlorobenzonitrile, (2S,4R)-2-amino-4-[[2-chloro-5-(trifluoromethyl)phenyl]thio]-5-thiazolebutanol, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-6-(trifluoromethyl)-3-pyridinecarbonitrile, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chlorobenzonitrile, N-[4-[2-(3-chlorobenzylamino)ethyl]phenyl]thiophene-2-carboxamidine, or guanidinoethyldisulfide;
- an acetylcholinesterase inhibitor such as donepezil;
- a prostaglandin E2 subtype 4 (EP4) antagonist such as N-[({2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl}amino)-carbonyl]-4-methylbenzenesulfonamide or 4-[(1S)-1-({[5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl}amino)ethyl]benzoic acid;
- a leukotriene B4 antagonist; such as 1-(3-biphenyl-4-ylmethyl-4-hydroxy-chroman-7-yl)-cyclopentanecarboxylic acid (CP-105696), 5-[2-(2-Carboxyethyl)-3-[6-(4-methoxyphenyl)-5E- hexenyl]oxyphenoxy]-valeric acid (ONO-4057) or DPC-11870;
- a 5-lipoxygenase inhibitor, such as zileuton, 6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy-methyl]-1-methyl-2-quinolone (ZD-2138), or 2,3,5-trimethyl-6-(3-pyridylmethyl),1,4-benzoquinone (CV-6504);
- a sodium channel blocker, such as lidocaine;
- a 5-HT3 antagonist, such as ondansetron;
- a chemotherapy drug such as oxaliplatin, 5-fluorouracil, leukovolin, paclitaxel
and the pharmaceutically acceptable salts and solvates thereof.
Such combinations offer significant advantages, including synergistic activity, in therapy.
The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors.
A therapeutically effective amount of a compound of formula (I) or a pharmaceutical composition thereof includes a dose range from about 0.05 mg to about 3000 mg, in particular from about 1 mg to about 1000 mg or, more particularly, from about 10 mg to about 500 mg of active ingredient in a regimen of about once a day or more than once a day, for example two, three or four times a day for an average (70 kg) human; although, it is apparent to one skilled in the art that the therapeutically effective amount for active compounds of the invention will vary as will the diseases, syndromes, conditions, and disorders being treated.
For oral administration, a pharmaceutical composition is preferably provided in the form of tablets containing about 0.01, about 10, about 50, about 100, about 150, about 200, about 250, and about 500 milligrams of the inventive compound as the active ingredient.
Advantageously, a compound of formula (I) may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three and four times daily.
Optimal dosages of a compound of formula (I) to be administered may be readily determined and will vary with the particular compound used, the mode of administration, the strength of the preparation, and the advancement of the disease, syndrome, condition, or disorder. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to achieve an appropriate therapeutic level.
The above dosages are thus exemplary of the average case. There can be, of course, individual instances wherein higher or lower dosage ranges are merited, and such are within the scope of this invention.
Compounds of formula (I) may be administered in any of the foregoing compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever use of a compound of formula (I) is required for a subject in need thereof.
As antagonists of the TRPM8 ion channel, the compounds of formula (I) are useful in methods for treating and preventing a disease, a syndrome, a condition, or a disorder in a subject, including an animal, a mammal and a human in which the disease, the syndrome, the condition, or the disorder is affected by the modulation of TRPM8 receptors. Such methods comprise, consist of, and consist essentially of administering to a subject, including an animal, a mammal, and a human in need of such treatment or prevention a therapeutically effective amount of a compound, salt, or solvate of formula (I). In particular, the compounds of formula (I) are useful for preventing or treating pain, or diseases, syndromes, conditions, or disorders causing such pain, or pulmonary or vascular dysfunction. More particularly, the compounds of formula (I) are useful for preventing or treating inflammatory pain, inflammatory hypersensitivity conditions, neuropathic pain, anxiety, depression, and cardiovascular disease aggravated by cold, including peripheral vascular disease, vascular hypertension, pulmonary hypertension, Raynaud's disease, and coronary artery disease, by administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I).
Examples of inflammatory pain include pain due to a disease, condition, syndrome, disorder, or a pain state including inflammatory bowel disease, visceral pain, migraine, post operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, sinus headache, tension headache, or arachnoiditis.
One type of inflammatory pain is inflammatory hyperalgesia, which can be further distinguished as inflammatory somatic hyperalgesia or inflammatory visceral hyperalgesia. Inflammatory somatic hyperalgesia can be characterized by the presence of an inflammatory hyperalgesic state in which a hypersensitivity to thermal, mechanical and/or chemical stimuli exists. Inflammatory visceral hyperalgesia can also be characterized by the presence of an inflammatory hyperalgesic state, in which an enhanced visceral irritability exists.
Examples of inflammatory hyperalgesia include a disease, syndrome, condition, disorder, or pain state including inflammation, osteoarthritis, rheumatoid arthritis, back pain, joint pain, abdominal pain, musculoskeletal diseases, skin diseases, post operative pain, headaches, toothache, burn, sunburn, insect sting, neurogenic bladder, urinary incontinence, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, enteritis, irritable bowel syndrome, inflammatory bowel diseases including Crohn's Disease or ulcerative colitis.
One embodiment of the present invention is directed to a method for treating inflammatory somatic hyperalgesia in which a hypersensitivity to thermal, mechanical and/or chemical stimuli exists, comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of formula (I).
A further embodiment of the present invention is directed to a method for treating inflammatory visceral hyperalgesia in which a enhanced visceral irritability exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound, salt or solvate of formula (I).
A further embodiment of the present invention is directed to a method for treating neuropathic cold allodynia in which a hypersensitivity to a cooling stimuli exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound, salt or solvate of formula (I).
Examples of an inflammatory hypersensitivity condition include urinary incontinence, benign prostatic hypertrophy, cough, asthma, rhinitis and nasal hypersensitivity, itch, contact dermatitis and/ or dermal allergy, and chronic obstructive pulmonary disease.
Examples of a neuropathic pain include pain due to a disease, syndrome, condition, disorder, or pain state including cancer, neurological disorders, spine and peripheral nerve surgery, brain tumor, traumatic brain injury (TBI), spinal cord trauma, chronic pain syndrome, fibromyalgia, chronic fatigue syndrome, neuralgias (trigeminal neuralgia, glossopharyngeal neuralgia, postherpetic neuralgia and causalgia), lupus, sarcoidosis, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, central pain, neuropathies associated with spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, multiple sclerosis, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, oral neuropathic pain, Charcot's pain, complex regional pain syndrome I and II (CRPS I/II), radiculopathy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vulvodynia, or vidian neuralgia.
One type of neuropathic pain is neuropathic cold allodynia, which can be characterized by the presence of a neuropathy-associated allodynic state in which a hypersensitivity to cooling stimuli exists. Examples of neuropathic cold allodynia include allodynia due to a disease, condition, syndrome, disorder or pain state including neuropathic pain or neuralgia, pain arising from spine and peripheral nerve surgery or trauma, traumatic brain injury (TBI), trigeminal neuralgia, postherpetic neuralgia, causalgia, peripheral neuropathy, diabetic neuropathy, central pain, stroke, peripheral neuritis, polyneuritis, complex regional pain syndrome I and II (CRPS I/II) and radiculopathy.
Examples of anxiety include social anxiety, post traumatic stress disorder, phobias, social phobia, special phobias, panic disorder, obsessive compulsive disorder, acute stress, disorder, separation anxiety disorder, and generalized anxiety disorder.
Examples of depression include major depression, bipolar disorder, seasonal affective disorder, post natal depression, manic depression, and bipolar depression.
General Synthesis
Throughout the instant application, the following abbreviations are used with the following meanings:
DMF: N,N-Dimethylformamide
THF: Tetrahydrofuran
DMSO: Dimethylsulfoxide
EtOAc: Ethyl acetate
MeOH: Methanol
EtOH: Ethanol
DCM: Dichloromethane
DME: 1,2-dimethoxyethane
TFA: Trifluoroacetic acid
MeCN: Acetonitrile
Et3N: Triethylamine
DMAP: 4-Dimethylaminopyridine
EDC: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Hydrochloride
FMOC: 9-Fluorenylmethoxycarbonyl
HOBT: 1-Hydroxybenztriazole
HBTU: O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium Hexafluorophosphate
BOP: (Benzotriazol-1-yloxy)tris(dimethylamino) phosphonium Hexafluorophosphate
HPLC: High pressure liquid chromatography
tR: Retention time
MHz: Megahertz
NMR: Nuclear Magnetic Resonance
TLC: Thin layer chromatography
The term of "base" is likewise no particular restriction on the nature of the bases used, and any base commonly used in reactions of this type may equally be used here. Examples of such bases include: alkali metal hydroxides, such as lithium hydroxide, sodium hydroxide, potassium hydroxide, and barium hydroxide; alkali metal hydrides, such as lithium hydride, sodium hydride, and potassium hydride; alkali metal alkoxides, such as sodium methoxide, sodium ethoxide, and potassium t-butoxide; alkali metal carbonates, such as lithium carbonate, sodium carbonate, potassium carbonate, and cesium carbonate; alkali metal hydrogencarbonates, such as lithium hydrogencarbonate, sodium hydrogencarbonate, and potassium hydrogencarbonate; amines, such as N-methylmorpholine, triethylamine, tripropylamine, tributylamine, diisopropylethylamine, N-methylpiperidine, pyridine, 4-pyrrolidinopyridine, picoline, 2,6-di(t-butyl)-4-methylpyridine, quinoline, N,N-dimethylaniline, N,N-diethylaniline, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), lutidine, and colidine; alkali metal amides, such as lithium amide, sodium amide, potassium amide, lithium diisopropyl amide, potassium diisopropyl amide, sodium diisopropyl amide, lithium bis(trimethylsilyl)amide and potassium bis(trimethylsilyl)amide. Of these, triethylamine, diisopropylethylamine, DBU, DBN, DABCO, pyridine, lutidine, colidine, sodium carbonate, sodium hydrogencarbonate, sodium hydroxide, potassium carbonate, potassium hydrogencarbonate, potassium hydroxide, barium hydroxide, and cesium carbonate are preferred.
The reactions are normally and preferably effected in the presence of inert solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve reagents, at least to some extent. Examples of suitable solvents include, but not limited to: halogenated hydrocarbons, such as dichloromethane, chloroform, carbon tetrachloride, and dichloroethane; ethers, such as diethyl ether, diisopropyl ether, THF, and dioxane; aromatic hydrocarbons, such as benzene, toluene and nitrobenzene; amides, such as, DMF, N,N-dimethylacetamide, and hexamethylphosphoric triamide; amines, such as N-methylmorpholine, triethylamine, tripropylamine, tributylamine, diisopropylethylamine, N-methylpiperidine, pyridine, 4-pyrrolidinopyridine, N,N-dimethylaniline, and N,N-diethylaniline; alcohols, such as methanol, ethanol, propanol, isopropanol, and butanol; nitriles, such as acetonitrile and benzonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO) and sulfolane; ketones, such as acetone and diethylketone. Of these solvents, including but not limited to DMF, DMSO, THF, diethylether, diisopropylether, dimethoxyethane, acetonitrile, dichloromethane, dichloroethane and chloroform are preferred.
The invention is illustrated in the following non-limiting examples in which, unless stated otherwise: all reagents are commercially available, all operations were carried out at room or ambient temperature, that is, in the range of about 18-25 oC; evaporation of solvent was carried out using a rotary evaporator under reduced pressure with a bath temperature of up to about 60 oC; reactions were monitored by thin layer chromatography (tlc) and reaction times are given for illustration only; the structure and purity of all isolated compounds were assured by at least one of the following techniques: tlc (Merck silica gel 60 F254 precoated TLC plates or Merck NH2 F254 precoated HPTLC plates), mass spectrometry or nuclear magnetic resonance (NMR). Yields are given for illustrative purposes only. Flash column chromatography was carried out using Merck silica gel 60 (230-400 mesh ASTM) or Fuji Silysia Chromatorex (registered trademark) DU3050 (Amino Type, 30-50 micrometer) or Biotage silica (32-63 mm, KP-Sil) or Biotage amino bounded silica (35-75 mm, KP-NH). The purification of compounds using preparative LC-MS system was performed by the following apparatus and conditions ("Process A"); Apparatus; Waters MS-trigger AutoPurificationTM system Column; Waters XTerra C18, 19 x 50mm, 5mm particle, Method A; Methanol or acetonitrile / 0.05%(v/v) formic acid aqueous solution, Method B; Methanol or acetonitrile / 0.01%(v/v) ammonia aqueous solution. The purification using HPLC("Process B") was performed by the following apparatus and conditions: Apparatus; UV-trigger preparative HPLC system, Waters (Column; XTerra MS C18, 5 micrometer, 19 x 50 mm or 30 x 50 mm), Detector; UV 254 nm, Conditions; acetonitrile:0.05% formic acid aqueous solution or acetonitrile:0.01% aqueous ammonia solution; 20 mL/min (19 x 50 mm) or 40 mL/min (30 x 50 mm) at room temperature. Low-resolution mass spectral data (ESI) were obtained by the following apparatus and conditions: Apparatus; Waters Alliance HPLC system on ZQ or ZMD mass spectrometer and UV detector. Microwave reaction was conducted by Intiator (registered trademark) Sixty (Biotage). NMR data was determined at 270 MHz (JEOL JNM-LA 270 spectrometer) or 300 MHz (JEOL JNM-LA300) using deuterated chloroform (99.8% D) or dimethylsulfoxide (99.9% D) as solvent unless indicated otherwise, relative to tetramethylsilane (TMS) as internal standard in parts per million (ppm); conventional abbreviations used are: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, etc. Chemical symbols have their usual meanings; microL (microliter(s)), microg (microgram(s)), M (mol(s) per liter), L(liter(s)), mL (milliliter(s)), g (gram(s)), mg(milligram(s)), mol (moles), mmol (millimoles).
Conditions for determining LC-MS retention time:
Method A:
Apparatus: Waters Acquity Ultra Performance LC on TUV Detector and ZQ mass spectrometer
Column: XTerra MS C18 3.5 micrometer, 2.1x30 mm
Column Temperature: 45 oC
Solvents:
A1: acetonitrile
B1: 5 mM ammonium acetate aqueous solution
Figure JPOXMLDOC01-appb-T000001
Method B:
Apparatus: Waters Acquity Ultra Performance LC on TUV Detector and ZQ mass spectrometer
Column: XTerra MS C18 3.5micrometer, 2.1x30 mm
Column Temperature: 45 oC
Solvents:
A1: acetonitrile
B1: 5 mM ammonium acetate aqueous solution
Figure JPOXMLDOC01-appb-T000002
Conditions for determining HPLC retention time:
Method C:
Apparatus: Waters Acquity Ultra Performance LC on TUV Detector and ZQ mass spectrometer
Column: Waters ACQUITY C18, 2.1x100mm, 1.7 micrometer particle
Column Temperature: 60 oC
Solvents:
A1: 10 mM ammonium acetate aqueous solution
B1: Acetonitrile
Figure JPOXMLDOC01-appb-T000003
Method D:
Apparatus: Waters Alliance HPLC system on ZQ mass spectrometer and UV detector
Column: Waters SunFire C18 2.1x50mm, 3.5 micrometer particle
Column Temperature: 40 oC
Solvents:
A: Water (Mili-Q)
B: Acetonitrile
C: 1% formic acid aqueous solution
D: 1% ammonia aqueous solution
Figure JPOXMLDOC01-appb-T000004
Method E:
Apparatus: Waters Alliance HPLC system on ZQ mass spectrometer and UV detector
Column: Waters XBridge C18 2.1x50mm, 3.5 micrometer particle
Column Temperature: 40 oC
Solvents:
A: Water (Mili-Q)
B: acetonitrile
C: 1% formic acid aqueous solution
D: 1% ammonia aqueous solution
Figure JPOXMLDOC01-appb-T000005
All of the compounds of the formula (I) can be prepared by the procedures described in the general methods presented below or by the specific methods described in the Examples section and the Preparations section, or by routine modifications thereof. The present invention also encompasses any one or more of these processes for preparing the sulfamoyl benzoic acid derivatives of formula (I), in addition to any novel intermediates used therein.
In the following general methods, Ar1, Z, R1, R2, R3, R4, R5, R6, X, Y, m, n, p, and q are as previously defined for sulfamoyl benzoic acid derivatives of the formula (I) unless otherwise stated.
<Scheme-A>
Figure JPOXMLDOC01-appb-C000002
In Step A-a, the compounds of formula (IV) can be prepared by sulfonylation of the compound of formula (III) with the compound of formula (II) under, for example, known sulfonylation conditions in the presence of a base in an inert solvent. A preferred base is selected from, for example, but not limited to: an alkali or alkaline earth metal hydroxide, alkoxide, carbonate, halide or hydride, such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium tert-butoxide, sodium carbonate, potassium carbonate, potassium fluoride, sodium hydride or potassium hydride; or an amine such as triethylamine, tributylamine, diisopropylethylamine, 2,6-lutidine, pyridine or dimethylaminopyridine. Examples of suitable inert aqueous or non-aqueous organic solvents include: alcohols, such as methanol or ethanol; ethers, such as THF or 1,4-dioxane; acetone; dimethylformamide; halogenated hydrocarbons, such as DCM, 1,2-dichloroethane or chloroform; and pyridine; or mixtures thereof. The reaction can be carried out at a temperature in the range of from -10 oC to 150 oC, preferably in the range of from 20 oC to 60 oC. Reaction times are, in general, from 10 minutes to 4 days, preferably from 30 minutes to 24 hrs.
When Hal is a halogen group such as iodide, bromide, or chloride, in Step A-b, a compound of formula (I) can be prepared by N-substitution reaction of a compound of formula (IV) with alkyl halide (V) in the presence of a base in an inert solvent.
Examples of suitable bases include: potassium carbonate, sodium carbonate and cesium carbonate. Examples of suitable solvents include: 1,4-dioxane, acetonitrile, DMSO and DMF. This reaction can be carried out in the presence of a suitable additive agent. Examples of such additive agents include: sodium iodide and potassium iodide. The reaction can be carried out at a temperature of from 20 oC to 150 oC, more preferably from 20 oC to 100 oC. Reaction times are, in general, from 5 minutes to 96 hours, more preferably from 30 minutes to 24 hrs.
<Scheme-B>
Figure JPOXMLDOC01-appb-C000003
When LG is a suitable leaving group such as O-trifluoromethanesulfonate, O-tosylate, O-mesylate, iodide, bromide, or chloride, in Step B-a, a compound of formula (VIII) can be prepared by N-alkylation and/or N-arylation of a compound of formula (VII) with a compound of formula (VI) in the presence of a base in an inert solvent. Examples of suitable bases include: potassium carbonate, sodium carbonate and cesium carbonate. Examples of suitable solvents include: 1,4-dioxane, acetonitrile, DMSO and DMF. The reaction can be carried out at a temperature of from 0 oC to 200 oC, more preferably from 20 oC to 160 oC. Reaction times are, in general, from 5 minutes to 96 hrs, more preferably from 30 minutes to 24 hrs. In an alternative case, the reaction can be carried out with microwave system in the presence of a same base in a same inert solvent. The reaction can be carried out at a temperature in the range of from 100 oC to 200 oC, preferably in the range of from 120 oC to 150 oC. Reaction times are, in general, from 10 minutes to 5 hrs, preferably from 15 minutes to 3 hr.
In Step B-b, a compound of formula (I) can be prepared from a compound of formula (VIII) by the method described in Step A-a above. A preferred inert solvent is pyridine. The reaction can be carried out at a temperature in the range of from 100 oC to 150 oC, preferably in the range of from 110 oC to 140 oC. Reaction times are, in general, from 10 minutes to 4 days, preferably from 24 hrs to 48 hrs.
<Scheme-C>
Figure JPOXMLDOC01-appb-C000004
In Step C-a, a compound of formula (IX) can be prepared from a compound of formula (VII) by the method described in Step A-a above.
When Hal is a halogen group such as iodide, bromide, or chloride, in Step C-b, a compound of formula (I) can be prepared from a compound of formula (IX) by the method described in Step B-a above.
<Scheme-D>
Figure JPOXMLDOC01-appb-C000005
When LG is a suitable leaving group such as O-trifluoromethanesulfonate, O-tosylate, O-mesylate, iodide, bromide, or chloride and B ring is (C3-C6)cycloalkyl and aryl, in Step D-a, the compound of formula ((I)-b) can be prepared by coupling of a compound of formula ((I)-a) with (C3-C6) cycloalkyl or aryl metal reagents in water-organic co-solvent mixture under coupling conditions in the presence of a suitable transition metal catalyst and in the presence or absence of a base. Examples of suitable transition metal catalysts include: tetrakis(triphenylphosphine)palladium(0), bis(triphenylphosphine)palladium(ll) chloride, copper(0), copper(l) acetate, copper(l) bromide, copper(l) chloride, copper(l) iodide, copper(l) oxide, copper(ll) trifluoromethanesulfonate, copper(ll) acetate, copper(ll) bromide, copper(ll) chloride, copper(ll) iodide, copper(ll) oxide, copper(ll) trifluoromethanesulfonate, palladium(ll) acetate, palladium(ll) chloride, bis(acetonitrile)dichloropalladium(II), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0) and [1,1'-bis(diphenylphosphino)ferrocene] palladium(ll) dichloride. Preferred catalysts are tetrakis(triphenylphosphine)palladium(0), bis(triphenylphosphine)palladium(ll) chloride, palladium(ll) acetate, palladium(ll) chloride, bis(acetonitrile)dichloropalladium(0), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0) and [1,1-bis(diphenylphosphino)ferrocene]palladium(ll) dichloride.
Examples of suitable (C3-C6) cycloalkyl and aryl metal reagents include, but not limited to, boronic acids such as cyclopropylboronic acid, benzene boronic acid and 4-pyridinyl boronic acid; boronic esters such as cyclopropylboronic acid pinacol ester and benzeneboronic acid pinacol ester, benzeneboronic acid neopentyl glycol ester; benzeneboronic acid N-methyldiethanolamine ester; and trifluoroborate salts such as potassium phenyltrifluoroborate.
Examples of suitable organic solvent for the water-organic co-solvent mixture include: THF; 1,4-dioxane; DMF; acetonitrile; alcohols, such as methanol or ethanol; halogenated hydrocarbons, such as DCM, 1,2-dichloroethane, chloroform or carbon tetrachloride; and diethylether; in the presence or absence of an aqueous base such as aqueous potassium hydroxide, sodium hydroxide, lithium hydroxide, sodium bicarbonate, sodium cabonate or potassium carbonate. This reaction can be carried out in the presence of a suitable additive agent. Examples of such additive agents include: triphenylphosphine, tri-tert-butylphosphine, 1,1'-bis(diphenylphosphino)ferrocene, tri-2-furylphosphine, tri-o-tolylphosphine, 2-(dichlorohexylphosphino)biphenyl, triphenylarsine, tetrabutylammonium chloride, tetrabutylammonium fluoride, lithium acetate, lithium chloride, triethylamine, potassium or sodium methoxide, sodium hydroxide, cesium carbonate, tripotassium phosphate, sodium carbonate, sodium bicarbonate, and/or sodium iodide. The reaction can be carried out at a temperature of from 0 oC to 200 oC, more preferably from 20 oC to 150 oC. Reaction times are, in general, from 5 minutes to 96 hrs, more preferably from 30 minutes to 24 hrs. In an alternative case, the reaction can be carried out with microwave system in the presence of a base in an inert solvent. The reaction can be carried out at a temperature in the range of from 100 oC to 200 oC, preferably in the range of from 120 oC to 150 oC. Reaction times are, in general, from 10 minutes to 3 hrs, preferably from 15 minutes to 1 hr.
<Scheme-E>
Figure JPOXMLDOC01-appb-C000006
When LG is a suitable leaving group such as O-trifluoromethanesulfonate, O-tosylate, O-mesylate, iodide, bromide, or chloride and D is C1-C 4 alkyl, C3-C6 cycloalkyl and aryl, in Step E-a, an amide compound of formula ((I)-d) can be prepared by coupling reaction of a compound of formula ((I)-c) with alkyl, cycloalkyl or aryl metal reagents (D-metal reagents) according to the method described in Step D-a above. Examples of suitable akyl metal regents include boronic acids such as methyl boronic acid (or trimethylboroxine), boronic esters such as tert-butyllboronic acid pinacol ester; and trifluoroborate salts such as potassium methyltrifluoroborate
<Scheme-F>
Figure JPOXMLDOC01-appb-C000007
When LG is a suitable leaving group such as O-trifluoromethanesulfonate, O-tosylate, O-mesylate, iodide, bromide, or chloride, in Step F-a, the compound of formula ((I)-f) can be prepared by reacting the compound of formula ((I)-e) with carbon monoxide and alcohol (e.g. MeOH or EtOH) in the presence of a catalyst and/or base in an inert solvent. Examples of suitable catalysts include: palladium reagents, such as palladium(II) acetate or bis(dibenzylideneacetone)palladium(II). Examples of suitable bases include: N,N-diisopropylethylamine, N-methylmorpholine or triethylamine. If desired, this reaction may be carried out in the presence or absence of an additive such as 1,1'-bis(diphenylphosphino)ferrocene, triphenylphosphine or 1,3-bis(diphenylphosphino)propane (DPPP). Examples of suitable solvents include: acetone; nitromethane; DMF; sulfolane; DMSO; NMP; 2-butanone; acetonitrile; halogenated hydrocarbons such as DCM, 1,2-dichloroethane or chloroform; or ethers, such as THF or 1,4-dioxane. The reaction can be carried out at a temperature of from 0 oC to 200 oC, more preferably from 20 oC to 120 oC. Reaction times are, in general, from 5 minutes to 96 hrs, more preferably from 30 minutes to 24 hrs.
<Scheme-G>
Figure JPOXMLDOC01-appb-C000008
In Step G-a, an acid compound of formula ((I)-g) can be prepared by hydrolysis of the ester compound of formula ((I)-f) in an inert solvent. The hydrolysis can be carried out by conventional procedures. In a typical procedure, the hydrolysis is carried out under basic conditions, e.g. in the presence of sodium hydroxide, potassium hydroxide or lithium hydroxide. Suitable solvents include, for example: alcohols such as methanol, ethanol, propanol, butanol, 2-methoxyethanol, and ethylene gylcol; ethers such as THF, DME, and 1,4-dioxane; amides such as DMF and hexamethylphospholictriamide; and sulfoxides such as DMSO. Preferred solvents are methanol, ethanol, propanol, THF, DME, 1,4-dioxane, DMF, and DMSO. This reaction can be carried out at a temperature in the range of from -20 oC to 100 oC, usually from 20 oC to 65 oC for from 30 minutes to 24 hrs, usually from 60 minutes to 10 hrs.
In Step G-b, an amide compound of formula ((I)-h) can be prepared by the coupling reaction of an amine compound (R11R12NH) with the acid compound of formula ((I)-g) in the presence or absence of a coupling reagent in an inert solvent. This reaction can be also carried out via activated carboxylic derivatives. Suitable coupling reagents are those typically used in peptide synthesis including, for example, not limited to, phosgene, triphosgene, ethyl chloroformate, isobutyl chloroformate, diphenyl phosphoryl azide (DPPA), diethyl phosphoryl cyanide (DEPC), carbodiimides [e.g., N,N'-dicyclohexylcarbodiimide(DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI)], imidazolium derived reagents [e.g., 1, 1'-carbonyldiimidazole (CDI), 2-chloro-1, 3-dimethylimidazolidinium hexafluorophosphate (CIP)], phosphonium salts [e.g., Benzotriazol-1-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), Benzotriazol-1-yl-oxy-tripyrrolidinophosphonium hexafluorophosphate (PyBOP (registered trademark)), Bromo-tripyrrolidinophosphonium hexafluorophosphate (PyBrop (registered trademark)), uronium and guanidinium salts [e.g., O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), O-(6-chlorobenzotriazol-1-yl)- N,N,N',N'-tetramethyluronium hexafluorophosphate (HCTU)], miscellaneous coupling reagents [e.g., 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), (2-bromo-1-ethylpyridinium tetrafluoroborate) (BEP), 2-bromo-1-methylpyridinium iodide (BMPI)]. The reaction can be carried out in the presence of a base such as, 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), N,N-diisopropylethylamine, N-methylmorpholine or triethylamine. The reaction is normally and preferably effected in the presence of a solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved and that it can dissolve the reagents, at least to some extent. Examples of suitable solvents include: acetone; nitromethane; DMF; N-Methyl-2-piperidone (NMP); sulfolane; DMSO; 2-butanone; acetonitrile; halogenated hydrocarbons, such as DCM, 1,2-dichloroethane, chloroform; and ethers, such as THF and 1,4-dioxane. The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. The preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting material or reagent used. However, in general, we find it convenient to carry out the reaction at a temperature of from -20 oC to 100 oC, more preferably from about 0 oC to 60 oC. The time required for the reaction can also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 5 minutes to 1 week, more preferably from 30 minutes to 24 hrs, will usually suffice.
<Scheme-H>
Figure JPOXMLDOC01-appb-C000009
In Step H-a, a compound of formula ((I)-j) can be prepared by hydrogenation of a compound of formula ((I)-i) under, for example, known hydrogenolysis conditions in the presence of a suitable metal catalyst under a hydrogen atmosphere, or in the presence of hydrogen sources such as formic acid or ammonium formate, in an inert solvent. If desired, the reaction is carried out under acidic conditions, for example, in the presence of hydrochloric acid or acetic acid. A preferred metal catalyst is selected from, for example, nickel catalysts such as Raney nickel; Pd-C; palladiumhydroxide-carbon; platinumoxide; platinum-carbon; ruthenium-carbon; Fe; Zn; Sn; and SnCl2. Examples of suitable inert aqueous or non-aqueous organic solvents include: alcohols, such as methanol, ethanol or ammonic methanol; ethers, such as THF or 1,4-dioxane; acetone; dimethylformamide; halogenated hydrocarbons, such as DCM, 1,2-dichloroethane or chloroform; and acetic acid; or mixtures thereof. The reaction can be carried out at a temperature in the range of from 20 oC to 150 oC, preferably in the range of from 20 oC to 80 oC. Reaction times are, in general, from 10 minutes to 4 days, preferably from 30 minutes to 24 hrs. This reaction can be carried out under a hydrogen atmosphere at a pressure ranging from 1 to 100 atoms, preferably from 1 to 10 atoms.
When Ar3 is 5 to 10 membered aryl, in Step H-b, the compounds of formula ((I)-k) can be prepared by amidation reaction via the compound of formula ((I)-j) according to the method described in Step G-b above.
<Scheme-I>
Figure JPOXMLDOC01-appb-C000010
In Step I-a, the compounds of formula ((I)-l) can be prepared by reduction of the compound of formula ((I)-f). The reduction may be carried out in the presence of a suitable reducing agent in an inert solvent or without solvent. A preferred reducing agent is selected from, for example, but not limited to, NaBH4, LiAIH4, LiBH4, BH3-complex and (iso-butyl)2AlH. Reaction temperatures are generally in the range of from -78 oC to 100 oC, preferably in the range of from -70 oC to 60 oC. Reaction times are, in general, from 1 minute to a day, preferably from 3 hrs to 12 hrs. Examples of suitable solvents include: THF; 1,4-dioxane; DMF; acetonitrile; alcohols, such as methanol or ethanol, and halogenated hydrocarbons, such as DCM, 1,2-dichloroethane, chloroform or carbon tetrachloride.
<Scheme-J>
Figure JPOXMLDOC01-appb-C000011
In Step J-a, a compound of formula ((I)-o) can be prepared from a compound of formula ((I)-m) and/or ((I)-n) by the method described in Step H-a above.
In Step J-b, a compound of formula ((I)-p) can be prepared from a compound of formula ((I)-o) by the method described in Step A-a above. Instead of sulfonyl chloride compound (II), a preferred reagent is selected from, for example, but not limited to, acid chloride such as acetyl chloride and acid anhydride such as acetic anhydride.
In Step J-b, a compound of formula ((I)-q) can be prepared from a compound of formula ((I)-o) by the method described in Step A-a above. When E presents NH2, the corresponding compound is prepared from a compound of formula ((I)-o) and sulfamine.
In Step J-b, a compound of formula ((I)-r) can be prepared from a compound of formula ((I)-o) by the method described in Step A-a above. Instead of sulfonyl chloride compound (II), a preferred reagent is selected from, for example, but not limited to, isocyanate reagent such as trimethylsilyl isocyanate and N-carbonyl chloride such as N,N-dimethylcarbamoyl chloride.
All starting materials in the following general syntheses may be commercially available or obtained by conventional methods known to those skilled in the art. The key intermediate methyl 4-(chlorosulfonyl)benzoate can be prepared by the method described in Chemistry & Biology (2002) 9, 113.
Each of the final compounds was purified by preparative LC-MS system (''Process A''). After purification, mass spectrum (MS) and chemical purity were measured by HPLC-QC method using condition C, D or E. In general, "the preparative LC-MS system in usual manner" means the purification using ''Process A''.
Example 1
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
To a pyridine (5 mL) solution of 3-chloro-5-(trifluoromethyl)pyridin-2-amine (1.0 g, 5.1 mmol) was added methyl 4-(chlorosulfonyl)benzoate (1.3 g, 5.6 mmol) and the mixture was refluxed for 14 hrs. The mixture was concentrated under reduced pressure. The residue was dissolved in DCM. The organic layer was then washed with 2 M aqueous HCl solution and sat. NaHCO3, dried over MgSO4. After the filtration to separate solvent and MgSO4, the solvent was removed under reduced pressure to give 550 mg (27% yield) of methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate as a dark solid that was used in the next step without further purification;
Figure JPOXMLDOC01-appb-I000001
LC-MS (Method A) m/z: M+1 obs 394.8; tR = 2.92 min.
Step-2: Methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1, 550 mg, 1.4 mmol) was dissolved into DMF (5 mL). To the mixture were added K2CO3 (2.1 g, 15.0 mmol) and benzyl bromide (1.7 g, 10.0 mmol) at room temperature. The mixture was refluxed for 18 hrs. After being filtered off, the filtrate was concentrated under reduced pressure, the residue was applied to a silica gel chromatography column and eluted with a hexane/EtOAc = 4/1 to furnish 310 mg (46% yield) of the titled compound as a white solid;
Figure JPOXMLDOC01-appb-I000002
LC-MS (Method A) m/z: M+1 484.8; tR = 3.54 min.
Step-3: 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
To the solution of methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 1, 1.1 g, 2.2 mmol) in THF (20 mL) was added 2 M aqueous NaOH solution (10 mL, 20.0 mmol) at room temperature and the mixture was refluxed at 90 oC with stirring for 3 hrs. The reaction was quenched with water and the product was extracted with EtOAc. The organic layer was then washed with brine, dried over Na2SO4. After the filtration to separate solvent and Na2SO4, the solvent was removed under reduced pressure to give the residue, which was recrystallized from diisopropyl ether to furnish 807 mg (99% yield) of the titled compound as a white solid.;
Figure JPOXMLDOC01-appb-I000003
LC-MS (Method A) m/z: M+1 obs 470.8; tR = 3.12 min.
Example 2
4-(N-Benzyl-N-(3-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: N-Benzyl-3-(trifluoromethyl)pyridin-2-amine
To a suspension of 2-chloro-3-(trifluoromethyl)pyridine (500 mg, 2.8 mmol) and K2CO3 (1.9 g, 13.8 mmol) in DMF (5 mL) was added benyzyl amine (0.9 g, 8.3 mmol) at room temperature and the mixture was stirred for 16 hrs at 110 oC. The reaction was quenched with water and the product was extracted with (EtOAc/toluene = 4/1). The organic layer was then washed with brine, dried over Na2SO4. After the filtration to separate solvent and Na2SO4, the solvent was removed under reduced pressure to give the residue, which was applied to an amino-silica gel chromatography column and eluted with a hexane/EtOAc = 19/1 to furnish 363 mg (52% yield) of the titled compound as a white solid;
Figure JPOXMLDOC01-appb-I000004
LC-MS (Method A) m/z: M+1 obs 253.0, tR = 3.28 min.
Step-2: 4-(N-Benzyl-N-(3-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
To a solution of N-benzyl-3-(trifluoromethyl)pyridin-2-amine (step-1 of Example 2, 40 mg; 0.16 mmol) in pyridine (1 mL) was added 4-(chlorosulfonyl)benzoic acid (350 mg, 1.6 mmol) at room temperature. The reaction mixture was stirred at 80 oC for 2 hrs. After the reaction mixture was cooled to room temperature, DMAP (3.9 mg, 0.03 mmol) was added to the mixture. The reaction mixture was refluxed with stirring for 2 days. After the reaction mixture was cooled to room temperature, the reaction was quenched with sat. NaHCO3 aqueous solutions and the product was extracted with DCM. The organic layer was then washed with brine, dried over Na2SO4. After the filtration to separate solvent and Na2SO4, the solvent was removed under reduced pressure to give the residue. The residue was diluted with methanol and applied onto a strong cation exchange cartridge (BondElute (registered trademark) SCX, 1 g/6 mL, Varian Inc.), and the solid phase matrix was rinsed with MeOH (6 mL). The crude mixture was eluted in a collection tube with 1 M ammonia in MeOH (6 mL) and concentrated in vacuo. The residue was purified by preparative LC-MS (Process A) to give 2.0 mg (3% yield) of the titled compound.
Example 3
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide
Step-1: N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide
Prepared as in step-1 of Example 1 from benzenesulfonyl chloride;
Figure JPOXMLDOC01-appb-I000005
LC-MS (Method A) m/z: M+1 obs 336.9, tR = 2.97 min.
Step-2: N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide
Prepared as in step-2 of Example 1 from N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl) benzenesulfonamide (step-1 of Example 3);
Figure JPOXMLDOC01-appb-I000006
Example 4
N-(3-(Trifluoromethyl)phenyl)benzenesulfonamide
Prepared as in step-1 of Example 1 from 3-(trifluoromethyl)aniline and benzenesulfonyl chloride;
Figure JPOXMLDOC01-appb-I000007
LC-MS (Method A) m/z: M+1 obs 301.9, tR = 3.09 min.
Example 5
N-(2-(4-Methylpiperazin-1-yl)-2-oxoethyl)-N-(3-(trifluoromethyl)phenyl)benzenesulfonamide
Step-1: tert-Butyl 2-(N-(3-(trifluoromethyl)phenyl)phenylsulfonamido)acetate
To a suspension of sodium hydride (93 mg, 2.3 mmol) in THF (5 mL) was added a solution of methyl N-(3-(trifluoromethyl)phenyl)benzenesulfonamide (Example 4, 500 mg, 1.7 mmol) in THF (1 mL) at 0 oC. After being stirred at 0 oC for 20 min, tert-butyl 2-bromoacetate (260 mg, 1.3 mmol) was added to the mixture. The reaction mixture was refluxed at 90 oC with stirring for 4 hrs. The reaction was quenched with sat. ammonium chloride and the product was extracted with EtOAc. The organic layer was then washed with brine, dried over Na2SO4. After the filtration to separate solvent and Na2SO4, the solvent was removed under reduced pressure to give the residue, which was applied to a silica gel chromatography column and eluted with a hexane/EtOAc = 4/1 to furnish 624 mg (91% yield) of the titled compound as a colorless oil;
Figure JPOXMLDOC01-appb-I000008
Step-2: 2-(N-(3-(Trifluoromethyl)phenyl)phenylsulfonamido)acetic acid
To a solution of tert-butyl 2-(N-(3-(trifluoromethyl)phenyl)phenylsulfonamido)acetate (step-1 of Example 5, 620 mg, 1.5 mmol) in DCM (1 mL) was added trifluoroacetic acid (1 mL) at room temperature. The reaction mixture was stirred at room temperature for 1 hr and concentrated in vacuo to give 453 mg (84% yield) of the titled compound as a white solid;
Figure JPOXMLDOC01-appb-I000009
LC-MS (Method A) m/z: M+1 obs 359.9, tR = 2.90 min.
Step-3: N-(2-(4-Methylpiperazin-1-yl)-2-oxoethyl)-N-(3-(trifluoromethyl)phenyl)benzenesulfonamide
To a suspension of 2-(N-(3-(trifluoromethyl)phenyl)phenylsulfonamido)acetic acid (step-2 of Example 5, 30 mg, 0.08 mmol) and 1-methylpiperazine (13 mg, 0.13 mmol) in DCM (2 mL) were added Et3N (25 mg, 0.25 mmol), EDC (21 mg, 0.1 mmol) and HOBt (6.4 mg, 0.04 mmol) respectively. The reaction mixture was stirred at room temperature for 18 hrs. The solvent was evaporated by N2-flow. The resulting resideu was dissolved into EtOAc and water was added to the mixture. The organic layer was then washed with brine, dried over Na2SO4. After the filtration to separate solvent and Na2SO4, the solvent was removed under reduced pressure to give the residue. The residue was diluted with MeOH and applied onto a strong cation exchange cartridge (BondElute (registered trademark) SCX, 1 g/6 mL, Varian Inc.), and the solid phase matrix was rinsed with MeOH (6 mL). The crude mixture was eluted in a collection tube with 1 M ammonia in MeOH (6 mL) and concentrated in vacuo. The residue was purified by preparative LC-MS to give 15 mg, (41% yield) of the titled compound.
Example 6
N-(2-Oxo-2-(piperidin-1-yl)ethyl)-N-(3-(trifluoromethyl)phenyl)benzenesulfonamide
Prepared as in Example 5 - step-3 from piperidine.
Example 7
N-Benzyl-2-(N-(3-(trifluoromethyl)phenyl)benzenesulfonamido)acetamide
Prepared as in Example 5 - step-3 from benzyl amine.
Example 8
N-Phenyl-2-(N-(3-(trifluoromethyl)phenyl)benzenesulfonamido)acetamide
Prepared as in Example 5 - step-3 from aniline.
Example 9
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(hydroxymethyl)benzene-1-sulfonamide
To a solution of methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 1, 40 mg, 0.08 mmol) in THF (1 mL) was added lithium alminium hydride (3.1 mg, 0.08 mmol) at room temperature. After being stirred at room temperature for 30 min, EtOAc was added to the reaction mixture. H2O and 2 M NaOH aqueous solution were added carefully until forming white precipitate. MgSO4 was added to the suspension. After being filtered off, the filtrate was concentrated in vacuo. The residue was diluted with MeOH and applied onto a strong cation exchange cartridge (BondElute (registered tredemark) SCX, 1 g/6 mL, Varian Inc.), and the solid phase matrix was rinsed with MeOH (6 mL). The crude mixture was eluted in a collection tube with 1 M ammonia in MeOH (6 mL) and concentrated in vacuo. The residue was purified by preparative LC-MS to give 9.9 mg (26% yield) of the titled compound.
Example 10
4-(Benzyl(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzamide
Prepared as in Example 5 - step-3 from 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid (Example 1) and ammonium chloride.
Example 11
4-(Benzyl(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-N-methylbenzamide
Prepared as in Example 5 - step-3 from 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid (Example 1) and methyl amine.
Example 12
4-(Benzyl(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-N,N-dimethylbenzamide
Prepared as in Example 5 - step-3 from 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid (Example 1) and dimethyl amine.
Example 13
4-(Benzyl(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-N-(2-hydroxyethyl)benzamide
Prepared as in Example 5 - step-3 from 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid (Example 1) and ethanolamine.
Example 14
4-(N-Benzyl-N-(5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-benzylsulfamoyl)benzoate
To a solution of benzyl amine (200 mg, 1.9 mmol) and Et3N (570 mg, 5.6 mmol) in DCM (3 mL) was added methyl 4-(chlorosulfonyl)benzoate (440 mg, 1.9 mmol) at room temperature. After being stirred at room temperature for 2 hrs, sat. ammonium chloride was added to the mixture. The product was extracted with DCM. The organic layer was then washed with brine, dried over Na2SO4. After the filtration to separate solvent and Na2SO4, the solvent was removed under reduced pressure to give the residue, which was applied to a silica gel chromatography column and eluted with a hexane/EtOAc = 2/1 to furnish 274 mg (48% yield) of the titled compound as a white solid;
Figure JPOXMLDOC01-appb-I000010
LC-MS (Method A) m/z: M+1 obs 306.0, tR = 2.92 min.
Step-2: Methyl 4-(N-benzyl-N-(5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
To a solution of methyl 4-(N-benzylsulfamoyl)benzoate (step-1 of Example 14, 60 mg, 0.20 mmol) and 2-chloro-5-(trifluoromethyl)pyridine (43 mg, 0.24 mmol) in 1,4-dioxane (2mL) were added Cs2CO3 (96 mg, 0.30 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (17 mg, 0.03 mmol) at room temperature. The mixture was stirred at room temperature for 5 min, palladium acetate (4 mg, 0.02 mmol) was added to the mixture. The mixture was stirred at 115 oC for 3 hrs using microwave oven. The resulting precipitate was removed by filtration and washed with dioxane. The filtrate was concentrated under reduced pressure to give the residue, which was applied to a silica gel chromatography column and eluted with a hexane/EtOAc = 4/1 to furnish 42 mg (47% yield) of the titled compound as a brown oil;
Figure JPOXMLDOC01-appb-I000011
LC-MS (Method A) m/z: M+1 obs 450.9, tR = 3.54 min.
Step-3: 4-(N-Benzyl-N-(5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Prepared as in Example 1 - step-3 from methyl 4-(N-benzyl-N-(5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 14).
Example 15
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoate
To a mixture of methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (prepared in step 1 of Example 1, 30 mg, 0.076 mmol) and 1-(bromomethyl)-4-(trifluoromethoxy)benzene (39 mg, 0.152 mmol) in DMF (0.5 mL) were added Cs2CO3 (99 mg, 0.304 mmol) and NaI (11 mg, 0.076 mmol) at room temperature. The mixture was stirred at 90 oC for 1 day. The mixture was quenched with H2O, extracted with EtOAc, dried over Na2SO4, filtered and concentrated. The residual oil was used next step without purification.
LC-MS (Method A) m/z: M+1 obs 568.8, tR = 3.69 min.
Step-2:
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
To a solution of methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoate (prepared in step-1 of Example 15, crude) in THF (0.5 mL) was added 2 M aqueous NaOH solution at room temperature. The mixture was stirred at 50 oC for 3 hrs. The mixture was acidified by 2 M aqueous HCl (0.5 mL) solution, extracted with DCM, dried over Na2SO4, filtered and concentrated. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 16
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxybenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxybenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-methoxybenzene;
LC-MS (Method A) m/z: M+1 obs 514.9, tR = 3.49 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxybenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxybenzyl)sulfamoyl)benzoate (step-1 of Example 16). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 17
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-fluorobenzene;
LC-MS (Method A) m/z: M+1 obs 502.9, tR = 3.54 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoate (step-1 of Example 17). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 18
4-(N-(4-tert-Butylbenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(4-(tert-butyl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-(tert-butyl)benzene;
LC-MS (Method A) m/z: M+1 obs 540.9, tR = 3.84 min.
Step-2: 4-(N-(4-tert-Butylbenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-(tert-butyl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 18). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 19
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-cyclohexylethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-cyclohexylethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and (2-bromoethyl)cyclohexane;
LC-MS (Method A) m/z: M+1 obs 505.0, tR = 3.87 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-cyclohexylethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-cyclohexylethyl)sulfamoyl)benzoate (step-1 of Example 19). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 20
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-fluorobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-fluorobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-2-fluorobenzene;
LC-MS (Method A) m/z: M+1 obs 503.12, tR = 3.48 min.
Step-2: 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-fluorobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-fluorobenzyl)sulfamoyl)benzoate (step-1 of Example 20). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 21
4-(N-Benzyl-N-(4-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-benzyl-N-(4-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 14 from methyl 4-(N-benzylsulfamoyl)benzoate (step-1 of Example 14) and 2-chloro-4-(trifluoromethyl)pyridine;
LC-MS (Method A) m/z: M+1 obs 451.14, tR = 3.48 min.
Step-2: 4-(N-Benzyl-N-(4-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(4-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 21). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 22
4-(N-Benzyl-N-(6-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-benzyl-N-(6-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 14 from methyl 4-(N-benzylsulfamoyl)benzoate (step-1 of Example 14) and 2-chloro-6-(trifluoromethyl)pyridine;
LC-MS (Method A) m/z: M+1 obs 451.14, tR = 3.47 min.
Step-2: 4-(N-Benzyl-N-(6-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(6-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 22). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 23
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(chloromethyl)-3-(trifluoromethyl)benzene;
LC-MS (Method A) m/z: M+1 obs 553.08, tR = 3.63 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 23). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 24
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-methoxybenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-methoxybenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-3-methoxybenzene;
LC-MS (Method A) m/z: M+1 obs 515.08, tR = 3.50 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-methoxybenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-methoxybenzyl)sulfamoyl)benzoate (step-1 of Example 24). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 25
4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethoxy)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-3-(trifluoromethoxy)benzene;
LC-MS (Method A) m/z: M+1 obs 569.08, tR = 3.67 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethoxy)benzyl)sulfamoyl)benzoate (step-1 of Example 25). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 26
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,4-difluorobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,4-difluorobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-2,4-difluorobenzene;
LC-MS (Method A) m/z: M+1 obs 521.07, tR = 3.50 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,4-difluorobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,4-difluorobenzyl)sulfamoyl)benzoate (step-1 of Example 26). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 27
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methylbenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methylbenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-methylbenzene;
LC-MS (Method A) m/z: M+1 obs 499.07, tR = 3.59 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methylbenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methylbenzyl)sulfamoyl)benzoate (step-1 of Example 27). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 28
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-isopropylbenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-isopropylbenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(chloromethyl)-4-isopropylbenzene;
LC-MS (Method A) m/z: M+1 obs 527.13, tR = 3.73 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-isopropylbenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-isopropylbenzyl)sulfamoyl)benzoate (step-1 of Example 28). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 29
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopropylmethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopropylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and (bromomethyl)cyclopropane;
LC-MS (Method A) m/z: M+1 obs 449.10, tR = 3.43 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopropylmethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopropylmethyl)sulfamoyl)benzoate (step-1 of Example 29). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 30
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(2-bromoethoxy)-4-fluorobenzene;
LC-MS (Method A) m/z: M+1 obs 533.06, tR = 3.48 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoate (step-1 of Example 30). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 31
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(chloromethyl)-2-(trifluoromethyl)benzene;
LC-MS (Method A) m/z: M+1 obs 533.01, tR = 3.60 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 31). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 32
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-chlorobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-chlorobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-chloro-4-(chloromethyl)benzene;
LC-MS (Method A) m/z: M+1 obs 519.03, tR = 3.60 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-chlorobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-chlorobenzyl)sulfamoyl)benzoate (step-1 of Example 32). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 33
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyanobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyanobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(bromomethyl)benzonitrile;
LC-MS (Method A) m/z: M+1 obs 510.04, tR = 3.37 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyanobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyanobenzyl)sulfamoyl)benzoate (step-1 of Example 33). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 34
4-(N-Benzyl-N-(3-methylpyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-methylpyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 3-methylpyridin-2-amine in the presence of DMAP (0.2 eq.);
Figure JPOXMLDOC01-appb-I000012
LC-MS (Method A) m/z: M+1 obs 307.27, tR = 2.57 min.
Step-2: Methyl 4-(N-benzyl-N-(3-methylpyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 34) and (bromomethyl)benzene;
LC-MS (Method A) m/z: M+1 obs 397.16, tR = 3.29 min.
Step-3: 4-(N-Benzyl-N-(3-methylpyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-methylpyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 34). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 35
4-(N-Benzyl-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 3,5-dichloropyridin-2-amine in the presence of DMAP (0.2 eq.);
Figure JPOXMLDOC01-appb-I000013
LC-MS (Method A) m/z: M+1 obs 361.07, tR = 2.93 min.
Step-2: Methyl 4-(N-benzyl-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and (bromomethyl)benzene;
LC-MS (Method A) m/z: M+1 obs 451.04, tR = 3.44 min.
Step-3: 4-(N-Benzyl-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 35). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 36
4-(N-Benzyl-N-(3-chloro-5-methylpyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-methylpyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 3-chloro-5-methylpyridin-2-amine in the presence of DMAP (0.2 eq.);
Figure JPOXMLDOC01-appb-I000014
LC-MS (Method A) m/z: M+1 obs 341.11, tR = 2.82 min.
Step-2: Methyl 4-(N-benzyl-N-(3-chloro-5-methylpyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 36) and (bromomethyl)benzene;
LC-MS (Method B) m/z: M+1 obs 431.16, tR = 2.61 min.
Step-3: 4-(N-Benzyl-N-(3-chloro-5-methylpyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-methylpyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 36). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 37
4-(N-Benzyl-N-(3-chloropyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloropyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 3-chloropyridin-2-amine in the presence of DMAP (0.2 eq.);
Figure JPOXMLDOC01-appb-I000015
LC-MS (Method A) m/z: M+1 obs 327.10, tR = 2.62 min.
Step-2: Methyl 4-(N-benzyl-N-(3-chloropyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 37) and (bromomethyl)benzene;
LC-MS (Method B) m/z: M+1 obs 417.14, tR = 2.43 min.
Step-3: 4-(N-Benzyl-N-(3-chloropyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 37). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 38
4-(N-Benzyl-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 5-chloro-3-methylpyridin-2-amine in the presence of DMAP (0.2 eq.);
LC-MS (Method A) m/z: M+1 obs 341.15, tR = 2.93 min.
Step-2: Methyl 4-(N-benzyl-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and (bromomethyl)benzene;
LC-MS (Method B) m/z: M+1 obs 431.16, tR = 2.76 min.
Step-3: 4-(N-Benzyl-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 38). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 39
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-(trifluoromethyl)benzene;
LC-MS (Method A) m/z: M+1 obs 553.06, tR = 3.62 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 39). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 40
4-(N-(2-Chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(2-chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-2-chloro-4-fluorobenzene;
LC-MS (Method B) m/z: M+1 obs 537.07, tR = 2.97 min.
Step-2: 4-(N-(2-Chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(2-chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 40). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 41
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(2,2,2-trifluoroethoxy)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(2,2,2-trifluoroethoxy)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-(2,2,2-trifluoroethoxy)benzene;
LC-MS (Method B) m/z: M+1 obs 583.13, tR = 2.93 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(2,2,2-trifluoroethoxy)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(2,2,2-trifluoroethoxy)benzyl)sulfamoyl)benzoate (step-1 of Example 41). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 42
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,5-difluorobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,5-difluorobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-3,5-difluorobenzene;
LC-MS (Method B) m/z: M+1 obs 521.13, tR = 2.88 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,5-difluorobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,5-difluorobenzyl)sulfamoyl)benzoate (step-1 of Example 42). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 43
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(bromomethyl)-1-fluoro-2-(trifluoromethyl)benzene;
LC-MS (Method B) m/z: M+1 obs 571.12, tR = 2.97 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 43). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 44
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,6-difluorobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,6-difluorobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 2-(bromomethyl)-1,3-difluorobenzene;
LC-MS (Method B) m/z: M+1 obs 521.13, tR = 2.79 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,6-difluorobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,6-difluorobenzyl)sulfamoyl)benzoate (step-1 of Example 44). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 45
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-difluorobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-difluorobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(bromomethyl)-1,2-difluorobenzene;
LC-MS (Method B) m/z: M+1 obs 521.13, tR = 2.88 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-difluorobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-difluorobenzyl)sulfamoyl)benzoate (step-1 of Example 45). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 46
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,5-difluorobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,5-difluorobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 2-(bromomethyl)-1,4-difluorobenzene;
LC-MS (Method B) m/z: M+1 obs 521.13, tR = 2.84 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,5-difluorobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,5-difluorobenzyl)sulfamoyl)benzoate (step-1 of Example 46). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 47
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-dichlorobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-dichlorobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(bromomethyl)-1,2-dichlorobenzene;
LC-MS (Method B) m/z: M+1 obs 555.05, tR = 3.07 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-dichlorobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-dichlorobenzyl)sulfamoyl)benzoate (step-1 of Example 47). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 48
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-chlorobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-chlorobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-3-chlorobenzene;
LC-MS (Method B) m/z: M+1 obs 519.09, tR = 2.95 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-chlorobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-chlorobenzyl)sulfamoyl)benzoate (step-1 of Example 48). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 49
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(chloromethyl)-4-(1-methylcyclopropyl)benzene;
LC-MS (Method B) m/z: M+1 obs 539.2, tR = 3.15 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoate (step-1 of Example 49). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 50
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(chloromethyl)-4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzene;
LC-MS (Method A) m/z: M+1 obs 595.16, tR = 3.70 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzyl)sulfamoyl)benzoate (step-1 of Example 50). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 51
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethoxy)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-2-(trifluoromethoxy)benzene;
LC-MS (Method A) m/z: M+1 obs 569.14, tR = 3.60 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethoxy)benzyl)sulfamoyl)benzoate (step-1 of Example 51). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 52
3-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 3-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
To a suspension of NaH (60% in oil, 146 mg, 3.82 mmol) in THF (30 mL) was added 3-chloro-5-(trifluoromethyl)pyridin-2-amine (500 mg, 2.54 mmol) at 0 oC and stirred at room temperature for 1 h. Then, to the mixture was added methyl 3-(chlorosulfonyl)benzoate (597 mg, 2.54 mmol) at 0 oC and stirred at room temperature for 2 hrs. The mixture was acidified by 2 M aqueous HCl solution, extracted with EtOAc (2 times), dried over Na2SO4, filtered and concentrated. The residue was applied to a silica gel column chromatography and eluted with hexane/EtOAc = 1/1 to furnish 455 mg (45% yield) of the titled compound as a pale yellow solid;
Figure JPOXMLDOC01-appb-I000016
LC-MS (Method A) m/z: M+1 obs 395.15, tR = 3.00 min.
Step-2: Methyl 3-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 3-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 52) and (bromomethyl)benzene;
LC-MS (Method B) m/z: M+1 obs 454.18, tR = 2.84 min.
Step-3: 3-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 3-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 52). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 53
4-(N-Benzyl-N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 3-fluoro-5-(trifluoromethyl)pyridin-2-amine;
Figure JPOXMLDOC01-appb-I000017
LC-MS (Method A) m/z: M+1 obs 379.16, tR = 2.85 min.
Step-2: Methyl 4-(N-benzyl-N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 53) and (bromomethyl)benzene;
LC-MS (Method B) m/z: M+1 obs 469.17, tR = 2.79 min.
Step-3: 4-(N-Benzyl-N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-Benzyl-N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 53). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 54
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(bromomethyl)-4-(trifluoromethyl)benzene;
LC-MS (Method B) m/z: M+1 obs 519.09, tR = 2.97 min.
Step-2: 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 54). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 55
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-(trifluoromethyl)benzene;
LC-MS (Method B) m/z: M+1 obs 499.20, tR = 3.00 min.
Step-2: 4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 55). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 56
4-(N-Benzyl-N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 1 from methyl 4-(chlorosulfonyl)benzoate and 2-chloro-4-(trifluoromethyl)aniline in the presence of DMAP (0.2 eq.);
Figure JPOXMLDOC01-appb-I000018
LC-MS (Method B) m/z: M-1 obs 392.10, tR = 2.42min.
Step-2: Methyl 4-(N-benzyl-N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoate (step-1 of Example 56) and (bromomethyl)benzene;
LC-MS (Method A) m/z: M+1 obs 484.09, tR = 3.55 min.
Step-3: 4-(N-Benzyl-N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoate (step-2 of Example 56). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 57
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-morpholinoethyl)sulfamoyl)benzoic acid
Step-1: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-morpholinoethyl)sulfamoyl)benzoic acid
To a mixture of methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1, 30 mg, 0.076 mmol) and 4-(2-chloroethyl)morpholine hydrochloride (28 mg, 0.152 mmol) in DMF (0.3 mL) were added Cs2CO3 (99 mg, 0.304 mmol) and NaI (11 mg, 0.076 mmol) at room temperature. The mixture was irradiated with micro-wave (150 oC, 1 h). The mixture was acidified by 2 M aqueous HCl solution, extracted with DCM, dried over Na2SO4, filtered and concentrated. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 58
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 2-(bromomethyl)pyridine hydrobromide;
LC-MS (Method B) m/z: M+1 obs 486.2, tR = 2.48 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoate (step-1 of Example 58). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 59
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-phenylpropyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-phenylpropyl)sulfamoyl)benzoate
To a mixture of methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1, 30 mg, 0.076 mmol) and (3-bromopropyl)benzene (30 mg, 0.152 mmol) in DMF (0.6 mL) were added Cs2CO3 (99 mg, 0.304 mmol) and NaI (11 mg, 0.076 mmol) at room temperature. The mixture was irradiated with micro-wave (150 oC, 30 min). The mixture was acidified by 2 M aqueous HCl solution, extracted with DCM, dried over Na2SO4, filtered and concentrated. The residue was used next step without purification.
LC-MS (Method B) m/z: M+1 obs 513.2, tR = 3.00 min
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-phenylpropyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-phenylpropyl)sulfamoyl)benzoate (step-1 of Example 59). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 60
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 4-(bromomethyl)-1-fluoro-2-(trifluoromethyl)benzene.
Step-2: 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 60). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 61
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(bromomethyl)-4-fluorobenzene.
Step-2: 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoate (step-1 of Example 61). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 62
4-(N-(4-Chloro-3-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(4-chloro-3-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 4-(bromomethyl)-1-chloro-2-fluorobenzene.
Step-2: 4-(N-(4-Chloro-3-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-chloro-3-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 62). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 63
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(bromomethyl)-4-(trifluoromethoxy)benzene.
Step-2: 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoate (step-1 of Example 63). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 64
4-(N-(3,5-Dichloropyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(bromomethyl)-2-(trifluoromethyl)benzene.
Step-2: 4-(N-(3,5-Dichloropyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 64). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 65
4-(N-(4-Chloro-3-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(4-chloro-3-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(bromomethyl)-1-chloro-2-fluorobenzene.
Step-2: 4-(N-(4-Chloro-3-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-chloro-3-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 65). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 66
4-(N-(4-Chloro-3-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(4-chloro-3-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 4-(bromomethyl)-1-chloro-2-(trifluoromethyl)benzene.
Step-2: 4-(N-(4-Chloro-3-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-chloro-3-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 66). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 67
4-(N-(3,5-Dichloropyridin-2-yl)-N-(3-fluoro-4-methylbenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(3-fluoro-4-methylbenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 4-(bromomethyl)-2-fluoro-1-methylbenzene.
Step-2: 4-(N-(3,5-Dichloropyridin-2-yl)-N-(3-fluoro-4-methylbenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(3-fluoro-4-methylbenzyl)sulfamoyl)benzoate (step-1 of Example 67). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 68
4-(N-(3,5-dichloropyridin-2-yl)-N-(4-methyl-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-methyl-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 4-(bromomethyl)-1-methyl-2-(trifluoromethyl)benzene.
Step-2: 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-methyl-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-methyl-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 68). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 69
4-(N-(3-Chloro-4-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-4-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 4-(bromomethyl)-2-chloro-1-fluorobenzene.
Step-2: 4-(N-(3-Chloro-4-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-4-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 69). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 70
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(chloromethyl)-4-(1-methylcyclopropyl)benzene.
Step-2: 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoate (step-1 of Example 70). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 71
4-(N-(3-Chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(bromomethyl)-2-chloro-1-fluorobenzene.
Step-2: 4-(N-(3-chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 71). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 72
4-(N-(4-Chloro-2-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(4-chloro-2-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(bromomethyl)-4-chloro-2-(trifluoromethyl)benzene.
Step-2: 4-(N-(4-Chloro-2-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-chloro-2-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 72). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 73
4-(N-(3,5-Dichloropyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(2-bromoethoxy)-4-fluorobenzene.
Step-2: 4-(N-(3,5-Dichloropyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoate. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 74
4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 35) and 1-(4-(chloromethyl)phenyl)pyrrolidin-2-one.
Step-2: 4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3,5-dichloropyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoate (step-1 of Example 74). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 75
4-(N-(4-Chloro-2-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(4-chloro-2-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and 1-(bromomethyl)-4-chloro-2-(trifluoromethyl)benzene.
Step-2: 4-(N-(4-Chloro-2-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-chloro-2-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 75). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 76
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and 4-(bromomethyl)-1-fluoro-2-(trifluoromethyl)benzene.
Step-2: 4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoate (step-1 of Example 76). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 77
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(3-chloro-4-fluorobenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(3-chloro-4-fluorobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and 4-(bromomethyl)-2-chloro-1-fluorobenzene.
Step-2: 4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(3-chloro-4-fluorobenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(3-chloro-4-fluorobenzyl)sulfamoyl)benzoate (step-1 of Example 77). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 78
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and 1-(bromomethyl)-4-(trifluoromethoxy)benzene.
Step-2: 4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoate (step-1 of Example 78). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 79
4-(N-(4-Chloro-3-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(4-chloro-3-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and 4-(bromomethyl)-1-chloro-2-(trifluoromethyl)benzene.
Step-2: 4-(N-(4-Chloro-3-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-chloro-3-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 79). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 80
4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 38) and 1-(4-(bromomethyl)phenyl)pyrrolidin-2-one.
Step-2: 4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(5-chloro-3-methylpyridin-2-yl)-N-(4-(2-oxopyrrolidin-1-yl)benzyl)sulfamoyl)benzoate (step-1 of Example 80). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 81
4-(N-(2-Chloro-4-(trifluoromethyl)phenyl)-N-(2-morpholinoethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)-N-(2-morpholinoethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 59 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(2-chloroethyl)morpholine hydrochloride;
LC-MS (Method B) m/z: M+1 obs 507.2, tR = 2.50 min.
Step-2: 4-(N-(2-Chloro-4-(trifluoromethyl)phenyl)-N-(2-morpholinoethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)-N-(2-morpholinoethyl)sulfamoyl)benzoate (step-1 of Example 81). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 82
4-(N-(2-Chloro-4-(trifluoromethyl)phenyl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 2-(bromomethyl)pyridine hydrobromide;
LC-MS (Method B) m/z: M+1 obs 485.2, tR = 2.63 min.
Step-2: 4-(N-(2-Chloro-4-(trifluoromethyl)phenyl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)-N-(pyridin-2-ylmethyl)sulfamoyl)benzoate. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 83
4-(N-(2-Chloro-4-(trifluoromethyl)phenyl)-N-(2-(piperidin-1-yl)ethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)-N-(2-(piperidin-1-yl)ethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 59 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(2-chloroethyl)piperidine hydrochloride.
Step-2: 4-(N-(2-Chloro-4-(trifluoromethyl)phenyl)-N-(2-(piperidin-1-yl)ethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(2-chloro-4-(trifluoromethyl)phenyl)-N-(2-(piperidin-1-yl)ethyl)sulfamoyl)benzoate. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Examples 84-139 were selected from commercially available compounds.
Example 140
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trimethylsilyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trimethylsilyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 1 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate and (4-(bromomethyl)phenyl)trimethylsilane;
LC-MS (Method A) m/z: M+1 obs 556.97, tR = 3.28 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trimethylsilyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 1 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trimethylsilyl)benzyl)sulfamoyl)benzoate (step-1 of Example 140). The further purification was carried out by preparative LC-MS system using the condition in Table 6.
Example 141
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-cyanocyclopropyl)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-cyanocyclopropyl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 1 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate and 1-(4-(bromomethyl)phenyl)cyclopropanecarbonitrile;
LC-MS (Method A) m/z: M+1 obs 549.89, tR = 3.45 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-cyanocyclopropyl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 1 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-cyanocyclopropyl)benzyl)sulfamoyl)benzoate (step-1 of Example 141). The further purification was carried out by preparative LC-MS system using the condition in Table 6.
Example 142
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate and (1-(pyridin-2-yl)piperidin-4-yl)methanamine hydrochloride;
LC-MS (Method A) m/z: M+1 obs 390.08, M-1 obs 388.11, tR = 2.57 min.
Step-2: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoate (step-1 of Example 142);
LC-MS (Method A) m/z: M+1 obs 568.91, tR = 3.42 min.
Step-3: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoate (step-2 of Example 142). The further purification was carried out by preparative LC-MS system using the condition in Table 6.
Example 143
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-methylbenzoic acid
Step-1: methyl 4-(N-benzylsulfamoyl)-2-methylbenzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from N-benzyl-4-bromo-3-methylbenzenesulfonamide;
LC-MS (Method A) m/z: M-1 obs 318.13, tR = 3.00 min.
Step-2: Methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-methylbenzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-benzylsulfamoyl)-2-methylbenzoate (step-1 of Example 143);
LC-MS (Method A) m/z: M+1 obs 498.95, tR = 3.59 min.
Step-3: 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-methylbenzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-methylbenzoate (step-2 of Example 143). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 144
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-6-hydroxypyridine-3-sulfonamide
Step-1: N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-6-hydroxypyridine-3-sulfonamide
A mixture of N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-6-methoxypyridine-3-sulfonamide (step-2 of Example 189, 166.9 mg, 0.365 mmol), 4 M HCl in 1,4-dioxane solution (0.18 mL, 0.729 mmol) in 1,4-dioxane (2 mL) was heated at 55 oC overnight. After cooling, the reaction mixture was concentrated using by a rotary evaporator to give 115 mg (71% yield) of the titled compound as a brown oil. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 145
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methylbenzoic acid
Step-1: Methyl 4-(N-benzylsulfamoyl)-3-methylbenzoate
The titled compound was prepared according to the procedure described in step-3 of Example 188 from N-benzyl-4-bromo-2-methylbenzenesulfonamide;
LC-MS (Method A) m/z: M-1 obs 318.10, tR = 2.97 min.
Step-2: Methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methylbenzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-benzylsulfamoyl)-3-methylbenzoate (step-1 of Example 145);
LC-MS (Method A) m/z: M+1 obs 498.90, tR = 3.55 min.
Step-3: 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methylbenzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methylbenzoate (step-2 of Example 145). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 146
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methoxybenzoic acid
Step-1: Methyl 4-(N-benzylsulfamoyl)-2-methoxybenzoate
The titled compound was prepared according to the procedure described in step-3 of Example 188 from N-benzyl-4-bromo-2-methoxybenzenesulfonamide;
LC-MS (Method A) m/z: M+1 obs 336.06, M-1 obs 334.08, tR = 2.88 min.
Step-2: Methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methoxybenzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-benzylsulfamoyl)-3-methoxybenzoate (step-1 of Example 146);
LC-MS (Method A) m/z: M+1 obs 514.98, tR = 3.52 min.
Step-3: 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methoxybenzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methoxybenzoate (step-2 of Example 146). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 147
2-(4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)phenyl)acetic acid
Step-1: Ethyl 2-(4-(N-benzylsulfamoyl)phenyl)acetate
The titled compound was prepared according to the procedure described in step-1 of Example148 from ethyl 2-(4-(chlorosulfonyl)phenyl)acetate and benzylamine;
Figure JPOXMLDOC01-appb-I000019
LC-MS (Method A) m/z: M+1 obs 334.08, tR = 2.93 min.
Step-2: Ethyl 2-(4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)phenyl)acetate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from ethyl 2-(4-(N-benzylsulfamoyl)phenyl)acetate (step-1 of Example 147) and 2,3-dichloro-5-(trifluoromethyl)pyridine;
LC-MS (Method A) m/z: M+1 obs 513.00, tR = 3.55 min.
Step-3: 2-(4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)phenyl)acetic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from 2-(4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)phenyl)acetate (step-2 of Example 147).
Figure JPOXMLDOC01-appb-I000020
The further purification was carried out by preparative LC-MS system using the condition in Table 6.
Example 148
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-phenethylsulfamoyl)benzoic acid
Step-1: Methyl 4-(N-phenethylsulfamoyl)benzoate
To a solution of 2-phenylethanamine (200 mg, 1.65 mmol) in DCM (10 mL) was added methyl 4-(chlorosulfonyl)benzoate (prepared in step-1 of Example1, 387 mg, 1.65 mmol) and Et3N (501 mg, 4.95 mmol) at 0 oC, and stirred at room temperature for 1 hr. The mixture was poured into 1 M aqueous HCl solution, extracted with DCM, dried over Na2SO4, filtered and concentrated. The residual solid was collected to give the titled compound (298 mg, 57%) as a white solid.
LC-MS (Method A) m/z: M+1 obs 320.11, tR = 2.99 min.
Step-2: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-phenethylsulfamoyl)benzoate
A mixture of methyl 4-(N-phenethylsulfamoyl)benzoate (step-1 of Example 148, 74 mg, 0.231 mmol), 2,3-dichloro-5-(trifluoromethyl)pyridine (50 mg, 0.231 mmol) and Cs2CO3 (226 mg, 0.694 mmol) in MeCN (1.2 mL) was irradiated with micro-wave (160 oC, 15 min). The reaction mixture was poured into H2O, extracted with EtOAc, dried over Na2SO4, filtered and concentrated to give the titled compound as crude.
LC-MS (Method B) m/z: M+1 obs 498.95, tR = 2.92 min.
Step-3: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-phenethylsulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-phenethylsulfamoyl)benzoate (step-2 of Example 148). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 149
4-(N-Benzyl-N-(3-cyclopropyl-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 52 from methyl 4-(chlorosulfonyl)benzoate and 3-bromo-5-(trifluoromethyl)pyridin-2-amine;
LC-MS (Method A) m/z: M+1 obs 438.91, tR = 2.95 min.
Step-2: Methyl 4-(N-benzyl-N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
To a mixture of methyl 4-(N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 149, 1.18 g, 2.69 mmol) and (bromomethyl)benzene (1.38 g, 8.06 mmol) in DMF (0.5 mL) was added Cs2CO3 (3.51 g, 10.75 mmol) and NaI (403 mg, 2.69 mmol) at room temperature. The mixture was stirred at 90 oC for 3 hr. The mixture was diluted with EtOAc, quenched with 1 M aqueous HCl solution, extracted with EtOAc, dried over Na2SO4, filtered and concentrated. The residue, which was applied to an amino-silica gel chromatography column and eluted with a hexane/EtOAc = 4/1 to furnish 645 mg (45% yield) of the title as a white solid.;
Figure JPOXMLDOC01-appb-I000021
LC-MS (Method A) m/z: M+1 obs 528.88, tR = 3.72 min
Step-3: 4-(N-Benzyl-N-(3-cyclopropyl-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
A mixture of methyl 4-(N-benzyl-N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 149, 40 mg, 0.071 mmol), cyclopropylboronic acid (12 mg, 0.142 mmol), Pd(PPh3)4 and sat. NaHCO3 (0.4 mL) in THF (0.8 mL) was irradiated with micro-wave (150 oC, 15 min). Then, to the reaction mixture was added THF (0.5 mL) and 2 M aqueous NaOH solution (0.5 mL), and stirred at 50 oC for 1 hr. The mixture was acidified by 2 M aqueous HCl solution, extracted with DCM, dried over Na2SO4, filtered and concentrated. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 150
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyclopropylbenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 149 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-bromo-4-(bromomethyl)benzene;
Figure JPOXMLDOC01-appb-I000022
LC-MS (Method A) m/z: M+1 obs 564.74 tR = 3.60 min
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyclopropylbenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and cyclopropylboronic acid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 151
4-(N-Benzyl-N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 149). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 152
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-methyl-1H-pyrazol-4-yl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 153
4-(N-Benzyl-N-(3-methyl-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-benzyl-N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 154
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(pyridin-3-yl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-Bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and 3-(1,3,2-dioxaborinan-2-yl)pyridine. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 155
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(thiophen-2-yl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and thiophen-3-ylboronic acid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 156
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(pyridin-4-yl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and pyridin-4-ylboronic acid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 157
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(furan-2-yl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and furan-2-ylboronic acid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 158
4-(N-([1,1'-Biphenyl]-4-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and phenylboronic acid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 159
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(oxazol-5-yl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxazole. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 160
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-((6-(trifluoromethyl)pyridin-3-yl)methyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from (6-(trifluoromethyl)pyridin-3-yl)methanamine.
LC-MS (Method A) m/z: M+1 obs 375.01, M-1 obs 373.04, tR = 2.87min.
Step-2: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)sulfamoyl)benzoate
A mixture of methyl 4-({[6-(trifluoromethyl)pyridin-3-yl]methyl}sulfamoyl)benzoate (step-1 of Example 160, 30 mg, 0.080 mmol), 2,3-dichloro-5-(trifluoromethyl)pyridine (104 mg, 0.401 mmol) and Cs2CO3 (78 mg, 0.240 mmol) in DMSO (0.7 mL) was stirred at 90 oC for 3 hr. The reaction mixture was used next step without purification.
Step-3: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from the reaction mixture in step-2 of Example 160. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 161
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(picolinamido)benzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-nitrobenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 149 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 1-(bromomethyl)-4-nitrobenzene;
Figure JPOXMLDOC01-appb-I000023
LC-MS (Method A) m/z: M+1 obs 529.90 tR = 3.43 min
Step-2: Methyl 4-(N-(4-aminobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
To a solution of methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-nitrobenzyl)sulfamoyl)benzoate (step-1 of Example 161, 336 mg, 0.634 mmol) in MeOH (5 mL) and DCM (2 mL) was added SnCl2 (1.20 g, 6.34 mmol). The mixture was stirred at 50 oC for 3 hr. The mixture was cooled to 0 oC, quenched with sat. NaHCO3, and stirred at room temperature for 1 hr. The mixture was filtered (using Celite pad). The filtrate was extracted with DCM, dried over Na2SO4, filtered and concentrated. The residual oil was used next step without purification.
LC-MS (Method A) m/z: M+1 obs 499.90, tR = 3.20 min.
Step-3: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(picolinamido)benzyl)sulfamoyl)benzoate
A mixture of methyl 4-(N-(4-aminobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 161, 75 mg, 0.15 mmol), picolinic acid (37 mg, 0.30 mmol), HBTU (114 mg, 0.30 mmol) and Et3N (61 mg, 0.60 mmol) in DCM was stirred at room temperature for 1 day. The mixture was quenched with sat. NaHCO3, extracted with DCM, dried over Na2SO4, filtered and concentrated to give the titled compound as crude.
LC-MS (Method A) m/z: M+1 obs 604.92, tR = 3.42 min.
Step-4: 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(picolinamido)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(picolinamido)benzyl)sulfamoyl)benzoate (step-3 of Example161). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 162
4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(6-methoxypyridin-3-yl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and (6-methoxypyridin-3-yl)boronic acid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 163
4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(6-methylpyridin-3-yl)benzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-3 of Example 149 from methyl 4-(N-(4-bromobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 150) and (6-methylpyridin-3-yl)boronic acid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 164
4-(N-([1,1'-Biphenyl]-3-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-([1,1'-biphenyl]-3-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 3-(bromomethyl)-1,1'-biphenyl.
Step-2: 4-(N-([1,1'-Biphenyl]-3-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-([1,1'-biphenyl]-3-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 164). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 165
4-(N-([1,1'-Biphenyl]-2-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-([1,1'-biphenyl]-2-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 2-(bromomethyl)-1,1'-biphenyl.
Step-2: 4-(N-([1,1'-Biphenyl]-2-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-([1,1'-biphenyl]-2-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 165). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 166
(R)-4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoic acid
Step-1: (R)-Methyl 4-(N-(1-phenylethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate (step-1 of Example 1) and (R)-1-phenylethanamine;
Figure JPOXMLDOC01-appb-I000024
LC-MS (Method A) m/z: M-1 obs 318.10, tR = 2.93 min.
Step-2: (R)-Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and (R)-methyl 4-(N-(1-phenylethyl)sulfamoyl)benzoate (step-1 of Example 166);
Figure JPOXMLDOC01-appb-I000025
LC-MS (Method A) m/z: M+1 obs 394.99 (fragment signal), tR = 3.54 min.
Step-3: (R)-4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from (R)-methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoate (step-2 of Example 166). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 167
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-2-ylmethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(thiophen-2-ylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate and thiophen-2-ylmethanamine;
Figure JPOXMLDOC01-appb-I000026
LC-MS (Method A) m/z: M-1 obs 310.07, tR = 2.82 min.
Step-2: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-2-ylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(thiophen-2-ylmethyl)sulfamoyl)benzoate (step-1 of Example 167);
LC-MS (Method A) m/z: M+1 obs 490.82, tR = 3.40 min.
Step-3: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-2-ylmethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-2-ylmethyl)sulfamoyl)benzoate (step-2 of Example 167). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 168
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclohexylmethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(cyclohexylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate (step-1 of Example 1) and cyclohexylmethanamine;
LC-MS (Method A) m/z: M-1 obs 310.14, tR = 3.12 min.
Step-2: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclohexylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(cyclohexylmethyl)sulfamoyl)benzoate (step-1 of Example 168);
LC-MS (Method A) m/z: M+1 obs 490.98, tR = 3.70 min.
Step-3: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclohexylmethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclohexylmethyl)sulfamoyl)benzoate (step-2 of Example 168). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 169
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-phenoxybenzyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(4-phenoxybenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate (step-1 of Example 1) and (4-phenoxyphenyl)methanamine; LC-MS (Method A) m/z: M-1 obs 396.11, tR = 3.19 min.
Step-2: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-phenoxybenzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(4-phenoxybenzyl)sulfamoyl)benzoate (step-1 of Example 169);
Figure JPOXMLDOC01-appb-I000027
LC-MS (Method A) m/z: M+1 obs 183.22 (fragment signal), tR = 3.70 min.
Step-3: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-phenoxybenzyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-phenoxybenzyl)sulfamoyl)benzoate (step-2 of Example 169). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 170
4-(N-(4-(1H-Pyrazol-1-yl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(4-(1H-pyrazol-1-yl)benzyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate and (4-(1H-pyrazol-1-yl)phenyl)methanamine;
LC-MS (Method A) m/z: M+1 obs 372.02, M-1 obs 370.09, tR = 2.80 min.
Step-2: Methyl 4-(N-(4-(1H-pyrazol-1-yl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 15 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(4-(1H-pyrazol-1-yl)benzyl)sulfamoyl)benzoate (step-1 of Example 170);
Figure JPOXMLDOC01-appb-I000028
LC-MS (Method A) m/z: M+1 obs 550.94, tR = 3.39 min.
Step-3: 4-(N-(4-(1H-Pyrazol-1-yl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(4-(1H-pyrazol-1-yl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 170). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 171
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclobutylmethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(cyclobutylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate (step-1 of Example 1) and cyclobutylmethanamine;
LC-MS (Method A) m/z: M-1 obs 282.18, tR = 2.92 min.
Step-2: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclobutylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(cyclobutylmethyl)sulfamoyl)benzoate (step-1 of Example 171);
LC-MS (Method A) m/z: M+1 obs 462.93, tR = 3.55 min.
Step-3: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclobutylmethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclobutylmethyl)sulfamoyl)benzoate (step-2 of Example 171). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 172
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-3-ylmethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(thiophen-3-ylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1of Example 148 from methyl 4-(chlorosulfonyl)benzoate and thiophen-3-ylmethanamine;
LC-MS (Method A) m/z: M-1 obs 310.07, tR = 2.82 min.
Step-2: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-3-ylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(thiophen-3-ylmethyl)sulfamoyl)benzoate (step-1 of Example 172);
LC-MS (Method A) m/z: M+1 obs 490.86, tR = 3.42 min.
Step-3: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-3-ylmethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-3-ylmethyl)sulfamoyl)benzoate (step-2 of Example 172). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 173
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-cyanobenzenesulfonamide
Step-1: N-benzyl-4-cyanobenzenesulfonamide
The titled compound was prepared according to the procedure described in step-1 of Example 148 from 4-cyanobenzene-1-sulfonyl chloride and phenylmethanamine;
LC-MS (Method A) m/z: M-1 obs 271.11, tR = 2.79 min.
Step-2: N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-cyanobenzenesulfonamide
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and N-benzyl-4-cyanobenzenesulfonamide (step-1 of Example 173). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 174
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(2H-tetrazol-5-yl)benzenesulfonamide
Step-1: N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(2H-tetrazol-5-yl)benzenesulfonamide
A mixture of N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-cyanobenzenesulfonamide (step-2 of Example 173, 60 mg, 0.13 mmol) , NaN3 (52 mg, 0.80 mmol), and NH4Cl (43 mg, 0.80 mmol) in DMF (5 mL) was heated at 110 oC overnight. After cooling, quenched by 1 M HCl aqueous solution, and extracted with toluene/EtOAc (2/1), washed with water, dried over MgSO4, filtered, and the filtrate was concentrated to give 73 mg (quant. yield) of the titled compound as a yellow solid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 175
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-methoxybenzenesulfonamide
Step-1: N-Benzyl-4-methoxybenzenesulfonamide
The titled compound was prepared according to the procedure described in step-1 of Example 148 from 4-methoxybenzene-1-sulfonyl chloride and phenylmethanamine;
LC-MS (Method A) m/z: M-1 obs 276.13, tR = 2.82 min.
Step-2: N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-methoxybenzenesulfonamide
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and N-benzyl-4-methoxybenzenesulfonamide (step-1 of Example 175). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 176
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(methylsulfonamidomethyl)benzenesulfonamide
Step-1: 4-(Aminomethyl)-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide
A mixture of N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-cyanobenzenesulfonamide (step-2 of Example 173, 188 mg, 0.42 mmol),and Raney Nickel (0.05 mL, Raney (registered trademark) 2800) in 1 M NH3 in MeOH solution (20 mL) was stirred under hydrogen atmosphere for 16 hrs. The mixture was filtered through a pad of celite, washed with MeOH, the filtrate was concentrated to give a brown oil. The residual oil was diluted with MeOH, applied onto a strong cation exchange cartridge (BondElute (registered trademark) SCX, 1 g/6 mL, Varian Inc.), and the solid phase matrix was rinsed with methanol (6 mL). The crude mixture was eluted in a collection tube with 1 M NH3 in MeOH (6 mL) and concentrated gave 179 mg (94% yield) of the titled compound as a clear colorless oil.
LC-MS (Method A) m/z: M+1 obs 455.95; tR = 2.87 min
Step-2: N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(methylsulfonamidomethyl)benzenesulfonamide
To a solution of 4-(aminomethyl)-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide (step-1 of Example 176, 40 mg, 0.088 mmol) and Et3N (18 mg, 0.18 mmol) in DCM (4 mL) was addedand methanesulfonyl chloride (10 mg, 0.88 mmol) at room temperature, and stirred for 2 hrs at room temperature. The mixture was washed with 2 M aqueous HCl solution, dried over MgSO4, filtered, and the filtrate was concentrated gave 30 mg (64% yield) of the titled compound as a pale yellow oil. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 177
N-(4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzyl)acetamide
Step-1: N-(4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzyl)acetamide
The titled compound was prepared according to the procedure described in step-2 of Example 176 from 4-(aminomethyl)-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide (step-1 of Example 176) and acetyl chloride. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 178
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(((N,N-dimethylsulfamoyl)amino)methyl)benzenesulfonamide
Step-1: N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(((N,N-dimethylsulfamoyl)amino)methyl)benzenesulfonamide
The titled compound was prepared according to the procedure described in step-2 of Example 176 from 4-(aminomethyl)-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide (step-1 of Example 176) and dimethylsulfamoyl chloride. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 179
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-((3,3-dimethylureido)methyl)benzenesulfonamide
Step-1: N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-((3,3-dimethylureido)methyl)benzenesulfonamide
The titled compound was prepared according to the procedure described in step-2 of Example 176 from 4-(aminomethyl)-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide (step-1 of Example 176) and dimethylcarbamic chloride. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 180
4-(N-Benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 1 from 5-bromo-3-chloropyridin-2-amine and methyl 4-(chlorosulfonyl)benzoate.
LC-MS (Method A) m/z: M+1 obs 406.87, M-1 obs 404.90; tR = 2.94 min.
Step-2: Methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 180) and (bromomethyl)benzene.
LC-MS (Method A) m/z: M+1 obs 496.78; tR = 3.43 min.
Step-3: 4-(N-Benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 181
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-chlorobenzoic acid
Step-1: Ethyl 4-(N-benzylsulfamoyl)-3-chlorobenzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from ethyl 3-chloro-4-(chlorosulfonyl)benzoate and phenylmethanamine;
LC-MS (Method A) m/z: M+1 obs 353.98 M-1 obs 351.98, tR = 3.12 min.
Step-2: Ethyl 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-chlorobenzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and ethyl 4-(N-benzylsulfamoyl)-3-chlorobenzoate (step-1 of Example 181);
LC-MS (Method A) m/z: M+1 obs 532.86, tR = 3.65 min.
Step-3: 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-chlorobenzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from ethyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-chlorobenzoate (step-2 of Example 181). The further purification was carried out by preparative LC-MS system using the condition in Table 6.
Example 182
4-(N-Benzyl-N-(3-chloro-5-phenylpyridin-2-yl)sulfamoyl)benzoic acid
Step-1: 4-(N-Benzyl-N-(3-chloro-5-phenylpyridin-2-yl)sulfamoyl)benzoic acid
A mixture of methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180, 35 mg, 0.071 mmol), phenylboronic acid (17 mg, 0.14 mmol), Pd(PPh3)4 (8 mg, 7 micromol), and sat. NaHCO3 (0.4 mL) in dioxane (0.8 mL) was irradiated with micro-wave (150 oC, 15 min). After cooling to room temperature, the mixture was added 2 M aqueous NaOH solution (0.5 mL), THF (1 mL), and the mixture was heated at 60 oC for 2 hrs. After cooling to room temperature, 2M aqueous HCl solution (0.5 mL) was added and extracted with DCM, dried over Na2SO4, filtered and concentrated gave crude product as brown oil. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 183
4-(N-Benzyl-N-(3-chloro-5-(furan-2-yl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: 4-(N-Benzyl-N-(3-chloro-5-(furan-2-yl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-1 of Example 182 from methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180) and furan-2-ylboronic acid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 184
4-(N-Benzyl-N-(3-chloro-5-(thiophen-3-yl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: 4-(N-Benzyl-N-(3-chloro-5-(thiophen-3-yl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-1 of Example 182 from methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180) and thiophen-3-ylboronic acid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 185
4-(N-Benzyl-N-(3-chloro-5-(2-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: 4-(N-Benzyl-N-(3-chloro-5-(2-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-1 of Example 182 from methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180) and (2-methoxyphenyl)boronic acid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 186
4-(N-Benzyl-N-(3-chloro-5-(4-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: 4-(N-Benzyl-N-(3-chloro-5-(4-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-1 of Example 182 from methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180) and (4-methoxyphenyl)boronic acid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 187
4-(N-Benzyl-N-(3-chloro-5-(3-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid
Step-1: 4-(N-Benzyl-N-(3-chloro-5-(3-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-1 of Example 182 from methyl 4-(N-benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoate (step-2 of Example 180) and (3-methoxyphenyl)boronic acid. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 188
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-chlorobenzoic acid
Step-1: N-Benzyl-4-bromo-3-chlorobenzenesulfonamide
The titled compound was prepared according to the procedure described in step-1 of Example 148 from 4-bromo-3-chlorobenzene-1-sulfonyl chloride and phenylmethanamine;
LC-MS (Method A) m/z: M-1 obs 359.88, tR = 3.18 min.
Step-2: N-Benzyl-4-bromo-3-chloro-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide
The titled compound was prepared according to the procedure described in step-1 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and N-benzyl-4-bromo-3-chlorobenzenesulfonamide (step-1 of Example 188);
LC-MS (Method A) m/z: M-1 obs 540.71, tR = 3.73 min.
Step-3: Methyl 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-chlorobenzoate
A mixture of N-benzyl-4-bromo-3-chloro-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide (step-2 of Example 188, 20 mg, 0.037 mmol), Pd(OAc)2 (0.8 mg, 4 micromol), 1,3-bis(diphenylphosphino)propane (1.5 mg, 4 micromol), and Et3N (11 mg, 0.11 mmol) in DMF/MeOH (5 mL/2 mL) was heated at 100 oC overnight under carbon monooxide atmosphere. After cooling, the mixture was added water, extracted with diethyl ether (2 times). The combined organic phase were washed with water, brine, dried over Na2SO4, filtered, and the filtrae was concentrated to give a yellow brown solid, which was applied to a silica gel column chromatography and eluted with hexane/EtOAc = 6/1 to furnish 11 mg (57% yield) of the titled compound as a clear yellow oil;
Figure JPOXMLDOC01-appb-I000029
LC-MS (Method A) m/z: M+1 obs 518.83, tR = 3.54 min.
Step-4: 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-chlorobenzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-chlorobenzoate (step-3 of Example 188). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 189
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-6-methoxypyridine-3-sulfonamide
Step-1: N-Benzyl-6-methoxypyridine-3-sulfonamide
The titled compound was prepared according to the procedure described in step-1 of Example 148 from 6-methoxypyridine-3-sulfonyl chloride and phenylmethanamine;
LC-MS (Method A) m/z: M+1 obs 279.13 M-1 obs 277.15, tR = 2.82 min.
Step-2: N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-6-methoxypyridine-3-sulfonamide
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and N-benzyl-6-methoxypyridine-3-sulfonamide (step-1 of Example 189). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 190
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-fluorobenzoic acid
Step-1: N-Benzyl-4-bromo-2-fluorobenzenesulfonamide
The titled compound was prepared according to the procedure described in step-1 of Example 148 from 4-bromo-2-fluorobenzene-1-sulfonyl chloride and phenylmethanamine;
LC-MS (Method A) m/z: M-1 obs 343.96, tR = 3.07 min.
Step-2: Methyl 4-(N-benzylsulfamoyl)-3-fluorobenzoate
The titled compound was prepared according to the procedure described in step-3 of Example 188 from N-benzyl-4-bromo-2-fluorobenzenesulfonamide (step-1 of Example 190);
LC-MS (Method A) m/z: M-1 obs 322.08, tR = 2.92 min.
Step-3: Methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-fluorobenzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-benzylsulfamoyl)-3-fluorobenzoate (step-2 of Example 190);
LC-MS (Method A) m/z: M+1 obs 502.90, tR = 3.48 min.
Step-4: 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-fluorobenzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-fluorobenzoate (step-3 of Example 190). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 191
4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-fluorobenzoic acid
Step-1: N-Benzyl-4-bromo-3-fluorobenzenesulfonamide
The titled compound was prepared according to the procedure described in step-1 of Example 148 from 4-bromo-3-fluorobenzene-1-sulfonyl chloride and phenylmethanamine;
LC-MS (Method A) m/z: M-1 obs 343.99, tR = 3.09 min.
Step-2: Methyl 4-(N-benzylsulfamoyl)-2-fluorobenzoate
The titled compound was prepared according to the procedure described in step-3 of Example 188 from N-benzyl-4-bromo-3-fluorobenzenesulfonamide (step-1 of Example 191);
LC-MS (Method A) m/z: M-1 obs 322.08, tR = 2.97 min.
Step-3: Methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-fluorobenzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-benzylsulfamoyl)-2-fluorobenzoate (step-2 of Example 191);
LC-MS (Method A) m/z: M+1 obs 502.90, tR = 3.47 min.
Step-4: 4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-fluorobenzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-fluorobenzoate (step-3 of Example 191). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 192
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopentylmethyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(cyclopentylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate and cyclopentylmethanamine;
LC-MS (Method A) m/z: M-1 obs 296.14, tR = 2.99 min.
Step-2: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopentylmethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(cyclopentylmethyl)sulfamoyl)benzoate (step-1 of Example 192);
Figure JPOXMLDOC01-appb-I000030
LC-MS (Method A) m/z: M+1 obs 476.99, tR = 3.62 min.
Step-3: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopentylmethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopentylmethyl)sulfamoyl)benzoate (step-2 of Example 192). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 193
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylcyclopropyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(1-phenylcyclopropyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate and 1-phenylcyclopropanamine, hydrochloride;
LC-MS (Method A) m/z: M-1 obs 330.10, tR = 2.93 min.
Step-2: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylcyclopropyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and methyl 4-(N-(1-phenylcyclopropyl)sulfamoyl)benzoate (step-1 of Example 193); LC-MS (Method A) m/z: M+1 obs 510.80, tR = 3.54 min.
Step-3: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylcyclopropyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylcyclopropyl)sulfamoyl)benzoate (step-2 of Example 193). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 194
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-((N,N-dimethylsulfamoyl)amino)benzenesulfonamide
Step-1: N-Benzyl-4-nitrobenzenesulfonamide
The titled compound was prepared according to the procedure described in step-1 of Example 148 from 4-nitrobenzene-1-sulfonyl chloride and phenylmethanamine;
Figure JPOXMLDOC01-appb-I000031
LC-MS (Method A) m/z: M-1 obs 291.11, tR = 2.86 min.
Step-2: N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-nitrobenzenesulfonamide
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and N-benzyl-4-nitrobenzenesulfonamide (step-1 of Example 194);
Figure JPOXMLDOC01-appb-I000032
LC-MS (Method A) m/z: M+1 obs 471.91, tR = 3.45 min.
Step-3: 4-Amino-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide
A MeOH (8mL) solution of N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-nitrobenzenesulfonamide (step-2 of Example 194, 381 mg, 0.807 mmol) and 5% Platinum on charcoal type 128 PASTE (Johnson Matthey, 0.05 g) was stirred at room temperature under hydrogen atmosphere for 3 hrs. The catalyst (0.05 g) was added and stirred for 10 hrs. The catalyst was filtered off through a celite pad and the filtrate was concentrated. The residue was purified by silica gel column chromatography (hexane/EtOAc = 95/5 to 4/1) to give 328 mg (92% yield) of the titled compound as yellow grease.
Figure JPOXMLDOC01-appb-I000033
LC-MS (Method A) m/z: M+1 obs 441.95, tR = 3.20 min.
Step-4: N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-((N,N-dimethylsulfamoyl)amino)benzenesulfonamide
To a solution of 4-amino-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide (step-4 of Example 194, 25 mg, 0.057 mmol) and Et3N (7.44 mg, 0.074 mmol) in CH3CN (2 mL) was added dimethylsulfamoyl chloride (9.09 microL, 0.085 mmol) at room temperature. The resulting solution was stirred for 2 hrs at room temperature, then 70 oC for 3 hrs. The resulting mixture was concentrated. The whole was added pyridine (1 mL) and dimethylsulfamoyl chloride(12 microL, 0.112 mmol), The resulting mixture was stirred at 70 oC for 8 hrs. The reaction mixture was extracted with EtOAc (15mL) and water (30mL). The organic layer was dried over MgSO4 and concentrated to give 37 mg (119% Yield) of the title compound. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 195
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-ureidobenzenesulfonamide
To a solution of 4-amino-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide (step-3 of Example 194, 30.6 mg, 0.069 mmol) and 4-dimethylaminopyridine (0.85 mg, 0.0069 mmol) in THF (2 mL) was added trimethylsilyl isocyanate (21.4 microL, 0.173 mmol) at room temperature. The resulting solution was stirred for 3 hrs, and then refluxed for 5hr and cooled to room temperature. The reaction mixture was added trimethylsilyl isocyanate (15 microL, 0.121 mmol) and refluxed overnight. The resulting mixture was quenched with water and extracted with EtOAc, dried over MgSO4 and concentrated. The crude product was purified by silylca gel column chromatograph (hexane/EtOAc = 1/0 to 0/1) to give 25.8 mg (77% Yield) of the title compound. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 196
N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(sulfamoylamino)benzenesulfonamide
To the mixture of 4-amino-N-benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide (step-3 of Example 194, 22.3 mg, 0.050 mmol) and 1,4-dioxane (2 mL) was added sulfamide (19.4 mg, 0.202 mmol) and the whole was refluxed for 18 hrs. The reaction mixture was concentrated and the crude product was purified by silyca gel column chromatography (hexane/EtOAc = 1/0 to 2/1) to give 11.3mg (43% Yield) of the title compound. The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 197
(S)-4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoic acid
Step-1: (S)-Methyl 4-(N-(1-phenylethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 148 from methyl 4-(chlorosulfonyl)benzoate (step-1 of Example 1) and (S)-1-phenylethanamine;
LC-MS (Method A) m/z: M-1 obs 318.10, tR = 2.93 min.
Step-2: (S)-Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-2 of Example 148 from 2,3-dichloro-5-(trifluoromethyl)pyridine and (S)-methyl 4-(N-(1-phenylethyl)sulfamoyl)benzoate (step-1 of Example 197);
LC-MS (Method A) m/z: M+1 obs 394.94 (fragment signal), tR = 3.48 min.
Step-3: (S)-4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from (S)-methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoate (step-2 of Example 194). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 198
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((2-phenylthiazol-4-yl)methyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((2-phenylthiazol-4-yl)methyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 4-(chloromethyl)-2-phenylthiazole;
LC-MS (Method B) m/z: M+1 obs 566.9, tR = 2.70 min.
Step-2: 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((2-phenylthiazol-4-yl)methyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((2-phenylthiazol-4-yl)methyl)sulfamoyl)benzoate (step-1 of Example 198). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Example 199
4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((5-phenyl-1,2,4-oxadiazol-3-yl)methyl)sulfamoyl)benzoic acid
Step-1: Methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((5-phenyl-1,2,4-oxadiazol-3-yl)methyl)sulfamoyl)benzoate
The titled compound was prepared according to the procedure described in step-1 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate (step-1 of Example 1) and 3-(chloromethyl)-5-phenyl-1,2,4-oxadiazole;
LC-MS (Method B) m/z: M+1 obs 552.9, tR = 2.84 min.
Step-2: 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((5-phenyl-1,2,4-oxadiazol-3-yl)methyl)sulfamoyl)benzoic acid
The titled compound was prepared according to the procedure described in step-2 of Example 15 from methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((5-phenyl-1,2,4-oxadiazol-3-yl)methyl)sulfamoyl)benzoate (step-1 of Example 199). The further purification was carried out by preparative LC-MS system in usual manner. HPLC-QC method, retention time and observed MS were summarized in Table 6.
Quality control analytical condition (Method B) used in Table 6 are described below for all examples.
All examples were identified as the described compounds with the chemical purity of greater than 90% by preparative LC-MS and HPLC-QC method. In Table 6, HPLC retention time and observed MS were measured by HPLC-QC method using condition C, D or E.


Figure JPOXMLDOC01-appb-T000006
Figure JPOXMLDOC01-appb-T000007
Figure JPOXMLDOC01-appb-T000008
Figure JPOXMLDOC01-appb-T000009
Figure JPOXMLDOC01-appb-T000010
Figure JPOXMLDOC01-appb-T000011
Figure JPOXMLDOC01-appb-T000012
Figure JPOXMLDOC01-appb-T000013
Figure JPOXMLDOC01-appb-T000014
Figure JPOXMLDOC01-appb-T000015
Figure JPOXMLDOC01-appb-T000016
Figure JPOXMLDOC01-appb-T000017
Figure JPOXMLDOC01-appb-T000018
Figure JPOXMLDOC01-appb-T000020
Figure JPOXMLDOC01-appb-T000021
Figure JPOXMLDOC01-appb-T000022
Figure JPOXMLDOC01-appb-T000023
Figure JPOXMLDOC01-appb-T000024
Figure JPOXMLDOC01-appb-T000025
Figure JPOXMLDOC01-appb-T000026
Figure JPOXMLDOC01-appb-T000027
Figure JPOXMLDOC01-appb-T000028
Figure JPOXMLDOC01-appb-T000029
Figure JPOXMLDOC01-appb-T000030
Figure JPOXMLDOC01-appb-T000031
Figure JPOXMLDOC01-appb-T000032
Figure JPOXMLDOC01-appb-T000033
Figure JPOXMLDOC01-appb-T000034
Figure JPOXMLDOC01-appb-T000035
Figure JPOXMLDOC01-appb-T000036
Figure JPOXMLDOC01-appb-T000037
Figure JPOXMLDOC01-appb-T000038
Figure JPOXMLDOC01-appb-T000039
Figure JPOXMLDOC01-appb-T000040
Figure JPOXMLDOC01-appb-T000041
Figure JPOXMLDOC01-appb-T000042
Figure JPOXMLDOC01-appb-T000043
Figure JPOXMLDOC01-appb-T000044
Figure JPOXMLDOC01-appb-T000045
Figure JPOXMLDOC01-appb-T000046
In Vitro human TRPM8 Functional Assay
The functional activity of compounds was determined by measuring changes in intracellular calcium concentration using a Ca2+-sensitive fluorescent dye, Fluo4 (Molecular Probes). The changes in fluorescent signal were monitored by the cell imaging technology by Hamamatsu Photonics's Functional Drug Screening System (FDSS). Increases in intracellular Ca2+ concentration were readily detected upon activation with menthol.
Cell Maintenance:
HEK293 cells stably expressing human TRPM8 were grown in T175 flasks, in a 5% CO2 humidified incubator to about 80% confluence. Media composition consisted of Dulbecco's Modified Eagle Medium (high glucose), 10% fetal calf serum (FCS), 100 units/ml Penicillin, 100 microg/ml Streptomycin and 600 microg/ml Geneticine.
Assay protocol:
Day One:
1. Plate-out HEK293-TRPM8 cells (40 microL medium containing 30,000 cells per well) into poly-D-lysine coated 384-well plates (BD FALCON) at 24 hours prior to assay.
2. Incubate at 37oC in 5% CO2.
Day Two:
1. Wash each well with 80 microl of assay buffer (see bellow) twice and leave 20 microl using plate washer, ELx-405 Select CW (BIO-TEK).
2. Add 20 microL of assay buffer containing 0.5 microM Fluo4-AM (Molecular Probes) and 0.005 % Pluronic F-127 to each well.
3. Place the plate at room temperature in dark for 1 hour.
4. Wash each well with 80 microL of assay buffer (see bellow) twice and leave 20 microL using plate washer, ELx-405 Select CW (BIO-TEK).
5. Add 20 microL of compound solutions into each well and leave the plate for 5 minutes under the dark at room temperature.
6. Measure activity by FDSS as follows:
- Set the assay plate on the stacker of FDSS
- Start the detection of fluorescence intensity
- After 30 sec, add 20 microL of 90 microM L-(-)-Menthol
IC50 values for compounds of the present invention were determined from 11-point dose-response studies. Curves were generated using the average of duplicate wells for each data point. Finally, the IC50 values are calculated with the best-fit dose curve determined by XLfit (ID Business Solutions Ltd.). The resultant data are displayed in Table 8.
Figure JPOXMLDOC01-appb-T000047
Table 8
Summary of the assay
Figure JPOXMLDOC01-appb-I000034

Figure JPOXMLDOC01-appb-T000048
Figure JPOXMLDOC01-appb-T000049
Figure JPOXMLDOC01-appb-T000050
Chronic constriction injury (CCI)-induced model of neuropathic pain; cold allodynia
Male Sprague-Dawley rats were housed in groups of two under a 12-h light/dark cycle (lights on at 07:00) with free access to food and water ad libitum. The CCI was made according to the method of Bennett GJ and Xie YK (Pain 1988, 33: 87-107). Rats (253-322 g) were anesthetized with intraperitoneal injection of sodium pentobarbital. The left common sciatic nerve was exposed at the level of the middle of the thigh and four ligatures were loosely tided around it by using 4-0 silk thread with about 1 mm space. Sham operation was performed in the same manner except of sciatic nerve ligation. Seven days following CCI surgery, cold allodynia was assessed using a cold plate (LHP-1700CP, TECA, USA) with a temperature controller (Mode13300-0, CAL Controls Inc, USA) as described by Tanimoto-Mori S et al. (Behav Pharmacol. 2008, 19: 85-90). The animals were habituated to the apparatus which consisted of a transparent acrylic box (10 x 12 x 12 cm) on a stainless-steel plate (15 x 33 cm). The surface of the cold plate held on 10 oC and the temperature of the plate was monitored continuously with a precision of 0.1 oC. For testing, the rat was placed on the cold plate and the paw withdrawal latency (PWL) was measured before and after the compound administration, with a cut-off value of 120 sec. The compounds of the invention or their vehicles were administered perorally, subcutaneously or intraperitoneally. The percentages of inhibition were calculated as follows;
Figure JPOXMLDOC01-appb-M000001
Some compounds of the invention showed potent activities in this model (>30% inhibition).
Chronic constriction injury (CCI)-induced model of neuropathic pain; static allodynia
Male Sprague-Dawley rats were housed in groups of two under a 12-h light/dark cycle (lights on at 07:00) with free access to food and water ad libitum. The CCI was made according to the method of Bennett GJ and Xie YK (Pain 1988, 33: 87-107). Rats (253-322 g) were anesthetized with intraperitoneal injection of sodium pentobarbital. The left common sciatic nerve was exposed at the level of the middle of the thigh and four ligatures were loosely tided around it by using 4-0 silk thread with about 1 mm space. Sham operation was performed in the same manner except of sciatic nerve ligation. Static allodynia was assessed using von Frey hairs (VFHs) at 14 days following CCI surgery as described by Field MJ et al. (Pain 1999, 83: 303-311). The animals were habituated to grid bottom cages prior to the start of experiment. VFHs in ascending order of force (0.16, 0.4, 0.6, 1, 1.4, 2, 4, 6, 8, 10, 15 and 26 g) were applied to the plantar surface of the hind paw. Each VFH was applied to the ipsilateral paw for 6 seconds or until a withdrawal response occurred. Once a withdrawal response was happened, the paw was re-test, starting with the next descending VFH until no response occurred. The lowest amount of force required to elicit a response was recorded as paw withdrawal threshold (PWT). Static allodynia was defined as present if animals responded to or below the innocuous 1.4 gram VFH. The compounds of the invention or their vehicles were administered perorally, subcutaneously or intraperitonealy. The percentages of inhibition were calculated as follows;
Figure JPOXMLDOC01-appb-M000002
Some compounds of the invention showed potent activities in this model (>30% inhibition).
Oxaliplatin-induced model of neuropathic pain; cold and mechanical allodynia
Male C57BL/6 mice or Sprague-Dawley rats 6 or 7 weeks old at the start of the experiment, were used. They were housed in groups under a 12-h light/dark cycle (lights on at 07:00) with free access to food and water ad libitum. The study was conducted according to the method of Gauchan, P et al. (Gauchan, P., et al. NeuroSci Lett, 2009, 458, 93-95). Oxaliplatin (Sigma, St. Louis, MO) was dissolved in 5% glucose. Oxaliplatin (3-4 mg/kg) was injected intraperitoneally once or twice a week for one or two-week. For the assessment of cold allodynia, licking time or behavioral score to acetone or PWL and paw withdrawal count on cold plate were measured. For acetone test, the animal was held by the hand and a droplet (50 microL) of acetone, formed on the flat-tip needle of a syringe, was gently touched to the plantar surface of the hind paw. The animal was immediately put in an acrylic cage with a transparent floor and the behaviors were videotaped from beneath. Measurement of time spent in licking of the plantar region over a 60 s period was made by video playback. Acetone was applied three times at a 10-15min interval and the average of licking time was calculated. For cold plate test, cold allodynia was assessed using a cold plate (LHP-1700CP, TECA, USA) with a temperature controller (Mode13300-0, CAL Controls Inc, USA) as described by Tanimoto-Mori S et al. (Behav Pharmacol. 2008, 19: 85-90). The animals were habituated to the apparatus which consisted of a transparent acrylic box (10 x 12 x 12 cm) on a stainless-steel plate (15 x 33 cm). The surface of the cold plate held on 10 oC and the temperature of the plate was monitored continuously with a precision of 0.1 oC. For testing, the animal was placed on the cold plate and PWL was measured before and after the compound administration, with a cut-off value of 180 sec. Mechanical allodynia was assessed using VFHs. The animals were habituated to grid or mesh bottom cages prior to the start of experiment. VFHs in ascending order of force (0.16, 0.4, 0.6, 1, 1.4, 2, 4, 6, 8, 10, 15 and 26 g) were applied to the plantar surface of the hind paw. Once a withdrawal response was happened, the paw was re-test, starting with the next descending VFH until no response occurred. The lowest amount of force required to elicit a response was recorded as paw withdrawal threshold (PWT). For testing, PWT was measured before and after the compound administration. .The compounds of the invention or their vehicles were administered perorally, subcutaneously or intraperitonealy.
Compounds of the invention showed potent activities on cold or mechanical allodynia in this model.
All publications, including but not limited to, issued patents, patent applications, and journal articles, cited in this application are each herein incorporated by reference in their entirety. Although the invention has been described above with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

Claims (12)

  1. A use of a compound of the following formula (I) for the manufacture of a medicament for the treatment of a condition or disorder mediated by TRPM8 receptor antagonistic activity
    Figure JPOXMLDOC01-appb-C000012
     wherein
    R1, R2, R3, R4, R5, and R6 are independently selected from the group consisting of hydrogen, C1-C4 alkyl , hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, and C3-C7 cycloalkyl; or alternatively R1 and R2, together with the atom to which they are attached, form a 3 to 6 membered ring which may contain oxygen and/or nitrogen; said ring is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, C1-C4 alkyl, and C1-C4 alkoxy; R3 and R4, together with the atom to which they are attached, form a 3 to 6 membered ring which may contain oxygen and/or nitrogen; said ring is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, C1-C4 alkyl, and C1-C4 alkoxy; R5 and R6, together with the atom to which they are attached, form a 3 to 6 membered ring which may contain oxygen and/or nitrogen; said ring is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, C1-C4 alkyl, and C1-C4 alkoxy;
    m is 0 or 1;
    n is 0, 1, 2 or 3;
    q is 0, 1, 2 or 3;
    A1, A2, A3 and A4 are independently selected from nitrogen atom and carbon atom; wherein the number of nitrogen is up to two;
    Z is H, Ar2 or a substituent represented by the formula: R7N(R8)C(=O)-, in which
    R7 and R8 are independently selected from hydrogen, C1-C4 alkyl, hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 alkylamino C1-C4 alkyl, di(C1-C4 alkyl)amino C1-C4 alkyl, 5 to 10 membered aryl, 5 to 10 membered aryl C0-C4 alkyl;
    said aryl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C8 cycloalkyl, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, C1-C4 alkylthio, and nitro;
    C3-C8 cycloalkyl, and 3 to 8 membered heterocyclyl C1-C4 alkyl;
    said heterocyclyl and alkyl may have independently 1 to 4 substituents independently selected from C1-C4 alkyl and halogen;
    or alternatively R7 and R8 together with nitrogen atom to which they are attached form a 4 to 8 membered ring which may contain nitrogen, oxygen or sulfur, wherein the 4 to 8 membered ring is optionally substituted with 1 to 6 substituents independently selected from the group consisting of hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C3-C7 cycloalkyl, amino, oxo, C1-C4 alkylamino, and di(C1-C4 alkyl)amino;
    Ar1 is aryl, which may optionally be substituted with halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, nitro, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, cyano, hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, C1-C4 alkylsulfonyl, aminosulfonyl, C1-C4 alkyl C(=O)-, HO(O=)C-, C1-C4 alkyl-O(O=)C-, R9N(R10)C(=O)-, C1-C4 alkylsulfonylamino, C3-C7 cycloalkyl, R9C(=O)N(R10)-, NH2(HN=)C-, or 5 to 10 membered aryl C0-C4 alkyl; said aryl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C7 cycloalkyl, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, C1-C4 alkylthio, and nitro;
    Ar2 is aryl, which may optionally be substituted with halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, nitro, C1-C4 alkylsilyl, di(C1-C4 alkyl)silyl, tri(C1-C4 alkyl)silyl, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, cyano, hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, C1-C4 alkylsulfonyl, aminosulfonyl, C1-C4 alkyl C(=O)-, HO(O=)C-, C1-C4 alkyl-O(O=)C-, R9N(R10)C(=O)-, C1-C4 alkylsulfonylamino, C3-C7 cycloalkyl, R9C(=O)N(R10)-, NH2(HN=)C-, 5 to 10 membered aryloxy or 5 to 10 membered aryl C0-C4 alkyl; said aryloxy, aryl and C3-C7 cycloalkyl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C7 cycloalkyl, cyano, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, C1-C4 alkylthio, R9N(R10)C(=O)- and nitro;
    R9 and R10 are independently selected from the definitions of R7 and R8;
    X is independently selected from HO(O=)C-C0-C4alkyl, hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C7 cycloalkyl, cyano, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, C1-C4 alkylthio, nitro, alkylsulfonyl, aminosulfonyl, C1-C4 alkyl C(=O)-, C1-C4 alkyl-O(O=)C-, R11N(R12)C(=O)-, C1-C4 alkylsulfonylamino, C1-C4 alkylsulfonylaminoalkyl, C3-C7 cycloalkyl, R11C(=O)N(R12)-, R11C(=O)N(R12)C1-C4alkyl, R11N(R12)SO2N(R13)C0-C4alkyl, R11N(R12)C(=O)N(R13)C0-C4alkyl, NH2(HN=)C-, C3-C7 cycloalkyl, 3 to 7 membered heterocyclyl, and 5 to 10 membered aryl C0-C4 alkyl; said heterocyclyl and alkyl may have independently 1 to 4 substituents independently selected from C1-C4 alkyl and halogen;
    R11, R12 and R13 are independently selected from the definitions of R7 and R8;
    p is 1, 2, 3, 4 or 5; when p is two or more than two, X may be same or different;
    Y is a chemical bond, oxygen atom, sulfur atom, or nitrogen atom; when Y is oxygen atom, sulfur atom, or nitrogen atom, said substituent Y may have a substituent independently selected from the definitions of R7 and R8;
    or a pharmaceutically acceptable salt thereof.
  2. The use as claimed in claim 1, wherein the condition or disorder is one or more of inflammatory, pain and urological diseases or disorders, including chronic pain, neuropathic pain including cold allodynia and diabetic neuropathy, postoperative pain, osteoarthritis, rheumatoid arthritic pain, cancer pain, neuralgia, neuropathies, algesia, nerve injury, migraine, cluster and tension headaches, ischaemia, irritable bowel syndrome, neurodegeneration, fibromyalgia, stroke, itch, psychiatric disorders including anxiety and depression and inflammatory disorders such as asthma and chronic obstructive pulmonary, or airways, disease i.e., COPD, pulmonary hypertension, anxiety, including other stress-related disorders, urological diseases or disorders such as detrusor overactivity or overactive bladder, urinary incontinence, neurogenic detrusor overactivity or detrusor hyperflexia, idiopathic detrusor overactivity or detrusor instability, benign prostatic hyperplasia, and lower urinary tract symptoms, and combinations thereof.
  3. A method for the treatment of a condition or disorder mediated by TRPM8 receptor antagonistic activity, in a mammalian subject, including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) described in claim 1 or the pharmaceutically acceptable salt thereof.
  4. The method as claimed in claim 3, wherein said condition or disorder is one or more of inflammatory, pain and urological diseases or disorders, including chronic pain, neuropathic pain including cold allodynia and diabetic neuropathy, postoperative pain, osteoarthritis, rheumatoid arthritic pain, cancer pain, neuralgia, neuropathies, algesia, nerve injury, migraine, cluster and tension headaches, ischaemia, irritable bowel syndrome, neurodegeneration, fibromyalgia, stroke, itch, psychiatric disorders including anxiety and depression and inflammatory disorders such as asthma and chronic obstructive pulmonary or airways, disease i.e., COPD, pulmonary hypertension, anxiety, including other stress-related disorders, urological diseases or disorders such as detrusor overactivity or overactive bladder, urinary incontinence, neurogenic detrusor overactivity or detrusor hyperflexia, idiopathic detrusor overactivity or detrusor instability, benign prostatic hyperplasia, and lower urinary tract symptoms, and combinations thereof.
  5. The compound of formula (I) as claimed in claim 1 wherein m is 0; and Ar1 is a 5 to 7 heterocyclic group.
  6. The compound of formula (I) as claimed in claim 5, wherein m is 0; and
    Ar1 is a 5 to 7 heterocyclic group selected from pyridinyl, pyrimidinyl, pyridazinyl, and triazinyl.
  7. The compound of formula (I) as claimed in claim 6, wherein m is 0;
    Ar1 is 2-pyridinyl or 3-pyridinyl; and A1, A2, A3 and A4 are carbon atom.
  8. The compound as claimed in any one of claims 5 to 7 which is selected from:
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)benzenesulfonamide;
    4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzamide;
    4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-N-methylbenzamide;
    4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-N,N-dimethylbenzamide;
    4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-N-(2-hydroxyethyl)benzamide;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxybenzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid;
    4-(N-(4-tert-Butylbenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-cyclohexylethyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-fluorobenzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-methoxybenzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,4-difluorobenzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-isopropylbenzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(4-fluorophenoxy)ethyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-chlorobenzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyanobenzyl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(2-Chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(2,2,2-trifluoroethoxy)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,5-difluorobenzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-difluorobenzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2,5-difluorobenzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3,4-dichlorobenzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-chlorobenzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1,1,1-trifluoro-2-methylpropan-2-yl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(2-chloro-4-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(3-phenylpropyl)sulfamoyl)benzoic acid;
    4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-fluorobenzyl)sulfamoyl)benzoic acid;
    4-(N-(4-Chloro-3-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3,5-Dichloropyridin-2-yl)-N-(2-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(4-Chloro-3-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(4-Chloro-3-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(3,5-Dichloropyridin-2-yl)-N-(3-fluoro-4-methylbenzyl)sulfamoyl)benzoic acid;
    4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-methyl-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-4-fluorobenzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(3,5-Dichloropyridin-2-yl)-N-(4-(1-methylcyclopropyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-4-fluorobenzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(4-Chloro-2-(trifluoromethyl)benzyl)-N-(3,5-dichloropyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(4-Chloro-2-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(3-chloro-4-fluorobenzyl)sulfamoyl)benzoic acid;
    4-(N-(5-Chloro-3-methylpyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoic acid;
    4-(N-(4-Chloro-3-(trifluoromethyl)benzyl)-N-(5-chloro-3-methylpyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trimethylsilyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-cyanocyclopropyl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((1-(pyridin-2-yl)piperidin-4-yl)methyl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-methylbenzoic acid;
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-6-hydroxypyridine-3-sulfonamide;
    4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methylbenzoic acid;
    4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-methoxybenzoic acid;
    2-(4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)phenyl)acetic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-phenethylsulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3-cyclopropyl-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-cyclopropylbenzyl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3-bromo-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(1-methyl-1H-pyrazol-4-yl)benzyl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3-methyl-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(pyridin-3-yl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(thiophen-2-yl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(pyridin-4-yl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(furan-2-yl)benzyl)sulfamoyl)benzoic acid;
    4-(N-([1,1'-Biphenyl]-4-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(oxazol-5-yl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(picolinamido)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(6-methoxypyridin-3-yl)benzyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(6-methylpyridin-3-yl)benzyl)sulfamoyl)benzoic acid;
    4-(N-([1,1'-Biphenyl]-3-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-([1,1'-Biphenyl]-2-ylmethyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    (R)-4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-2-ylmethyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclohexylmethyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-phenoxybenzyl)sulfamoyl)benzoic acid;
    4-(N-(4-(1H-Pyrazol-1-yl)benzyl)-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclobutylmethyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(thiophen-3-ylmethyl)sulfamoyl)benzoic acid;
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-cyanobenzenesulfonamide;
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(2H-tetrazol-5-yl)benzenesulfonamide;
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-methoxybenzenesulfonamide;
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(methylsulfonamidomethyl)benzenesulfonamide;
    N-(4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzyl)acetamide;
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(((N,N-dimethylsulfamoyl)amino)methyl)benzenesulfonamide;
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-((3,3-dimethylureido)methyl)benzenesulfonamide;
    4-(N-Benzyl-N-(5-bromo-3-chloropyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-chlorobenzoic acid;
    4-(N-Benzyl-N-(3-chloro-5-phenylpyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3-chloro-5-(furan-2-yl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3-chloro-5-(thiophen-3-yl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3-chloro-5-(2-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3-chloro-5-(4-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3-chloro-5-(3-methoxyphenyl)pyridin-2-yl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-chlorobenzoic acid;
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-6-methoxypyridine-3-sulfonamide;
    4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-3-fluorobenzoic acid;
    4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)-2-fluorobenzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(cyclopentylmethyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylcyclopropyl)sulfamoyl)benzoic acid;
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-((N,N-dimethylsulfamoyl)amino)benzenesulfonamide;
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-ureidobenzenesulfonamide;
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(sulfamoylamino)benzenesulfonamide;
    (S)-4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(1-phenylethyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((2-phenylthiazol-4-yl)methyl)sulfamoyl)benzoic acid;
    4-(N-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((5-phenyl-1,2,4-oxadiazol-3-yl)methyl)sulfamoyl)benzoic acid;
    4-(N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoic acid; and
    N-Benzyl-N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-4-(hydroxymethyl)benzene-1-sulfonamide.
  9. A compound of formula (IVa),
    Figure JPOXMLDOC01-appb-C000013
     wherein
    R1and R2 are independently selected from the group consisting of hydrogen, C1-C4 alkyl , hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, and C3-C7 cycloalkyl; or alternatively R1 and R2, together with the atom to which they are attached, form a 3 to 6 membered ring which may contain oxygen and/or nitrogen; said ring is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, hydroxy, C1-C4 alkyl, and C1-C4 alkoxy;
    m is 0;
    A1, A2, A3 and A4 are carbon atom;
    Ar1 is 2-pyridinyl or 3-pyridinyl; which may optionally be substituted with halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, nitro, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, cyano, hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, C1-C4 alkylsulfonyl, aminosulfonyl, C1-C4 alkyl C(=O)-, HO(O=)C-, C1-C4 alkyl-O(O=)C-, R9N(R10)C(=O)-, C1-C4 alkylsulfonylamino, C3-C7 cycloalkyl, R9C(=O)N(R10)-, NH2(HN=)C-, or 5 to 10 membered aryl C0-C4 alkyl; said aryl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C7 cycloalkyl, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, C1-C4 alkylthio, and nitro;
    R9 and R10 are independently selected from hydrogen, C1-C4 alkyl, hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 alkylamino C1-C4 alkyl, di(C1-C4 alkyl)amino C1-C4 alkyl, 5 to 10 membered aryl, 5 to 10 membered aryl C0-C4 alkyl;
    said aryl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C8 cycloalkyl, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, C1-C4 alkylthio, and nitro;
    C3-C8 cycloalkyl, and 3 to 8 membered heterocyclyl C1-C4 alkyl;
    said heterocyclyl and alkyl may have independently 1 to 4 substituents independently selected from C1-C4 alkyl and halogen;
    or alternatively R9 and R10 together with nitrogen atom to which they are attached form a 4 to 8 membered ring which may contain nitrogen, oxygen or sulfur, wherein the 4 to 8 membered ring is optionally substituted with 1 to 6 substituents independently selected from the group consisting of hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C3-C7 cycloalkyl, amino, oxo, C1-C4 alkylamino, and di(C1-C4 alkyl)amino;
    X is independently selected from halogen and C1-C4 alkyl;
    p is 1, 2, 3, or 4; when p is two or more than two, X may be same or different;
    PG is a protecting group;
    or a pharmaceutically acceptable salt thereof.
  10. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof, as claimed in any one of claims 5 to 8, and a pharmaceutically acceptable carrier.
  11. A pharmaceutical composition as claimed in claim 10, further comprising another pharmacologically active agent.
  12. A compound of formula (I) described in claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of a condition or disorder mediated by TRPM8 receptor antagonistic activity.
PCT/JP2010/003121 2009-05-01 2010-05-06 Sulfamoyl benzoic acid derivatives as trpm8 antagonists WO2010125831A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI1010017-2A BRPI1010017A2 (en) 2009-06-02 2010-05-06 use of a compound of formula (i), method for treating a condition or disorder mediated by trpm8 receptor antagonistic activity, compound of formula (i), compound of formula (iva) and pharmaceutical composition
KR1020117026215A KR20140071518A (en) 2009-05-01 2010-05-06 Sulfamoyl benzoic acid derivatives as trpm8 antagonists
CA2757761A CA2757761A1 (en) 2009-05-01 2010-05-06 Sulfamoyl benzoic acid derivatives as trpm8 antagonists
EP10769531A EP2424517A4 (en) 2009-05-01 2010-05-06 Sulfamoyl benzoic acid derivatives as trpm8 antagonists
MX2011011428A MX2011011428A (en) 2009-05-01 2010-05-06 Sulfamoyl benzoic acid derivatives as trpm8 antagonists.
RU2011148937/15A RU2011148937A (en) 2009-05-01 2010-05-06 SULFAMOILBENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS
US13/318,212 US20120094964A1 (en) 2009-05-01 2010-05-06 Sulfamoyl benzoic acid derivatives as trpm8 antagonists
CN2010800189757A CN102427810A (en) 2009-05-01 2010-05-06 Sulfamoyl benzoic acid derivatives as trpm8 antagonists
JP2011546471A JP2012525326A (en) 2009-05-01 2010-05-06 Sulfamoylbenzoic acid derivatives as TRPM8 antagonists

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21304909P 2009-05-01 2009-05-01
US61/213,049 2009-05-01
US21335709P 2009-06-02 2009-06-02
US61/213,357 2009-06-02
US27275909P 2009-10-30 2009-10-30
US61/272,759 2009-10-30

Publications (1)

Publication Number Publication Date
WO2010125831A1 true WO2010125831A1 (en) 2010-11-04

Family

ID=43031987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/003121 WO2010125831A1 (en) 2009-05-01 2010-05-06 Sulfamoyl benzoic acid derivatives as trpm8 antagonists

Country Status (9)

Country Link
US (1) US20120094964A1 (en)
EP (1) EP2424517A4 (en)
JP (1) JP2012525326A (en)
KR (1) KR20140071518A (en)
CN (1) CN102427810A (en)
CA (1) CA2757761A1 (en)
MX (1) MX2011011428A (en)
RU (1) RU2011148937A (en)
WO (1) WO2010125831A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012017166A2 (en) 2010-07-19 2012-02-09 Vaxconsulting Benzenesulfonamide-compound treatment of a pathological condition linked to an excessive effect of tnf
EP2481727A1 (en) 2011-01-28 2012-08-01 Dompe S.p.A. TRPM8 receptor antagonists
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
WO2012124825A1 (en) 2011-03-16 2012-09-20 Mitsubishi Tanabe Pharma Corporation Sulfonamide compounds having trpm8 antagonistic activity
EP2606888A1 (en) 2011-12-19 2013-06-26 Dompe' S.P.A. Trpm8 antagonists
WO2013092711A1 (en) 2011-12-19 2013-06-27 Dompe' S.P.A. Trpm8 antagonists
WO2014042238A1 (en) 2012-09-14 2014-03-20 田辺三菱製薬株式会社 Sulfonamide compound
JP2014074021A (en) * 2012-09-14 2014-04-24 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition
JP2014527511A (en) * 2011-06-24 2014-10-16 アムジエン・インコーポレーテツド TRPM8 antagonists and their use in therapy
WO2015197640A1 (en) 2014-06-23 2015-12-30 Dompe' Farmaceutici S.P.A. 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and asthma
KR20170015483A (en) 2014-06-10 2017-02-08 우베 고산 가부시키가이샤 Method for producing heteroaromatic sulfonamide compound
WO2017043092A1 (en) * 2015-09-11 2017-03-16 Raqualia Pharma Inc. Imidazolinone derivatives as trpm8 antagonists
EP3184524A1 (en) 2015-12-21 2017-06-28 Dompé farmaceutici S.p.A. 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists
US10428046B2 (en) 2014-06-10 2019-10-01 Ube Industries, Ltd. N-substituted sulfonamide compound and method for producing same
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
WO2020206118A1 (en) * 2019-04-02 2020-10-08 The University Of Chicago Remodilins to prevent or treat cancer metastasis, glaucoma, and hypoxia
WO2020206109A1 (en) * 2019-04-02 2020-10-08 The University Of Chicago Remodilins for airway remodeling and organ fibrosis
US10993939B2 (en) 2016-06-13 2021-05-04 Mitsubishi Tanabe Pharmaceutical Company Compositions for treating or preventing vasomotor symptoms
US12048685B2 (en) 2015-10-06 2024-07-30 Ora, Inc. Transient receptor potential cation channel subfamily m member 8 (TRPM8) antagonists and methods of use

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829026B2 (en) * 2010-10-01 2014-09-09 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists
WO2014065209A1 (en) * 2012-10-23 2014-05-01 日本曹達株式会社 Pyridine compound or salt thereof, pest control agent, insecticide or acaricide, and ectoparasite control agent
KR101708764B1 (en) * 2015-03-20 2017-02-21 재단법인 경기과학기술진흥원 Pharmaceutical composition for treating or preventing central nervous system disease
US11701334B2 (en) 2018-01-10 2023-07-18 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
US20220274921A1 (en) * 2019-07-11 2022-09-01 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
CN114053256B (en) * 2020-07-30 2023-07-18 中国科学院上海药物研究所 Compound for preventing and treating mental disorder diseases and application thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2259222A (en) * 1937-11-29 1941-10-14 May & Baker Ltd Preparation of sulphanilamide derivatives
US20010018523A1 (en) * 1998-09-04 2001-08-30 Lee Helen Tsenwhei Sulfonamide compounds and methods of treating atherosclerosis and restenosis
JP2006502209A (en) * 2002-10-11 2006-01-19 アクテリオン　ファマシューティカルズ　リミテッド Sulfonylamino-acetic acid derivatives
JP2006519785A (en) * 2003-02-20 2006-08-31 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド Phenylenediamineurotensin-II receptor antagonist and CCR-9 antagonist
WO2007034312A2 (en) * 2005-09-23 2007-03-29 Pfizer Products Inc. Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
WO2007091140A1 (en) * 2006-02-06 2007-08-16 Pfizer Products Inc. Substituted phenylsulfamoyl compounds as ppar agonists
WO2008008374A2 (en) * 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
JP2008509115A (en) * 2004-08-03 2008-03-27 サノフイ−アベンテイス Sulfonamide derivatives, their preparation and their therapeutic use
WO2009012430A1 (en) * 2007-07-18 2009-01-22 Janssen Pharmaceutica N.V. Sulfonamides as trpm8 modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3276958A (en) * 1959-04-06 1966-10-04 Merck & Co Inc Pyridine sulfonamide diuretics
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
ATE210637T1 (en) * 1996-10-16 2001-12-15 American Cyanamid Co PREPARATION AND APPLICATION OF ORTHO-SULFONAMIDO-ARYL-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
EP2374792A1 (en) * 2004-03-11 2011-10-12 Elan Pharmaceuticals Inc. N-substituted benzene sulfonamides
US7309709B2 (en) * 2004-04-01 2007-12-18 Pfizer Inc. Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
CN101326166A (en) * 2005-12-09 2008-12-17 索尔瓦药物有限公司 Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
DE602008000809D1 (en) * 2007-03-23 2010-04-29 Icagen Inc Ion channel inhibitors
CA2686651C (en) * 2007-05-25 2015-11-24 Abbott Gmbh & Co. Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
CL2008002430A1 (en) * 2007-08-20 2009-10-16 Glaxo Group Ltd Benzenesulfonamide derived compounds, cathepsin c inhibitors; pharmaceutical composition comprising them; and its use for the treatment of copd.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2259222A (en) * 1937-11-29 1941-10-14 May & Baker Ltd Preparation of sulphanilamide derivatives
US20010018523A1 (en) * 1998-09-04 2001-08-30 Lee Helen Tsenwhei Sulfonamide compounds and methods of treating atherosclerosis and restenosis
JP2006502209A (en) * 2002-10-11 2006-01-19 アクテリオン　ファマシューティカルズ　リミテッド Sulfonylamino-acetic acid derivatives
JP2006519785A (en) * 2003-02-20 2006-08-31 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド Phenylenediamineurotensin-II receptor antagonist and CCR-9 antagonist
JP2008509115A (en) * 2004-08-03 2008-03-27 サノフイ−アベンテイス Sulfonamide derivatives, their preparation and their therapeutic use
WO2007034312A2 (en) * 2005-09-23 2007-03-29 Pfizer Products Inc. Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
WO2007091140A1 (en) * 2006-02-06 2007-08-16 Pfizer Products Inc. Substituted phenylsulfamoyl compounds as ppar agonists
WO2008008374A2 (en) * 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
WO2009012430A1 (en) * 2007-07-18 2009-01-22 Janssen Pharmaceutica N.V. Sulfonamides as trpm8 modulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY 21 August 2008 (2008-08-21), "CN Benzoic acid, 3-amino-4-[(3-pyridinylamino) sulfonyl]-, methyl ester(CA INDEX NAME) MF C13 H13 N3 04 S SR", XP008158947, accession no. STN Database accession no. 1042505-53-2 *
DATABASE REGISTRY 28 December 2008 (2008-12-28), "CN Benzoic acid, 3-[[(6-methoxy-3-pyridinyl) amino]sulfonyl]-, methyl ester(CA INDEX NAME) MF C14 H14 N2 05 S SR", XP008158946, accession no. STN Database accession no. 1090791-43-7 *
See also references of EP2424517A4 *
ZHENG X. ET AL.: "Analgesic agents without gastric damage.. cyclooxygenase-I-selective inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 15, no. 2, 2007, pages 1014 - 1021, XP005882820 *

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012017166A3 (en) * 2010-07-19 2012-07-19 Vaxconsulting Benzenesulfonamide-compound treatment of a pathological condition linked to an excessive effect of tnf
WO2012017166A2 (en) 2010-07-19 2012-02-09 Vaxconsulting Benzenesulfonamide-compound treatment of a pathological condition linked to an excessive effect of tnf
US8975399B2 (en) 2010-07-19 2015-03-10 Jean-Francois Zagury Benzenesulfon amide-compound treatment of a pathological condition linked to an excessive effect of TNF
US8906946B2 (en) 2011-01-28 2014-12-09 Dompe' S.P.A. TRPM8 receptor antagonists
EP2481727A1 (en) 2011-01-28 2012-08-01 Dompe S.p.A. TRPM8 receptor antagonists
WO2012101244A1 (en) 2011-01-28 2012-08-02 Dompe' S.P.A. Trpm8 receptor antagonists
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
WO2012124825A1 (en) 2011-03-16 2012-09-20 Mitsubishi Tanabe Pharma Corporation Sulfonamide compounds having trpm8 antagonistic activity
AU2012229813B2 (en) * 2011-03-16 2015-09-03 Mitsubishi Tanabe Pharma Corporation Sulfonamide compounds having TRPM8 antagonistic activity
KR20140011385A (en) 2011-03-16 2014-01-28 미쓰비시 타나베 파마 코퍼레이션 Sulfonamide compounds having trpm8 antagonistic activity
KR101638672B1 (en) * 2011-03-16 2016-07-11 미쓰비시 타나베 파마 코퍼레이션 Sulfonamide compounds having trpm8 antagonistic activity
JP2014508105A (en) * 2011-03-16 2014-04-03 田辺三菱製薬株式会社 Sulfonamide compounds having TRPM8 blocking effect
US9540360B2 (en) 2011-03-16 2017-01-10 Mitsubishi Tanabe Pharma Corporation Sulfonamide compounds having TRPM8 antagonistic activity
CN103443080A (en) * 2011-03-16 2013-12-11 田边三菱制药株式会社 Sulfonamide compounds having TRPM8 antagonistic activity
US8987445B2 (en) 2011-03-16 2015-03-24 Mitsubishi Tanabe Pharma Corporation Sulfonamide compounds having TRPM8 antagonistic activity
JP2014527511A (en) * 2011-06-24 2014-10-16 アムジエン・インコーポレーテツド TRPM8 antagonists and their use in therapy
EP2606888A1 (en) 2011-12-19 2013-06-26 Dompe' S.P.A. Trpm8 antagonists
WO2013092711A1 (en) 2011-12-19 2013-06-27 Dompe' S.P.A. Trpm8 antagonists
US9585875B2 (en) 2011-12-19 2017-03-07 Dompé Farmaceutici S.P.A. TRPM8 antagonists
US9856246B2 (en) 2011-12-19 2018-01-02 Dompé Farmaceutici S.P.A. TRPM8 antagonists
EA025356B1 (en) * 2011-12-19 2016-12-30 Домпе Фармачеутичи С.П.А Trpm8 antagonists
JPWO2014042238A1 (en) * 2012-09-14 2016-08-18 田辺三菱製薬株式会社 Sulfonamide compounds
JP2014074021A (en) * 2012-09-14 2014-04-24 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition
WO2014042238A1 (en) 2012-09-14 2014-03-20 田辺三菱製薬株式会社 Sulfonamide compound
US9487488B2 (en) 2012-09-14 2016-11-08 Mitsubishi Tanabe Pharma Corporation Sulfonamide compound
KR20170015483A (en) 2014-06-10 2017-02-08 우베 고산 가부시키가이샤 Method for producing heteroaromatic sulfonamide compound
US10428046B2 (en) 2014-06-10 2019-10-01 Ube Industries, Ltd. N-substituted sulfonamide compound and method for producing same
US10519112B2 (en) 2014-06-10 2019-12-31 Ube Industries, Ltd. Method for producing heteroaromatic sulfonamide compound
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
US11046662B2 (en) 2014-06-23 2021-06-29 Dompé Farmaceutici S.P.A. 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8-inhibitors in treatment of neuralgia, pain, COPD and asthma
WO2015197640A1 (en) 2014-06-23 2015-12-30 Dompe' Farmaceutici S.P.A. 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and asthma
US10196368B2 (en) 2014-06-23 2019-02-05 Dompé Farmaceutici S.P.A. 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8-inhibitors in treatment of neuralgia, pain, COPD and asthma
WO2017043092A1 (en) * 2015-09-11 2017-03-16 Raqualia Pharma Inc. Imidazolinone derivatives as trpm8 antagonists
US12048685B2 (en) 2015-10-06 2024-07-30 Ora, Inc. Transient receptor potential cation channel subfamily m member 8 (TRPM8) antagonists and methods of use
US10246448B2 (en) 2015-12-21 2019-04-02 Dompé Farmaceutici S.P.A. 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as TRPM8 antagonists
EP3184524A1 (en) 2015-12-21 2017-06-28 Dompé farmaceutici S.p.A. 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists
US10993939B2 (en) 2016-06-13 2021-05-04 Mitsubishi Tanabe Pharmaceutical Company Compositions for treating or preventing vasomotor symptoms
WO2020206109A1 (en) * 2019-04-02 2020-10-08 The University Of Chicago Remodilins for airway remodeling and organ fibrosis
WO2020206118A1 (en) * 2019-04-02 2020-10-08 The University Of Chicago Remodilins to prevent or treat cancer metastasis, glaucoma, and hypoxia
EP3946301A4 (en) * 2019-04-02 2023-08-09 The University of Chicago Remodilins for airway remodeling and organ fibrosis

Also Published As

Publication number Publication date
RU2011148937A (en) 2013-06-10
EP2424517A4 (en) 2013-01-23
MX2011011428A (en) 2011-11-29
JP2012525326A (en) 2012-10-22
CA2757761A1 (en) 2010-11-04
CN102427810A (en) 2012-04-25
EP2424517A1 (en) 2012-03-07
KR20140071518A (en) 2014-06-12
US20120094964A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
EP2424517A1 (en) Sulfamoyl benzoic acid derivatives as trpm8 antagonists
US11603351B2 (en) Carboxamides as modulators of sodium channels
JP7465174B2 (en) Pyridonamide prodrugs useful as sodium channel modulators
JP6337109B2 (en) Sulfonamides as regulators of sodium channels
US9783501B2 (en) Substituted quinolines as modulators of sodium channels
US9421196B2 (en) Amides as modulators of sodium channels
JP6643545B2 (en) Azaspiro derivatives as TRPM8 antagonists
KR102295748B1 (en) Pyridone amides as modulators of sodium channels
EP2435407B1 (en) Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
US8809380B2 (en) Picolinamide derivatives as TTX-S blockers
US20230062053A1 (en) Carboxamides as modulators of sodium channels
US20220110923A1 (en) Esters and carbamates as modulators of sodium channels
WO2011018894A1 (en) Pyrrolopyrimidine derivatives as potassium channel modulators
US20240294512A1 (en) Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
US8829026B2 (en) Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080018975.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10769531

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010769531

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4017/KOLNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2757761

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/011428

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011546471

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20117026215

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011148937

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13318212

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1010017

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI1010017

Country of ref document: BR

Free format text: ESCLARECER, EM ATE 60 (SESSENTA) DIAS, A DIVERGENCIA NOS DADOS DAS PRIORIDADES QUE CONSTAM NA PUBLICACAO INTERNACIONAL WO/2010/125831 DE 04/11/2010 COMO US 61/213,049 DE 01/05/2009 E O CONSTANTE DA PETICAO INICIAL NO 020110019926 DE 28/02/2011 COMO US 61/213,049 DE 01/05/2010, POIS A DATA INTERFERE NA CONTAGEM DE PRAZOS PARA O PROCESSO.

ENP Entry into the national phase

Ref document number: PI1010017

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111101